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Abstract 
 
Background: Bacterial infections, particularly those of the respiratory tract, 
are a serious cause of mortality worldwide despite vaccinations and 
optimized treatment strategies. Prior to the introduction of antibiotics, passive 
immunotherapy was widely used to treat a range of bacterial infections. A 
successful opsonin based treatment, however, requires effective clearance by 
phagocytic cells. Augmented passive immunotherapy (API) is a novel 
treatment strategy that combines pathogen specific immunoglobulin (IVIG) 
and the immunomodulating peptide P4 to treat fulminant bacterial infections. 
Using in vivo, in vitro and ex vivo models of pneumococcal infection, this thesis 
aimed to describe host responses to API.  
Methods: The in vivo recruitment and activation of phagocytes following 
peptide treatment in the absence of infection was characterised using flow 
cytometry and electron microscope imaging. These findings were translated 
to murine infection models by treating pneumococcal septicemia with 
intravenous peptide administration and pneumococcal pneumonia with 
intranasal peptide administration. In vitro phagocytosis killing assays were 
used to determine the ability of P4 to augment bacterial killing of a range of 
pneumococcal serotypes and describe the involvement of phagocytic Fcγ 
receptors. Ex vivo assays of phagocytic function of human neutrophil and 
alveolar macrophages were used to translate murine and in vitro findings.  
Results: Peptide administration in the absence and presence of infection led 
to rapid recruitment of monocytes, neutrophils and macrophages and their 
activation as demonstrated by increased FcγR expression. Intravenous 
peptide administration during septicemia led to significantly increased 
survival rates in models of invasive and acute invasive pneumococcal 
diseases in young and aged mice of various genetic backgrounds. Intranasal 
peptide administration during pneumonia prevented the onset of septicemia 
and subsequent host mortality. Increased survival was associated with 
reduced bacterial burden in affected tissue. Peptide treatment of neutrophil 
cell lines, human neutrophils and alveolar macrophages modulates FcγR 
expression resulting in augmented phagocytic killing of opsonised 
pneumococci. 
Conclusion: Augmented passive immunotherapy is a synergistic treatment 
that enhances natural host immune responses to infection by opsonizing 
pathogens and inducing their effective phagocytic clearance.  
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Preface 
 
 Opsono - Preparing …  
phago -  … to devour … 
cytosis  … a cell. 
 
The term phagocytosis was first coined in 1882 by Russian scientist Elie 
Metchnikoff who at the time was working in the laboratory of Louis Pasteur 
in France. Metchnikoff noted that “wandering cells” in starfish larvae would 
engulf particles he had previously injected [1]. This was the first time 
phagocytosis had been described and recognized as being part of the immune 
response to infection: 
 
“These wandering cells in the body of the larva of a starfish, these cells eat 
food ... but they must eat up microbes too! Of course the wandering cells 
are what protect the starfish from microbes! Our wandering cells, the 
white cells of our blood—they must be what protects us from invading 
germs.” Elie Metchnikoff, 1882 
 
At the time these findings were controversial as competing researchers 
working in the laboratory of Robert Koch in Germany hypothesized that 
immunity against infection was delayed, and mediated through components 
present in serum. Previously, Koch’s laboratory had described the first 
success in immunotherapy by generating therapeutic antibodies for transfer 
in animal models of diphtheria and tetanus. In addition, Koch’s group noticed 
that serum generated following vaccination would lyse bacteria in the 
absence of immune cells, further supporting their theory of the importance of 
serum in immunity [2].  
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Debate as to the nature of immune responses to infection would continue 
until British scientists Wright and Douglas followed up on Metchnikoff’s 
paradigm-shifting discovery. They performed experiments in which immune 
cells were allowed to phagocytose bacteria with normal or heat inactivated 
serum [3]. Their conclusions would support the notion of a cellular innate 
immune response hypothesized in the Pasteur laboratory: 
 
“We have here conclusive proof that the blood fluids modify the bacteria in 
a manner which renders them a ready prey to the phagocytes. We may 
speak of this as an “opsonic” effect and we may employ the term 
“opsonins” to designate the elements in the blood fluid which produce this 
effect.” Wright et al, 1903 
 
Confirmatory evidence eventually led to the 1908 Nobel Prize in Medicine 
awarded to both Metchnikoff (Pasteur) and Ehrlich (Koch) for their work in 
describing phagocytes as part of an innate immune response utilizing 
components of a delayed immune response. During his acceptance speech, 
Ehrlich suggested a mechanism by which these two systems could interact: 
  
“There are a series of … substances, probably mostly of protein nature, 
which … lure … these structures [into cells] by … the opsonins on the one 
hand, and the … toxins … on the other. I describe all the [substances] … 
as nutriceptors and would regard these … as the source of the antibodies 
which are theoretically and practically so important.” Paul Ehrlich, Nobel 
Lecture, 1908 
 
While Ehrlich was wrong in stating that “nutriceptors” were the source of 
antibody, he correctly suggested that receptors would aid phagocytes to 
interact with opsonized particles. These were the first descriptions of an 
interaction between innate cellular immunity and adaptive serum based 
immunity that would open the door to the technologies of vaccination and 
serum therapy.  
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The media recognized the impact these discoveries had on medicine and 
health and hailed their potential as new treatments (Figure 1). Bacterial 
diseases, particularly tuberculosis and pneumonia, were causing a high 
burden of mortality at the time. Clinical treatments using crude plant extracts 
or other anti-microbial compounds such as arsenic and hexamine were 
largely ineffective. 
 
 
Figure 1 – (A) Article published in the New York Times in 1907 highlighting the discovery of 
opsonins in serum by British scientists Wright & Douglas, and a successful clinical application of 
passive immunotherapy. (B) Article published in Science in 1891 describing the first use of passive 
immunotherapy against tetanus and diphtheria by German scientist Behring and his Japanese co-
worker Shibasaburō. 
 
Since then, our understanding of opsonins, opsonic receptors, phagocytes and 
passive immunotherapy has vastly improved but the fundamental principles 
suggested by Metchnikoff, Wright and Ehrlich remain the same. This thesis 
revisits these principles by describing the current knowledge of 
opsonophagocytosis, phagocytes and serum therapy and assesses the 
potential of a novel augmented passive immunotherapy to treat 
pneumococcal diseases.  
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A. Opsonophagocytosis 
 
Phagocytosis is the process in which specialized immune cells called 
phagocytes engulf foreign particles, pathogens, dead or dying cells. In order 
to facilitate phagocytosis of pathogens, serum proteins (opsonins) bind to and 
mark pathogens for removal [4]. Immunoglobulin, complement and non-
specific opsonins are proteins that can opsonize pathogens and together can 
recognize >10 billion potential targets [5]. To some extent, phagocytosis can 
occur independent of opsonins but this is limited to small particles, or 
recognition of molecules highly conserved throughout pathogen species. 
Figure 2 depicts five ways in which particles can be internalized into 
phagocytes.  
 
 
Figure 2 - There are several ways in which phagocytes can engulf particles. Either with the help of 
opsonins including antibody, complement and non-specific opsonins (top) or without opsonins 
through the direct recognition of Pathogen-associated molecular patterns (PAMPs) using pattern 
recognition receptors (PRR) or through pinocytosis (bottom). 
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The process of opsonophagocytosis can be broken down into several steps. 
First, an invading pathogen is exposed to serum proteins that are able to 
recognize and bind to it thereby forming an immune complex (1.1). This is 
then recognized by surface bound phagocytic receptors found on immune 
cells (1.2). Ligation of these receptors leads to the internalization of the 
immune-complex and subsequent destruction of the pathogen (1.3). 
 
1.1 Opsonins 
1.1.1 Immunoglobulin 
Immunoglobulin (antibodies) are “Y” shaped globular plasma proteins 
produced by B-cells as part of the adaptive immune response to infection [6]. 
Immunoglobulin consists of two identical heavy and two identical light 
polypeptide chains, where both heavy and light chains have constant and 
variable domains (Figure 3) [7].  
 
 
Figure 3 – Immunoglobulin structure. (A.) Schematic of Immunoglobulin showing the heavy (blue) 
and light (green) chains. Each chain is further divided into variable (marked as ‘V’) and constant 
(marked as ‘C’) domains. (B.) 3D model of Immunoglobulin showing the heavy (blue) and light 
(green) chains. Adapted from [8] and protein data bank (PDB) 1IGT. 
 
The structure of immunoglobulin can be divided depending on its function. 
The top “v” shape is called the Fab region (Fragment, antigen binding) in which 
the variable domains are able to recognize and bind to specific molecules 
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(antigens) on a pathogen. Antigens are non-self molecules that usually make 
up important parts of a pathogen, such as capsule or membrane proteins used 
by bacteria to adhere to epithelial cells. The bottom “I” shape is responsible 
for binding to immune cells and is called the Fc region (Fragment, 
crystallizable), composed of the constant domains of two heavy chains that 
bind to Fc receptors on immune cells. 
 
Immune complex 
Antibody binding one or more antigens leads to the formation of an immune 
complex that can aggregate thereby facilitating more antigen binding by 
antibodies (Figure 4).  Once formed, immune complexes are able to activate 
the complement system, initiate their own clearance through phagocytosis by 
effector cells [9] or be excreted into mucosal surfaces [10]. Failure to clear 
immune complex leads to their deposition into tissue such as kidney, skin, 
lungs joints, or blood vessels and the development of autoimmune diseases 
including systemic lupus erythematosus (SLE) and arthritis [11]. 
  
 
Figure 4 - Two possible outcomes following the formation of an immune complex. Antibody binds to 
antigen on pathogens and aggregates forming an immune complex. This is then either recognized by 
phagocytes leading to phagocytosis or activates the complement system leading to further 
opsonisation and bacterial lysis.  
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Immunoglobulin opsonisation 
There are four classes of immunoglobulin able to opsonize pathogens (IgG, 
IgA, IgM and IgE) each with separate specificities. Immunoglobulin can be 
complexed into dimers to form IgA or pentamers to form IgM. IgA is the most 
abundant antibody in mucosal surfaces (S-IgA, secretory IgA) where it acts to 
prevent the colonization of bacteria. In serum, IgA is able to opsonize 
invading pathogens and initiate inflammation as well as phagocytosis [12]. 
IgM is primarily found in serum during the early stages of infection. On its 
own, IgM is an ineffective opsonin but contributes to opsonisation through 
the formation of immune complexes and activation of complement [13]. IgE is 
present in low quantities and mostly opsonizes parasitic infections [14]. The 
most important immunoglobulin in defence against infection is IgG as it is 
able to opsonize a wide range of pathogens and mediates effective 
phagocytosis. IgG is the most abundant immunoglobulin in serum and the 
only immunoglobulin capable of crossing the placenta thereby transferring 
passive immunity to a foetus. IgG also makes up >95% of total 
immunoglobulin in passive immunotherapy [15]. As such IgG as an opsonin 
will be reviewed in detail for the purpose of this thesis.  
Immunoglobulin G 
There are four different isotypes of IgG, IgG1, IgG2, IgG3 and IgG4, with 
structural differences shown in Figure 5 [16]. These isotypes vary in the size 
of their hinge region and also with respect to the antigen for which they are 
specific to. IgG1 and IgG3 target protein antigens and are potent activators of 
the complement system. IgG2 is most likely to bind to carbohydrate antigens, 
common throughout bacterial species, and has a weak ability to activate the 
complement system. IgG4, which is unable to activate the complement 
system, makes up ~5% of total IgG and is mostly associated with the response 
to chronic stimulation due its anti-inflammatory properties [17].  
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Figure 5 - The four isotypes of human IgG and their characteristics in terms of total % of IgG, role in 
host response, Fc-receptor affinity and ability to activate the complement system. Adapted from [18]. 
 
The binding of immunoglobulin to an antigen is the first step in the 
opsonophagocytosis of a pathogen, but it can also be used to deactivate the 
function of a toxin. For example, immunoglobulin is produced against the S. 
pneumoniae virulence factor pneumolysin, a pore forming toxin that causes 
much of the damage associated with pneumococcal disease [19]. Binding of 
antibody to pneumolysin leads to the deactivation of the protein and 
therefore limits potential damage [20]. Similarly, snake venom induces the 
production of neutralizing anti-venom IgG in the host which is also used in 
therapeutic sera [21].  
 
Importantly, however, antibodies are proteins that bridge the gap between 
the innate and adaptive immune system. Both systems rely on each other as 
without immunoglobulin there is minimal recognition of pathogens by 
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phagocytes (with few exceptions [22]) and without phagocytes there is 
minimal killing of opsonized pathogens.  
 
1.1.2 The complement system 
The complement system forms part of the innate immune system and is a 
general term used to describe a set of more than 30 soluble plasma proteins 
(>15% of total globular plasma protein) and their receptors which assist, or 
complement, the humoral immune response to infection [23]. Activation of the 
complement system occurs through classical, alternative, or lectin pathways 
in a cascade like fashion. In general terms, a complement cascade consists of 
inactive proteins activated through cleavage by a protease, which in turn 
converts the next protein into a protease able to cleave the next protein and so 
on. Each cascade is activated differently, but converge at cleavage of the C3 
protein, the most abundant of complement proteins. Activation of C3 leads to 
further protein cleavage and ultimately (a) the formation of a membrane 
attack complex (MAC), (b) recruitment of phagocytes through chemotaxis or 
(c) opsonisation for phagocytosis (Figure 6) [24].  
 
 
Figure 6 - Three possible outcomes of C3 cleavage following the activation of the complement system 
via the classical, alternative or lectin pathway. (A.) >13 complement proteins assemble on the 
membrane of a pathogen to form a pore causing leakage of fluids and cell death. (B.) Activated 
components of the complement system (C3a and C5a) have chemotactic properties that recruit 
phagocytes to the site of inflammation. (C.) Complement proteins deposit onto the surface of 
pathogens thereby marking (opsonizing) the pathogen for phagocytosis. 
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Activation of complement 
Activation of the complement system occurs through classical, alternative, or 
lectin pathways. The classical pathway is activated through contact with 
antibody-bound antigens. The initial protein of the classical pathway is C1, a 
complex of proteins consisting of six molecules of C1q, two molecules of C1r 
and two molecules of C1s [25]. The constant domains of IgG and IgM 
immunoglobulin have binding sites for C1q that can activate the C1 complex, 
albeit at different concentrations. A single molecule of IgM, compared with 
several molecules of IgG, is needed to activate the C1 complex [17]. Activation 
of C1 complex leads to the cleaving of C4 and C2 proteins and the subsequent 
formation a C4b2a complex able to cleave and activate C3 protein (Figure 7). 
 
 
Figure 7 - Classical activation of the complement system. Immunoglobulin binds to antigen forming 
an immune complex, which binds to the C1 complex (via C1q) thereby activating it. Activated C1 is 
then able to cleave protein C2 and C4, creating subparts that form a C3 protease (C4b2a). This 
complex is then able to initiate the three functions of complement. 
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The lectin pathway, similarly to the classical pathway, is activated in the 
presence of opsonins [26]. Activation of the lectin pathway, however, occurs 
following non-specific opsonisation with either mannose-binding lectin or 
ficolin [23]. Activation of the lectin pathway has been shown to be critical in 
protecting against pneumococcal infections [27].  
 
The alternative pathway is activated through low-level spontaneous 
conversion of C3 into C3b. This process, however, is tightly regulated to avoid 
damage to host cells. C3b is quickly deactivated either through contact with 
sialic acid (present on mammalian cells but not pathogens) or through 
binding to the regulatory protein Factor H, a soluble glycoprotein present in 
serum. Factor H binds glycosaminoglycans (GAGs) present on mammalian 
cells but not pathogens and prevents complement deposition through 
degradation of C3b and the alternative pathway C3 protease [28].  
 
Complement opsonisation 
Complement activation is followed by complement opsonisation. In 
particular, complement opsonisation occurs following cleavage of protein C3 
into C3a, C3b and C3bi (inactive C3b). Internal thioester bonds of C3 exposed 
on C3b and C3bi following cleavage covalently bind to hydroxyl groups on 
carbohydrates and proteins commonly found on the surface of bacteria, 
viruses and protozoa [23, 24]. Complement mediated opsonisation via the 
classical pathway enhances antibody mediated phagocytosis and vice versa 
[29]. In the presence of anti-capsule antibodies on bacterial pathogens, 
complement deposition is greatly enhanced which in turn increases the 
efficacy of opsonophagocytosis [30]. In contrast, complement opsonisation via 
the lectin or alternative pathway leads to opsonophagocytosis at much lower 
rates than in the presence of antibody.  
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Complement inhibition 
Pathogens have developed mechanisms to inhibit complement deposition. 
Streptococcus pneumoniae, for example, uses the virulence factors PspA and 
CbpA to deactivate complement [31]. PspA is anchored to phosphocholine 
moieties on the pneumococcal capsule thereby preventing C-reactive proteins 
(see 1.1.3) to attach and activate complement [32]. CbpA prevents 
complement deposition by binding human Factor H which degrades 
components of the complement C3b and the alternative pathway C3 protease 
[33]. 
 
1.1.3 Non-specific opsonins 
C-reactive protein (CRP) is an evolutionary conserved plasma protein 
produced and secreted by the liver during early inflammation. CRP is 
primarily synthesized by hepatocytes [34], but under some circumstances also 
by epithelial cells from the respiratory tract [35], renal epithelial cells [36] and 
neuronal cells [37]. Levels of CRP in circulating blood are associated with the 
severity of infection and used as a clinical indicator of treatment success [38]. 
It was discovered in the 1930s that CRP binds phosphocholine expressed on 
the surface of dead or dying cells as well as some pathogens including 
Streptococcus pneumoniae, Haemophilus influenziae and Leishmania donovani [39]. 
Pathogen bound CRP can activate complement through the classical pathway 
[40] leading to complement opsonisation and to a much lesser extent the 
formation of a MAC [41]. In addition, pathogen bound CRP can associate 
with ficolins and activate the lectin-mediated complement pathway [42].  
 
Mannose binding lectin (MBL, Mannose binding protein) is a soluble C-type 
lectin primarily secreted into the bloodstream by hepatocytes [43]. MBL can 
recognize repetitive carbohydrate ligands (mannose, glucose, L-fucose) 
commonly found on microbial surfaces such as N. meningitides, S. aureus and 
S. pneumoniae [44]. Once bound to a pathogen, MBL binds to MBL-associated 
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serine proteases (MASP1-2), thereby creating a protease complex able to 
activate the lectin pathway of complement leading to opsonisation and 
bacterial lysis [29]. The presence of MASP-2 is essential in activating the lectin 
pathway during pneumococcal infection [27]. Similarly, deficiencies in MBL 
production can lead to an increased risk of pneumococcal infections [45, 46].   
 
Ficolins are lectin-like soluble serum proteins primarily produced by 
hepatocytes [47]. There are currently three known Ficolin proteins (L-ficolin, 
H-ficolin and M-ficolin) which can bind to pathogens and activate 
complement [48]. M—ficolin is the only ficolin isoform secreted by immune 
cells including monocytes [49] neutrophils [50], and alveolar epithelial cells 
[51]. Ficolins bind teichoic acid present in many cell walls of Gram(+) bacteria 
[52]. Similar to mannose binding lectin, ficolins associate with MBL/Ficolin-
associated serine proteases (MASP1-2) and activate the lectin pathway of 
complement [53]. 
 
Surfactant proteins (SP) are lipoproteins produced to reduce surface tension 
and can recognize and bind to repetitive carbohydrate structures [54]. In the 
lungs, SPs are produced by type II alveolar cells and released to form 
pulmonary surfactants. The most abundant surfactants are SP-A and SP–D, 
which together can bind a wide range of pathogens [55, 56]. Surfactant 
proteins are unable to activate complement but rather help by binding to and 
aggregating pathogens [57], stimulating phagocytes [58], initiating 
phagocytosis through the binding of SP specific receptors [54] and through 
antimicrobial actions [59]. 
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1.2 Phagocytic receptors 
There are broadly speaking two types of receptors found on phagocytes that 
are involved in the process of phagocytosis. These are (a) those that recognize 
opsonic molecules bound to a pathogen (opsonic receptors) and (b) those that 
directly recognize components of pathogens (non-opsonic receptors). The 
opsonic receptors include Fcγ and complement receptors and the non-opsonic 
receptors include C-type lectins and scavenger receptors. 
 
1.2.1 Fc receptors 
Fc receptors (FcR) are membrane proteins present on monocytes, 
macrophages, neutrophils, natural killer cells, mast cells and B-cells. They 
bind the Fc region of immunoglobulin and are classified with respect to the 
class of immunoglobulin to which they bind; IgA bind Fcα receptors, IgE bind 
Fcε receptors, IgG bind Fcγ receptors and IgM bind Fcμ receptors. The critical 
FcR for inducing phagocytosis of opsonized pathogens is FcγR [60] and as 
such will be reviewed in detail.  
 
To date, six Fcγ receptors have been identified in humans: FcγRI (CD64), 
FcγRIIA (CD32a), FcγRIIB (CD32b), FcγRIIC (CD32c), FcγRIIIA (CD16a) and 
FcγRIIIB (CD16b). An additional FcR able to bind IgG is FcRn (neonatal FcR), 
which transfers IgG into the placenta and breast milk and prevents IgG from 
degradation [61]. FcR-like proteins FcRL4, FcRL5 and TRIM21 also bind IgG 
(as well as IgA) but their role in immunity remains to be elucidated [62, 63].  
 
Murine Fcγ receptors are similar to humans, consisting of FcγRI, FcγRIIB and 
FcγRIII but mice have an additional receptor (FcγRIV) not present in humans 
[64]. In both humans and mice, FcγRI binds with high affinity to the Fc 
portion of IgG, while the other receptors have low to medium affinity. 
Crosslinking of IgG to Fcγ receptors leads to the activation of an 
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immunoreceptor tyrosine based activation motif (ITAM) contained in the 
cytoplasmic domain of the FcγR molecule. An exception in both mice and 
humans is FcγRIIB, where cross-linking results in inhibition of an immune 
response through activation of an immunoreceptor tryrosine inhibitory motif 
(ITIM) [65]. The role inhibitory FcRs play in the immune system is still being 
elucidated but it has become clear that they form an essential role in 
regulating immune responses [66].  
 
Although crosslinking between different Fcγ receptors varies with respect to 
both affinity and avidity of IgG to the relevant FcγR, downstream signaling 
through the ITAM domain is similar for each IgG/receptor interaction and is 
shown in Figure 8 [67]. First, tyrosine kinases assemble by the ITAM motif 
and begin the rapid phosphorylation of the tail subunit of ITAM [68]. This in 
turn recruits Src family tyrosine kinases, such as Spleen Tyrosine Kinase 
(SYK), which activate several downstream processes including 
phosphoinositide 3-kinase (PI3K) and son of sevenless homologues (SOS) 
leading to an influx of Ca2+ and other activation signaling pathways [69, 70]. 
SYK is believed to be essential for phagocytosis as it activates Arp2/3, a 
protein complex involved in mediating the branching of the actin skeleton 
used to engulf pathogens [71]. Inhibition of the SYK protein prevents actin 
dynamics and therefore blocks phagocytosis [72].  
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Figure 8 – Activating FcγR ligation. When an immune complex (consisting of an antibody bound to 
an antigen) bind to Fcγ receptors, the immunoreceptor tyrosine-based activation motif (ITAM) 
region of the receptor is rapidly phosphorylated by tyrosine kinases. Phosphorylated ITAM then 
becomes a docking site for Spleen Tyrosine Kinase (SYK) proteins, which are able to initiate a 
variety of intracellular signaling pathways via the activation of phosphoinositide 3-kinase (PI3K) 
and son of sevenless homologues (SOS). These signaling pathways ensure effective phagocytosis of 
the FcγR bound opsonized particle.  
 
Importantly, Fcγ receptors are mobile proteins. Following activation, 
inactivated Fcγ receptors will migrate and cluster to the site of activation 
using lipid rafts [73]. This allows for further Fc-FcγR interactions and 
subsequent phosphorylation of ITAM motifs [74]. These findings led to the 
hypothesis that phagocytosis occurs in a zipper-like fashion where each Fcγ 
receptor ligation enhances the uptake [75]. Recently, however, it has been 
shown that increasing amounts of opsonizing IgG correlates with increased 
early signaling (receptor activation) but not with late signaling (actin 
dynamics) [76]. Instead, clustering and ligation of FcγR may serve to 
strengthen the attachment of opsonized particles while further downstream 
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signaling events dictate the activity and intensity of actin dynamics and 
subsequent uptake [77]. 
 
Current knowledge stipulates that regulation of FcγR expression is mediated 
through inflammation. That is, the presence of pro-inflammatory cytokines or 
mediators such as IFN-γ, TNF or lipopolysaccharide enhances the surface 
expression of Fcγ receptors [78]. As IgG competes with equal affinity for the 
activating FcγR as for the inhibitory FcγR, cells express activating FcγR at 
higher levels during inflammation in order to favour their binding [65]. While 
inflammation levels decrease and activating FcγR become occupied or 
internalized, inhibitory FcγR are ligated more frequently [79]. Ligation of 
inhibitory FcγR leads to phosphorylation of its ITIM motif and the 
recruitment of phosphatases including the tyrosine phosphatase SHP [66]. 
SHP inhibits downstream signaling of activating FcγR by dephosphorylating 
the ITAM motif, as well as inactivating SYK and PI3K leading to reduced 
expression of activating FcγRs and general dampening of immune responses 
[66].  
 
The regulation of FcγR expression is also mediated by complement. Increased 
expression of activating Fcγ receptors is dependent on the presence of C5a, an 
anaphylactic protein activated in the final stages of the complement cascade 
[80]. Similarly, the production of C5a protein is dependent on the presence of 
Fcγ receptors [81] suggesting that complement acts in a way that regulates 
FcγR expression and vice versa.  
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1.2.2 Complement receptors 
Complement receptors form part of the complement system. There is a range 
of complement receptors, mostly involved in the regulation of complement 
activation but also in complement’s role of initiating inflammation, 
chemotaxis and adhesion [82]. Currently, five receptors are known to be 
actively involved in phagocytosis. These are CR1, CR3 (a.k.a. Mac-1), CR4, 
CRIg and C1qR (Figure 9) [25, 82, 83]. The localization of these receptors 
differs. CR1, is present on leukocytes and erythrocytes [84], CR3 on all 
phagocytes while CRIg is present only on macrophages [85]. 
 
 
 
Figure 9 - Complement receptors CR1, CR3, CR4, CRiG and C1qR are involved in the phagocytosis of 
complement opsonised pathogens. Figure adapted from [82] 
 
Current knowledge on the signaling pathways and effector function of 
complement receptors is limited. The best-studied complement receptor is 
CR3, which is able to bind to iC3b opsonized pathogens [24]. C3 has also been 
shown to initiate the phagocytosis of non-opsonized Pseudomonas aeruginoas 
[86]. In contrast to Fcγ receptors, ligation of complement receptors is not 
sufficient to initiate phagocytosis. Instead, phagocytic cells require prior 
activation in order to initiate phagocytosis via complement receptors [82]. 
Similarly to Fcγ receptors, however, CR3 signaling has recently been shown 
to be dependent on phosphorylation of SYK protein kinases [87] but 
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phagocytosis in SYK knockout macrophages still occurs suggesting a less 
important role for SYK phosphorylation in complement receptors than in Fcγ 
receptors [88]. As complement receptors have many more functions than 
phagocytosis, including the regulation of complement and activation of other 
immune cells [82], the exact nature of complement receptor mediated 
phagocytosis remains to be elucidated. 
 
1.2.3 Non-specific receptors 
Molecules found on microorganisms, but not on mammalian cells, which are 
generally essential to the structure or survival of the microorganism are called 
pathogen associated molecular patterns (PAMPs). These highly conserved, 
repeating structures are in turn recognized by Pattern Recognition Receptors 
(PRR) on immune cells. PRRs can be divided into endocytic PRR, where 
ligation results in phagocytosis, and signaling PRR, where ligation results in 
intracellular signaling. Common endocytic PRR found on phagocytes are C-
type lectins and scavenger receptors while common signaling PRR include 
toll like receptors (TLRs) and Nod like receptors (NLRs).  
 
Toll like receptors (TLR) are a family of proteins that play an essential role in 
the recognition of a wide variety of PAMPs [89]. There are currently 10 
known human toll like receptors (TLR 1-10) expressed in various cells 
including monocytes, macrophages, neutrophils, dendritic cells, B-cells as 
well as epithelial cells [90, 91]. Surface expressed TLRs (TLR 1, -2, -4, -5, and -
6) are responsible for the recognition of bacterial products while TLRs 
localized into intracellular compartments (TLR 3, -7, -8 and -9) recognize viral 
products [92]. Ligation of TLRs leads to a complex signaling cascade specific 
to each TLR [93] resulting in activation of many transcription factors 
including nuclear factor (NF)-κB, a classical, proinflammatory gene 
transcription regulator [92-94].  There is debate as to the role TLRs play in 
phagocytosis. TLR ligation up-regulates genes responsible for autophagy 
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(degradation of intracellular proteins using phagosomes) [95] and aids during 
phagosome maturation [96] as well as up-regulating receptors required for 
phagocytosis (FcR, complement, Scavenger receptors) [97, 98]. TLR-
independent phagosome maturation, however, has also been reported [99]. 
While TLR ligation alone does not lead to uptake, it plays an important role in 
phagocytosis by activating immune cells through the recognition of 
pathogens and indirectly enhancing the process of phagocytosis [100-102].  
 
C-type lectins (CL) are a large family of proteins that able to recognize and 
bind sugar moieties on bacteria [103, 104], fungi [105], and viruses [106]. 
Binding was originally thought to be dependent on the presence of Ca2+ but 
several CL have shown to bind independent of this [43]. The best-studied C-
type lectin is the mannose receptor (MR). MRs are able to bind to repeating 
patterns of mannosyl- and fucosyl-containing glycoproteins, structures which 
are commonly found on yeast and certain bacteria including M. tuberculosis 
and S. pneumoniae [107]. MRs were originally believed to be restricted to 
macrophages but have since been detected on a variety of epithelial cells as 
well as monocyte derived dendritic cells [108, 109]. MR expression is 
modulated by cytokines including IL-4, IL-13, IL-10 (increased expression) 
and IFN-γ (decreased expression) [110]. Ligation of MRs in some studies led 
to phagocytosis [111] but it is generally accepted that receptor ligation assists, 
as opposed to being essential, in phagocytosis [112, 113]. Other 
transmembrane C-type lectins include DC-SIGN which binds fungi [105] and 
dectin which can bind yeast [114]. 
 
Scavenger receptors (SR) are transmembrane proteins able to detect and bind 
to lipopolysaccharide (LPS) and teichoic acid frequently found on bacterial 
pathogens. SRs also bind to apoptotic cells and some pathogens [115] as well 
as mop up, or “scavenge” small molecules. Scavenger receptor A (SR-A) and 
MARCO are the best studied. It has been shown that SR-A readily binds to 
lipoteichoic acid (LTA), a molecule frequently found on Gram(+) bacteria 
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[116]. Macrophages, which contain a range of SR, are able to bind to 
Staphylococcus aureus via SR-A leading to rapid phagocytic uptake of the 
pathogen [117, 118].  
 
MARCO is a SR that is structurally similar to SR-A, but has the ability to bind 
gram-negative as well as gram-positive bacteria [119]. The molecular 
signaling pathways initiated by SRs still need to be elucidated but it has been 
shown that LPS activation and phagocytosis leads to rapid up-regulation of 
MARCO and SR-A expression [119, 120]. In line with other non-specific 
phagocytic receptors, the role of SR may serve to enhance the immune 
response to infection as opposed to having primarily antimicrobial functions. 
 
1.3 Phagocytic uptake and killing 
Following opsonisation by plasma proteins and the recognition of opsonized 
molecules by phagocytic receptors, phagocytes begin the task of taking up 
and degrading the bacteria. The uptake is mediated through actin while the 
killing of pathogens occurs in matured phagolysosomes. 
 
1.3.1 Phagosome formation 
FcγR and complement ligation leads to a clustering of receptors, de novo actin 
polymerization and the branching of new actin filaments. In the case of FcγR, 
this is mediated through Arp2/3 complexes engaging with Rho proteins, 
responsible for actin polymerization, while C3 receptors engage directly with 
Rho proteins [121].  Actin polymerization guides the cell membrane around 
the pathogen to be phagocytosed allowing additional opsonins to engage in a 
zipper-like fashion with clustered Fcγ and complement receptors.  Once fully 
engulfed, the membrane-bound vacuole containing the pathogen, termed the 
phagosome, is internalized and detached from the cell main membrane [71]. 
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The phagosome is not initially able to kill pathogens as it is primarily 
composed of the plasma membrane from which it was derived and its fluid 
contents reflect the extracellular milieu [122]. As such, the phagosome is 
rapidly modified to become a potent anti-microbial compartment, called the 
phagolysosome, able to kill and degrade internalized pathogens. This is a 
complicated multi-step process involving fusion, acidification and activation 
of enzymes [123]. In general terms, the degradation of bacteria following 
phagocytosis can be divided into oxygen-dependent and oxygen-independent 
processes. 
 
1.3.2 Oxygen dependent degradation 
The respiratory burst (oxidative burst) is the consumption of oxygen and 
glucose to produce reactive oxygen species (ROS) during phagocytosis. ROS 
can non-specifically oxidize proteins, lipids, DNA and carbohydrates as well 
as destroy iron–sulphur centres used in the respiratory chains of 
microorganisms [124]. In neutrophils and macrophages, ROS are generated 
through the activation of enzymes, including Phox and NADPH oxidase. 
Phox is an enzyme complex generated during phagosome maturation while 
NADPH oxidase is a membrane bound enzyme activated during 
phagocytosis [125]. Both enzymes are capable of transferring electrons from 
NADPH to oxygen. This reaction creates the ROS superoxide, hydrogen 
peroxide, hydroxyl radicals and a variety of their by products. In neutrophils, 
fusion of granules into phagosomes causes the release of the granule 
myeloperoxidase, which utilizes hydrogen peroxide and chlorite to produce 
the highly toxic compound hypochlorite [126]. Individuals unable to initiate 
an oxidative burst are affected by chronic granulomatous disease (CGD) and 
exemplify the importance of oxygen dependent degradation of bacteria in 
phagocytosis. These individuals frequently succumb to bacterial infections, as 
they are unable to properly clear pathogens [127]. 
Chapter I  Introduction 
24 
1.3.3 Oxygen independent degradation 
There are more than 100 proteins taking part in the degradation of 
internalized bacteria in phagosomes [123]. These range from cationic proteins 
which damage microbial membranes, lysozyme which splits the mucopeptide 
in the bacterial wall, lactoferrin which sequesters the iron essential for 
bacterial survival and a range of hydrolytic enzymes which break down 
bacterial proteins [128]. While enzymatic degradation helps in the breakdown 
of bacteria, it is generally believed that the respiratory burst accounts for most 
of the killing [127].   
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B. Phagocytes 
 
2.1 Phagocytes 
Phagocytes form the first line of defence against pathogens. They are either 
already present at the site of infection or migrate in large numbers to the site 
of infection to assist other resident phagocytes during inflammation. Through 
their ability to detect and kill pathogens, release inflammatory mediators and 
present antigens to antibody producing cells, phagocytes are important 
orchestrators of the immune response to infection. 
 
2.1.1 Professional and non-professional phagocytes 
Phagocytic cells are divided into professional and non-professional 
phagocytes. Professional phagocytes possess a range of receptors necessary 
for efficient and effective phagocytosis. Important phagocytic cells include 
monocytes, macrophages and neutrophils. The other professional phagocytes 
(dendritic cells, basophils and eosinophils) have primary roles other than the 
clearance of pathogens. Non-professional phagocytes, such as epithelial cells 
and fibroblasts, can also engulf particles but lack specialized receptors 
making them less effective. For the purpose of this thesis, monocytes, 
macrophages and neutrophils will be reviewed with respect to their functions 
of migration and phagocytosis to clear pathogens.  
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2.1.2 Phagocyte hematopoiesis 
Hematopoiesis is the process by which stem cells in the bone marrow 
differentiate into blood cells including monocytes and neutrophils. Stem cells 
commit early on to become either monocytes via differentiation into 
monoblasts, or polymorphonuclear leukocytes (PMNL - neutrophils, 
eosinophils, basophils) via differentiation into myeloblasts.  
 
The production of monocytes takes approximately 1.5-3 days and involves 
differentiation from monoblasts to pro-monocyte and then into early 
monocytes through stimulation with monocyte colony stimulate factor (M-
CSF) and fms-like tyrosine kinase 3 ligand (Flt3-ligand) [129]. The production 
of PMNL takes approximately two weeks and involves differentiation into 
five cell types mediated by myeloid-specific growth factors (G-CSF and GM-
CSF). In the first week, myeloblasts differentiate to pro-myelocyte and then 
into myelocytes. The second week of differentiation leads to metamyelocytes, 
then into band forms and finally into PMNL, which enter the bloodstream 
terminally differentiated. In comparison, monocytes have the ability to 
further differentiate into tissue specific macrophages and dendritic cells. 
 
A simplified schematic of phagocyte hematopoiesis is shown in Figure 10.  
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Figure 10 – Simplified schematic of the origin, differentiation and localization of neutrophils, 
monocytes, macrophages and dendritic cells. Self-renewing hematopoietic stem cells replenish 
phagocytes of the innate immune system. Following differentiation into myeloid progenitors, 
monocytes are formed via differentiation into monoblasts. Granulocytes (shown as neutrophils) are 
formed via differentiation into myeloblasts. Monocytes and neutrophils exit the bone marrow into 
blood as differentiated cells. In a steady state, monocytes further migrate to tissue where they patrol 
tissue or differentiate into dendritic cells or macrophages. A large proportion of monocytes also 
migrate to the spleen to form a splenic monocyte reservoir. Neutrophils remain in the blood 
circulation until they apoptose or are recruited to a site of infection.  
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2.2 Monocytes 
Monocytes form part of the mononuclear phagocyte system (MPS) and can 
differentiate into dendritic cells and macrophages. Monocytes are usually 
identified by their large, invaginated nucleus following staining (Figure 11).  
 
 
Figure 11 - Circulating blood monocytes. (A) Scanning electron microscope image of a human blood 
monocyte. Adapted from Microscope Service of Universidad Autònoma de Barcelona (UAB). (B) 
Transmission electron micrograph image of a transverse section of a murine blood monocyte 
showing the invaginated nucleus characteristic of monocytes. TEM Image taken as part of this thesis. 
 
Monocytes are continuosly produced in the bone marrow and remain in the 
blood-stream for 1-3 days [130]. The function of monocytes is broad including 
replenishing tissue macrophages through differentiation, immune 
surveillance, promotion and resolution of inflammation and phagocytic 
clearance of pathogens [131, 132]. In the absence of infection, monocytes 
circulate in the blood, making up approximately 10% of circulating immune 
cells in humans (4% in mice), but are also stored in the bone marrow and 
spleen as a reservoir [133]. Monocytes give rise to macrophages and dendritic 
cells through differentiation during inflammation [134]. There are ongoing 
discussions in the description of monocyte subsets in murine and human 
hosts. A general distinction, however, can be made by classifying monocytes 
into resident and inflammatory monocytes. 
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2.2.1 Resident monocytes 
Resident monocytes constitute a minority of monocytes in humans (10-20%) 
and approximately half of all monocytes in mice [134]. They are recruited to 
all noninflamed tissues where they patrol or differentiate into a range of 
macrophages as shown in Figure 12.  
 
 
 
Figure 12 – Resident monocyte migration and differentiation into macrophages in the absence of 
infection. (1) Blood monocytes entering tissue differentiate into macrophages and either (2) adhere to 
the endothelium or enter tissue and (3) line/fix themselves to the perivascular endothelial layer. 
Differentiated macrophages in tissue can then (4) enter the lymphatic system via afferent lymph 
nodes or (5) adhere and fix themselves to epithelial layers. (6) Macrophages can further migrate 
within tissue to serosal spaces where they scavenge as free macrophages. Figure adapted from (DA 
Hums, DA Hughes). 
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Replenishment of tissue macrophages is not the only role of resident 
monocytes. During early inflammation, they secrete high amounts of pro-
inflammatory cytokines TNF-alpha and IL-1 in order to recruit other 
leukocytes and begin phagocytosing bacteria [135, 136]. Resident monocytes 
posess the phagocytic receptors FcγRI (CD16), FcγRII (CD32), FcγRIII (CD16), 
as well as complement and scavenger receptors resulting in high phagocytic 
activity [135]. In the later stages of inflammation, resident monocytes can 
switch to anti-inflammatory secreting cells and promote wound healing and 
angiogenesis [137]. 
 
2.2.2 Inflammatory monocytes 
Inflammatory monocytes constitue the majority of monocytes in humans (80-
90%) and make up half of all monocytes in mice [131]. During early 
inflammation, inflammatory monocytes are released from the bone marrow 
and splenic monocyte reservoir in response to CCL2 in blood [138]. 
Inflammatory moncytes express high levels of the C-C-receptor motif 2 
(CCR2) allowing them to respond quickly to CCL2, which is released during 
inflammation by monocytes, macrophages and dendritic cells [139]. As 
inflammatory monocytes are released from the bone marrow and spleen, they 
are recruited to affected tissues and draining lymph nodes using adhesion 
molecules present on both the monocyte (LFA-1) and epithelial cells (ICAM-1) 
[140]. Murine inflammatory monocytes are efficient at phagocytosing 
opsonized pathogens and subsequently initiate an inflammatory response 
[141, 142]. Human inflammatory moncytes are also effective at phagocytosis 
but respond to LPS through the secretion of anti-inflammatory cytokines 
including IL-10 suggesting that a regulatory role is assumed following 
recruitment and later in inflammation [136]. 
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2.2.3 Resident and inflammatory monocytes 
The interplay between resident and inflammatory monocytes has been 
thoroughly studied using murine models of disease and is shown in Figure 
13. Resident monocytes recognize invading pathogens through PRR and 
immediately begin phagocytosing bacteria and secreting pro-inflammatory 
cytokines to recruit leukocytes [130]. As inflammatory monocytes arrive to 
the site of infection, they express phagocytic receptors and begin clearing 
pathogens through phagocytosis and secretion of inflammatory cytokines 
[136]. Following the arrival of inflammatory monocytes, resident monocytes 
resume an anti-inflammatory role and begin the process of angiogenesis and 
clearance of apoptotic cells through the secretion of anti-inflammatory 
cytokines [130, 132, 135].  
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Figure 13 - Different roles and responses of resident and inflammatory monocytes to infection. 
Resident monocytes patrol the blood stream and tissue for potential pathogens. In case of an 
encounter, resident monocytes immediately begin phagocytosing and initiating an inflammatory 
response. This results in the influx of inflammatory monocytes that assist in bacterial clearance via 
phagocytosis and further inflammatory responses. Upon arrival of inflammatory monocytes, resident 
monocytes assume a wound repair, tissue remodeling and immunomodulatory role. Figure adapted 
from [131]. 
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2.3 Macrophages 
Macrophages are specialized phagocytic cells present in virtually all tissue 
that are derived from monocytes infiltrating into tissue during steady state 
and inflammation [134]. A common misconception is that macrophages are 
predominantly cells of the immune system. While they form an essential part 
in the defense against infection, macrophages are highly versatile assisting in 
tissue development, remodeling and repair in addition to immune 
surveillance. The wide range of tissue specific macrophages and their 
function in humans is shown in Figure 14.  
 
 
Figure 14 – Macrophages and their localization & function in the human body. Macrophages have 
many different functions depending on the tissue in which they reside. Common functions include 
tissue development and repair or immune surveillance. Areas of the body frequently exposed to the 
outer environment, such as the lungs and digestive tract, demand good immune surveillance and as 
such macrophages in these tissue have immune surveillance as their primary function (boxes). Other 
parts of the body, such as the spleen, strategically contain macrophages to monitor for pathogens in 
the circulatory system. The majority of macrophages however have functions that are essential for 
the homeostasis of the human body. Figure adapted from macrophages.com 
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The importance of macrophage function outside of the immune system is 
exemplified by mice deficient in colony-stimulating factors essential for the 
development and differentiation of macrophages [143]. In these mice, the 
development of the pancreas and nervous system as well as their fertility is 
detrimentally abnormal [143, 144].  
 
2.3.1 Macrophage phagocytosis 
Macrophages are prolific phagocytes. They possess a wide range of receptors, 
including PRR, MR, FcR and complement receptors that help decide on the 
outcome of phagocytosis [145, 146]. During steady state, macrophages 
scavenge cellular debris generated through tissue remodeling and remove 
apoptotic cells as well as red blood cells [147]. It is estimated that 2x1011 red 
blood cells are phagocytosed by macrophages each day, resulting in 
approximately 3 kg of iron and haemoglobin recycled per year [148]. Should a 
macrophage encounter a pathogen through phagocytic receptors, however, 
they change from being cells assisting in homeostasis to cells actively 
participating and orchestrating the immune response to infection [149]. In 
contrast, the phagocytosis of debris generated through tissue remodeling does 
not engage pathogen related phagocytic receptors and they remain cells 
participating in tissue homeostasis.  
 
2.3.2 Macrophage populations 
Following the engagement of PRR, macrophages can become either classically 
activated, wound healing or regulatory macrophages [150]. Classically 
activated macrophages have high antimicrobial capacity and perform the 
majority of phagocytic clearance of pathogens during infection as well as 
secreting pro-inflammatory cytokines [151]. Macrophages become classically 
activated in the presence of TNF and IFN-γ, cytokines produced by natural 
killer cells, T-helper cells and by nearby macrophages or in an autocrine 
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manner in the presence TLR stimulation [152]. Wound healing macrophages 
actively participate in reverting the damage caused by pathogens and the 
immune response. They are activated through exposure of IL-4 and IL-13; 
cytokines produced following tissue damage by PMNL and T-helper cells 
[153]. Wound healing macrophages have, for example, high arginase activity 
allowing them to mediate collagen formation for the production of 
extracellular matrices used to rebuild tissue [154]. Regulatory macrophages 
participate in the resolution phase of inflammation, having the ability to 
phagocytose apoptotic cells and restoring immune homeostasis thereby 
limiting the “collateral damage” [155]. They are activated through the 
exposure to IL-10 [156], a cytokine produced by, for example, regulatory T-
cells as well as by macrophages following the phagocytosis of apoptotic cells 
[157] and immune complexes [158].  
 
2.3.3 Alveolar macrophages 
Alveolar macrophages (AM) are the specialized macrophages of the lung and 
play a major role in the innate response against infections that spread to the 
distal airways [159]. They are responsible for clearing pathogens and 
recruiting other phagocytes during respiratory disease. The infiltration of 
phagocytes and other effector immune cells into the lungs, however, can 
cause severe damage to tissue and hinder gas exchange. AMs therefore need 
to carefully regulate immune responses to avoid unnecessary activation. This 
is challenging as the human lung is frequently exposed to smoke, toxic gases, 
particulate matter and other non-pathogenic antigens that can inflame tissue 
and cause “false positives”. In order to prevent this, AMs actively suppress 
their inflammatory activation through the down-regulation of phagocytic 
receptors [160].  In addition, AMs suppress the initiation of adaptive immune 
responses and prevent excessive inflammatory reactions to otherwise 
harmless antigens, as demonstrated in mouse models depleted of AMs which 
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show excess inflammation with both models of allergic and infection 
challenges [161].  
 
The regulation of alveolar macrophages is mediated through the lung 
environment. AMs adhere to alveolar epithelial cells (AEC) in non-
inflammatory conditions. This leads to the expression of αvβ6, an integrin 
able to suppress macrophage function via the activation of TGF-β [162]. When 
AMs encounter a pathogen through PRR, they detach from AEC leading to 
the rapid down regulation of αvβ6 and therefore TGF-β mediated immune 
suppression. This allows AMs to initiate immune responses including 
phagocytosing pathogens, secreting the pro-inflammatory cytokines IL-6 and 
TNF and recruiting phagocytes [163]. Immune suppression is re-instated 
when activated T-cells or inflammatory monocytes, who have assumed an 
anti-inflammatory role, encourage AMs to produce MMP-9, an activator of 
TGF-β, leading to their adhesion to AEC and subsequent expression of αvβ6 
[163].  
 
2.4 Neutrophils 
PMNL (Polymorphonuclear Leukocyte or granulocytes) include basophils, 
neutrophils and eosinophils and are cells in which small granules, as well as 
variably shaped nucleus, are visible in the cytoplasm (Figure 15). Neutrophils 
are the most abundant of all granulocytes making up approximately 50-70% 
of all circulating white blood cells and are the most important phagocytic 
granulocyte. In comparison, basophils and eosinophils make up 2-5% and 0.5-
1% of total white blood cells, respectively.  
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Figure 15 - Granulocytes (also known as polymorphonuclear cells) showing their characteristic 
granules in the cytoplasm and varying shapes and sizes of nuclei. 
 
Neutrophils exit the bone marrow as differentiated cells and, if left 
inactivated, circulate in the blood for an average of 5.4 days [164]. During 
inflammation, macrophages and epithelial cells, amongst other cells, secrete 
chemokines including formyl-methionylleucylphenylalanine (FMLP), 
leukotriene B4 (LTB4), and interleukin-8 (IL-8). These activate neutrophils and 
trigger their rapid migration in a gradient dependent fashion to the source of 
inflammation [165]. Protein expression is modulated during migration 
leading to cells becoming “sticky” and initiating a rolling motion through the 
forming and breaking of bonds between proteins expressed on neutrophils 
(integrins) and on epithelial cells (E-selectins, ICAM) close to the site of 
infection. Important integrins include the CD18 integrins LFA-1 
(CD11a/CD18) and Mac-1 (CD11b/CD18), as well as the CD29 integrin α4β1 
(CD49d/CD29), which bind to ICAM-1 [166]. Once at the high end of the 
chemokine gradient, tight adhesion occurs allowing the neutrophil to arrest 
movement and transmigrate into tissue through a process called diapedesis 
[166]. This process is also facilitated by increased vasodilation, increased 
permeability and blood flow as a result of inflammation. Once inside 
inflamed tissue, neutrophils phagocytose bacteria, release granules, form 
extracellular traps and modulate further immune responses. The lifespan of 
neutrophils in inflamed tissue averages between 1-2 days before they 
apoptose [167].  
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2.4.1 Neutrophil phagocytosis 
Inside inflamed tissue, neutrophils perform the crucial role of removing 
pathogens though phagocytosis.  Neutrophils express the major phagocytic 
receptors FcγRIIa and FcγRIIIB as well as complement receptor C3 while 
FcγRI is only expressed following TNF-alpha stimulation [168]. The 
importance of neutrophils in disease is exemplified in murine models of S. 
pneumoniae, K. pneumoniae and L. pneumophila, where depletion of neutrophils 
in otherwise resolving infection leads to host death [169-171].  
 
2.4.2 Neutrophil granules 
Neutrophils contain approximately 300 proteins (granules) classified into 
secretory, primary (azurophilic), secondary (specific) and tertiary granules 
[126]. These can either be shuttled into the membrane to act as ligands during 
migration, secreted to target extracellular pathogens at the site of infection 
(degranulation), or be shuttled into phagosomes to aid in the breakdown of 
phagocytosed pathogens [172].  Upon entering inflamed tissue, a short period 
of restraint ensues (15-45 minutes in vitro), prior to degranulation [173]. The 
period of restraint ensures that degranulation does not occur unnecessarily as 
it can be severely damaging to the host. Elastase, a primary granule for 
example, can deactivate virulence factors present on enterobacteria [174, 175] 
but also affects tissue integrity through the digestion of E-cadherin [176] 
which has been associated with the development of emphysema [177]. This, 
however, also aids in removing barriers of neutrophil-bacterial contact and to 
block escape routes for pathogens as well as leading to the leakage of serum 
proteins, such as complement and antibodies, into inflamed tissue [178].  
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2.4.3 Neutrophil extracellular traps 
Neutrophils undergo cell death specifically to form extracellular matrices 
(called neutrophil extracellular traps; NET) that can entrap and kill pathogens 
[179]. Figure 16 shows the release of NETs by neutrophils to entrap bacterial 
pathogens. 
  
 
Figure 16 - Neutrophil extracellular traps (NET) are formed through programmed cell death in order 
to entrap and kill pathogens. (A) In vitro stimulation of human neutrophils leads to NET formation 
entrapping Staphylococcus aureus (N=neutrophil). Image reproduced from [180] (B) Scanning 
electron micrograph of in vivo NET formation in a murine lung infected with Klebsiella pneumoniae. 
Image reproduced from [181]. 
 
Activation via phorbol myristate acetate (PMA), IL-8, lipopolysaccharide or 
whole pathogens leads to the formation of NET through a novel pathway of 
programmed cell death, termed ETosis [182]. DNA and histones released by 
neutrophils undergoing ETosis form the backbone of NETs while secreted 
neutrophilic granules such as elastase, cathepsin G and myeloperoxidase bind 
to NETs and act as antimicrobial agents against any trapped pathogen [183]. 
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NETs are abundantly produced at sites of infection, including in the lining of 
alveoli during pneumonia [184] and in the middle ear during otitis media 
[185]. Not surprisingly, however, pathogens such as Streptococcus pneumoniae 
have developed methods to free themselves from NETs via the expression of 
endonucleases [184] and the production deoxyribonuclease (DNase) [186].  
 
2.4.4 Neutrophil Immunomodulation 
Cytokines and granules released by neutrophils at the site of infection can act 
in an immunomodulatory manner as shown in Figure 17.  
 
 
Figure 17 – Schematic diagram depicting examples of neutrophil immunomodulation in inflamed 
tissue (N=neutrophil, M=monocytes, B=B-lymphocyte, T=T-lymphocyte, D=pre-dendritic cells). (1) 
BlyS and (2) IFNγ secreted by neutrophils leads to the activation of B-cells and T-cells, respectively. 
(3) Cathepsin G, a granules secreted by neutrophils leads to the activation of Chemerin, a 
chemoattractant for monocytes and dendritic cells. (4) Apoptotic neutrophils are cleared by 
macrophages leading to reduced IL-23 secretion by macrophages. This in turn leads to reduced IL-17 
secretion by stromal cells in the bone marrow and therefore reduced secretion of G-CSF by 
neutrophil progenitors. G-CSF is important for the release of neutrophils from the bone marrow. 
1 
2
3
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Neutrophils secrete low amounts of cytokines on a per-cell basis, and are 
often overlooked as important contributors to cytokine signaling. During an 
infection, however, neutrophils are the predominant cell type in inflamed 
tissue and, as a group of cells, contribute significant levels of cytokines. 
 
B Lymphocyte stimulator (BLyS), a cytokine belonging to the TNF ligand 
family, is secreted by neutrophils and acts as strong activator of B-cells [187]. 
Similarly, TNF-α is secreted in order to stimulate T-cell and monocyte 
activity. These combine to augment the adaptive immune response to 
infection. Granules also play an important role in the recruitment of immune 
cells to the site of infection. Azurophilic granules, such as azurorcidin, act as 
direct chemoattractants for mononuclear phagocytes and granulocytes [188, 
189]. Cathepsin G is able to convert prochemerin, a weak chemoattractant, 
into chemerin, a potent chemoattractant for granulocytes [190]. In addition to 
recruiting more cells to the site of infection, neutrophils can also indirectly 
limit their recruitment through programmed cell death. Uptake of apoptotic 
neutrophils by macrophages leads to the secretion of IL-23 and, through a 
signaling cascade, the retention of neutrophils in the bone marrow [191]. 
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C. Respiratory infections 
 
When pneumonia is at its height, the case is beyond remedy if he is 
not purged, and it is bad if he has dyspnoea, and urine that is thin 
and acrid, and if sweats come out about the neck and head, for such 
sweats are bad, as proceeding from the suffocation, rales, and the 
violence of the disease which is obtaining the upper hand. 
Hippocrates, ~ 460 BC – 370 BC 
 
3.1 Lungs: entry point for pathogens 
The above quotation shows that respiratory tract infections have long been a 
clinical problem. In order to understand why the human lung is frequently 
affected by pathogens, one must appreciate the level of exposure the 
respiratory tract is subjected to on a daily basis. Given a rate of 12-16 breaths 
per minute, it can be estimated that an adult breathes on average 17,000 – 
23,000 times a day. In the same time, approximately 7,200 liters of blood pass 
through the lungs for gas exchange on a surface area estimated to be about 
70m2 [192]. Gas exchange requires close contact between the inhaled oxygen 
and circulating blood and as such the body is physically only protected by a 
thin membrane in the lung compared to the multilayered protection afforded 
by human skin. This, alongside the temperature and humidity at which air 
enters the lung (37°C, 100%) creates an ideal setting for pathogens to enter the 
host and flourish. 
 
3.2 Pneumonia 
Pneumonia is defined as infection and inflammation leading to alveolar 
consolidation of the lung that can be caused by bacteria, viruses, fungi and 
parasites. Very young, old and immunocompromised populations are most 
frequently affected by pneumonia. The most common bacterial cause of 
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pneumonia is Streptococcus pneumoniae, alongside Haemophilus influenzae and 
Staphylococcus aureus. Pathogens enter the lungs either via direct inhalation or 
by seeding from biofilms of the nasopharynx. The presence of a pathogen in 
the lung is detected by alveolar macrophages or by pulmonary dendritic cells 
and causes the recruitment of leukocytes and inflammation. This leads to 
consolidation (fluid) in the alveoli, which hinders proper gas-exchange and 
interrupts the vital oxygen supply to tissues. Bacteria are the most common 
cause of pneumonia and these patients frequently have preceding or 
concurrent viral infections, particularly in immunocompromised individuals 
[193].  
 
3.2.1 Childhood pneumonia 
Pneumonia is listed by the WHO as the primary cause of child (<5yrs) deaths 
worldwide with >1 million deaths each year. It is estimated that 7-13% of 
childhood pneumonias progress to severe life-threatening diseases [194].  
There are up to 155 million new cases of childhood pneumonia each year 
where the majority is in developing countries (Table 1) [195].  
 
Table 1 - Estimated yearly new cases of childhood pneumonia by world regions. Adapted from [194] 
World Region 
Estimated no. 
new cases per 
year (millions) 
African 35.12 
Americas 7.84 
Eastern Mediterranean 19.67 
European 3.03 
South-East Asia 60.95 
Western Pacific 29.07 
Total  
for developing countries 
151.76 
Total  
for developed countries 
4.08 
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3.2.2 Adult pneumonia 
Although pneumonias are most frequent in children, adults are also 
susceptible where the risk of infection increases with age and is highest in 
populations >65 years [196]. 10-20% of cases of pneumonia in adults require 
hospitalization [197]. The 30-day mortality rate in adult patients admitted to 
ICU in the UK was 23-35% in 2008 and all-cause mortality as high as 28% 
[198].  
 
3.2.3 Sepsis secondary to pneumonia 
Sepsis secondary to pneumonia is caused when respiratory infections cannot 
be contained in the lung by the immune system. When bacteria enter the 
normally sterile blood circulation, an immense inflammatory reaction is 
initiated leading to and exaggerated immune response and potential organ 
failure. In developed countries, approximately 10% of hospital admissions of 
pneumonia are bacteraemic where 60% of these cases are caused by S. 
pneumoniae [199-202]. In the US sepsis is a common and frequently fatal 
condition, with as many deaths annually as those from acute myocardial 
infarction [203]. It is especially common in the elderly and is likely to increase 
substantially as the U.S. population age [203]. Since the 1980s, Gram(+) 
bacteria have been the most commonly isolated bacteria in sepsis in the US 
[204].  
 
3.2.4 Costs of pneumonia and sepsis 
The direct healthcare costs associated with pneumonia in the UK are high, 
previously estimated at £441 million annually [205].  The annual cost of 
treating pneumonia in the US is estimated to be $4.8 billion for patients aged 
>65 years and $3.6 billion for patients aged <65 years [206]. The estimated 
annual total cost of treating sepsis in the US were $16 billion nationally [203] 
and £2.5 billion in the UK. Pneumonia and sepsis secondary to pneumonia is 
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a significant health problem in children and adults and is associated with the 
use of extensive healthcare resources, occupying 30% of ICU beds in the UK 
[207].  
 
3.5 Streptococcus pneumoniae 
Streptococcus pneumoniae (pneumococcus), is the main cause of bacterial 
pneumonia, one of the leading causes of infectious disease deaths in sub-
Saharan Africa, and the biggest killer of children < 5 years worldwide [208]. S. 
pneumoniae was first discovered in 1881 by Louis Pasteur in France [209] and 
George Sternberg in the US [210] after injecting human saliva into rabbits and 
demonstrating pneumococci as the pathogen causing bacteraemia. This 
indirectly led to the development of the Gram stain in 1884 [211] which 
allowed for improved identification of pathogens in tissue preparations. 
Using the Gram stain it was established that in the late 19th and early 20th 
century, S. pneumoniae was the causative pathogen of most human lobar 
pneumonias [212, 213] as well as meningitis [214] and otitis media [215].  
 
3.5.1 Microbiology 
Originally named Diplococcus pneumoniae due to its morphological traits [216], 
S. pneumoniae is a capsulated, Gram(+) diplococcus that grows in chains [217]. 
It has a repertoire of 95 known different thick polysaccharide capsules 
(serotypes) that cover the peptidoglycan cell wall [218]. The presence of 
capsule is critical to the pneumococcus as it is used to evade opsonisation, 
and subsequent phagocytosis [219]. In addition to capsule, S. pneumoniae 
possesses a range of protein virulence factors used for colonization and 
invasion of the host [220]. Table 2 gives an overview of the function and 
mechanism of a selection of these. Pneumococcal virulence factors are 
embedded in the polysaccharide capsule as shown in Figure 18.  
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Table 2 - Selected virulence factors of S. pneumoniae and their mechanism of virulence & bacterial 
function. 
Virulence Factor Mechanism of Virulence Bacterial Function Ref 
PspA Inhibition of Complement Stabilization of capsular charge [221] 
PspC Inhibition of complement Adhesion, binding to IgA & C3 [221] 
PsaA Inhibition of complement ABC transporter (Mn2+) [222] 
CbpA Inhibition of complement Adhesion [223] 
PavA Host barrier translocation Modulates virulence factors [224] 
Hyaluronate 
lyase 
Spreading Degrades connective tissue [225] 
Neuraminidase Biofilm formation Degrades important glycans [226] 
Pneumolysin Inflammatory Pore forming excreted toxin [227] 
Autolysin Inflammatory Cytolysin [228] 
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Figure 18 – Electron microscope and schematic image of Streptococcus pneumoniae. (A) Ferritin-
labeled pneumococci highlighting the polysaccharide capsule as a shadow. Black dots around and 
within the capsule show the presence of pneumococcal virulence factor PspA by use of anti-PspA 
immunogold antibodies. Adapted from © Barry Gray. (B) Schematic diagram of S. pneumoniae 
showing a selection of pneumococcal virulence factors embedded into the polysaccharide capsule. 
Virulence factors are used to adhere to epithelial cells or evade phagocytosis amongst other functions 
(see Table 2 for further detail). Adapted from [229] 
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3.5.2 Pneumococcal surface adhesin A (PsaA) 
As P4 peptide (see 4.2) is derived from Pneumococcal surface adhesin A 
(PsaA), this virulence factor will be reviewed in detail. PsaA is a highly 
conserved 37 kDa protein comprising of 309 amino acid residues. It is a 
virulence factor of S. pneumoniae and can be found embedded in the 
membrane of all pneumococcal serotypes. PsaA is an essential ABC 
transporter and is involved in the adhesion to epithelial cells. Pneumococci in 
which the PsaA gene has been knocked out have >80% less capacity to adhere 
to type II pneumocytes (A549 and Detroit 562 cell lines) than the parent strain 
[222]. PsaA− insertion deletion mutants of S. pneumoniae D39 were also 
significantly less virulent than S. pneumoniae D39 parent strain, as 
demonstrated in a low-dose intra-peritoneal (IP) challenge model in mice. 
This may be due to several known characteristics of PsaA− mutants, including 
their impaired growth in an Mn2+ deficient environment, their reduced 
capacity to adhere to lung cells, and their hypersensitivity to oxidative stress 
[230-232]. Amongst other proteins such as PspA, PspC, PLY and NanA, 
antibodies against PsaA are found in patients recovering from pneumonia, 
otitis media and invasive pneumococcal disease (IPD) and mice immunized 
with combinations of Pnc virulence proteins, including PsaA, survived longer 
than the control group after pneumococcal challenge [233]. PsaA is capable of 
provoking both the humoral and cellular lineage of the immune system. 
Zhang et al. (149) showed that B-cells capable of producing IgA, IgG, and IgM 
in response to PsaA were present in the adenoidal mononuclear cells (MNC) 
in children, thereby demonstrating the participation of humoral immunity 
against pneumococci. PsaA also augments the immune response through the 
priming of T-helper 1 (Th-1) immunity [234]. A 28 amino acid fragment of 
PsaA forms the peptide P4 (see chapter I, section 4.1).  
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3.5.3 Transmission 
S. pneumoniae is spread via intimate contact, aerosol droplets or large-droplet 
secretions from symptomatic and asymptomatic carriers [235]. The 
pneumococcus can also colonize hands and fomites [236], although this only 
contributes to a small percentage of infections due to short survival.  
Transmission occurs frequently in close contact settings such as day-care 
centres [237], nursing homes [238], schools [239] and prisons [240]. Highly 
infectious strains have been shown to be able to move from city to city [241] 
and country to country [242].  
 
3.5.4 Colonization  
Transmission of S. pneumoniae is followed by the colonization of the 
nasopharyngeal tract by the bacterium. In order to effectively colonize the 
nasopharynx, pneumococci down-regulate expression of the polysaccharide 
capsule to allow membrane proteins to interact and adhere to epithelial cells 
[243]. Pneumococci remain in the nasopharynx asymptomatically for a limited 
duration or invade the host causing pneumococcal diseases. Nasopharyngeal 
carriage is more common in children than in adults [244, 245] and is known to 
be higher in developing countries than those found in developed countries 
[246]. In the Gambia, carriage rates are as high as 80% among babies aged <1 
month, compared to 20% in the U.K [247]. Other developing countries such as 
Zambia, Pakistan and The Philippines also exhibit high carriage rates [246].  
 
3.5.5 Disease 
Following aspiration from the nasopharynx to the lower respiratory tract, 
pneumococci undergo phase variation to increase or reduces expression of 
capsule depending on its environment [248]. This process is assisted by 
pneumolysin [249], a virulence factor able to inhibit cilliary beating of 
epithelial cells [250]. Pneumococci then repeat the adherence and invasion 
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steps to bronchoepithelial cells using a variety of virulence factors. Invasion 
into the peribronchiolar space is facilitated by the activation and damage of 
epithelial cells through inflammatory mediators [251]. In vitro, S. pneumoniae 
have been shown to bind to type-2 alveolar cells leading to their transfer from 
the lungs into blood by modulating microfilament assembly [252]. In vivo, 
adherence and invasion of bronchoepithelial cells by 4 h post-infection was 
observed as well as varying levels of pneumococcal penetration and 
internalisation into host cells and translocation through epithelial layers [253]. 
Once in blood, pneumococci can infect all organs and cause sepsis or cause 
meningitis through the infection of the meninges via blood, or directly from 
the upper respiratory tract [244]. 
 
3.5.6 Treatment 
Antibiotics have been the treatment of choice for various diseases caused by 
S. pneumoniae and Penicillin has been the mainstay of treatment. Resistance 
rates to penicillin are rising with over one third of isolates in the US being 
affected, while Central Europe is seeing 10% resistance rates [254]. In Senegal, 
resistance rates are as high as 62% although significantly lower in Ivory Coast 
(22%) and Morocco (9%) [255]. Furthermore, treatment with antibiotics is not 
the optimal solution, however, as it can cause complications in some patients. 
Especially in children, pneumococci reach high levels in cerebrospinal fluid 
before symptoms begin to appear. Treating such patients with antibiotics 
causes a sudden release of cell wall fragments that are responsible for the 
damage seen in cases of untreated meningitis, leading to further inflammation 
and dangerously high levels of inter-cranial pressure [256].  
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D. Augmented passive immunotherapy 
 
4.1 Passive immunotherapy 
Passive immunotherapy (serum therapy) is the transfer of pre-formed 
antibodies from an immune individual to a naïve or vulnerable individual 
thereby transferring immunity. Behring & Kitasato first described passive 
immunotherapy in 1890 despite their limited knowledge of the structure and 
function of antibodies [2]. This marked the beginning of passive 
immunotherapy against a variety of infections including pneumonia, 
meningitis, mumps, measles, polio, Spanish flu and many more [257-259]. 
Passive immunotherapy was the standard treatment for lobar pneumonia in 
the early 20th century and was reported to reduce hospital mortality from 90% 
to 45% [257, 260]. The discovery of antimicrobial compounds in the 1930s, 
however, led to the disuse of passive immunotherapy (Figure 19). Antibiotics 
had several advantages: they were cheaper, less toxic and more effective. 
 
 
Figure 19 – Study by Austrian & Gold (1964) from a hospital in Brooklyn (NY, USA) showing 
survival from pneumococcal bacteraemia following treatment with penicillin (90%, n=298), serum 
(55%, n=93) or untreated (15%, n=384). Successes in the use of antibiotics to treat pneumococcal 
diseases contributed to the disuse of serum therapy [261]. 
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4.1.1 Historical serum production 
Use of animals for the generation of therapeutic serum was implicated in the 
development of “serum sickness”, probably caused by hypersensitivity 
reactions to non-human antibody proteins and failure to clear immune 
complex leading to deposition in small vessels. Serum sickness was reported 
in 10-50% of recipients and manifested itself with rashes, proteinuria, and 
arthralgia [258]. In addition, the logistical challenges and costs of animal 
husbandry, purifying and refrigerating antibodies further added to the disuse 
of serum therapy. Initially, studies showing improved efficacy using a 
combined treatment of antibiotics and serum in animal models of 
pneumococcal [262], meningococcal [263] and scarlet fever [264] suggested 
using serum as an adjunct therapy. This, however, was not adapted as other 
studies debated the efficacy of adjunct treatments and serum still remained 
difficult to obtain [257].  
 
4.1.2 Modern serum production 
Improvements in antibody processing did not materialize until 1975 with the 
development of hybridoma technology to produce unlimited amounts of 
monoclonal antibody (mAb) and more recently the development of 
humanized antibody technology (hAb) [265] which abolished the issue of 
“serum sickness” [266]. Furthermore, improvements in the isolation of 
antibodies from human sera have led to the development of intravenous 
immunoglobulin (IVIG), a purified and processed serum able to be 
administered intravenously without toxicity (Figure 20). To produce IVIG, 
blood is collected from volunteers or paid individuals in blood donor 
collection centres or source collection plasma centres. Serum is isolated from 
blood through either automated apheresis or fractionation [267]. Automated 
apheresis separates blood and plasma through density, centrifugation or 
affinity methods and results in Fresh Frozen Plasma (FFP) that is suitable for 
direct patient infusion or further processing for IVIG production. 
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Fractionation is a multistep process that renders soluble plasma proteins 
insoluble which can then be separated through centrifugation [267]. Serum 
obtained through this method needs further processing before it can be 
administered safely into humans. IVIG usually contains serum pooled from 
>1000 human donors. A recent study looked at the efficacy of collecting large 
amounts of serum during an H1N1 epidemic. They found that plasma could 
be collected at a rate of more than 2000 L/week and the final IVIG product 
contained H1N1 antibody titers substantially higher than those collected 
before the emergence of the pandemic H1N1 virus [268]. 
 
 
Figure 20 - Immune serum then and now. (A.) Vial of anti-diphtheria immune serum dated 1895. 
Immune serum was produced by inoculating horses or goats with increasing doses of diphtheria 
toxins. Serum was then collected and bottled without further processing. (B.) Today, serum is 
collected from >1000 human blood donors and antibody isolated through fractionation or apheresis. 
Isolated antibody is then processed to produce an immune serum able to be administered 
intravenously (IVIG). 
 
4.1.3 Passive immunotherapy today 
Today, passive immunotherapy to treat infectious disease is regaining interest 
due to the advent of multi-drug resistant infections and the improved 
methods of obtaining serum. Modern IVIG has a broad repertoire of anti-
carbohydrate antibodies [269] and also contains specific opsonizing 
antibodies against a range of pathogens including methicillin and 
vancomycin-resistant Staphylococcus aureus, vancomycin-resistant enterococci 
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and penicillin-resistant Streptococcus pneumoniae [270]. Gram(-) pathogens are 
also readily opsonised using modern IVIG [270]. The formulation of IVIG is 
such that, for example, anti-CMV, anti-Haemophilus influenzae and anti-
Streptococcus pneumoniae antibodies have a median half-life of 26.4 days 
following administration into humans [271]. 
 
IVIG is increasingly being used to treat infectious diseases in clinical settings. 
A recent meta-analysis of randomized controlled studies looking at the use of 
IVIG in treating sepsis of children and neonates concluded that exogenous 
immunoglobulin exerts a significant effect on mortality in sepsis and septic 
shock [272]. Similarly, a meta-analysis of studies looking at the use of IVIG to 
treat adult sepsis demonstrated an overall reduction in mortality with the use 
of IVIG for the adjunctive treatment of severe sepsis and septic shock [273]. 
Large-scale clinical trials are necessary, however, to determine the efficacy of 
current IVIG formulations in treating sepsis and stimulate further research in 
passive immunotherapy against infectious diseases. 
 
One problem of using passive immunotherapy against infectious diseases is 
the necessity for frequent and/or continual administration of antibodies. This 
limitation is partly due to the inherent kinetics of an immune response during 
passive immunotherapy [274]. It involves a wide range of cellular events 
including effector cells such as neutrophils, monocytes, macrophages, 
dendritic cells and T and B cells. The extent of immunological stimulation of 
the effector cells is greatly influenced by the quality and quantity of antigen 
specific antibodies. The kinetics of an immune response in passive 
immunization is therefore greatly influenced by the time taken by the effector 
cells to respond to the antibodies, which in turn determines the frequency and 
amount of antibody required [275]. Expediting the response time could lead 
to a rapid and efficient elimination of target pathogens [274]. 
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4.2 P4 peptide 
P4 is a 28-amino acid peptide fragment of the pneumococcal virulence factor 
PsaA. [276]. P4 contains a functional epitope for the adherence of PsaA to 
nasopharyngeal cells [276]. A 3D model of the P4 epitope within PsaA is 
shown in Figure 21. This epitope adheres to epithelial cells via a binding 
moiety on human E-Cadherin receptors (an important glycoprotein in 
calcium-dependent binding at tight junctions between epithelial cells) [277].  
 
Figure 21 - Three-dimensional structure of Pneumococcal surface adhesin A (PsaA, Protein Database 
ID: 1PSZ) with the immunomodulating peptide fragment P4, highlighted in blue (Residues 251-278). 
N = N-terminal. 
 
4.2.1 Structure  
P4 peptide sequence is highly conserved within PsaA proteins from all 
pneumococcal serotypes and also amongst several other bacterial species. The 
LpeA protein from Listeria spp. in particular exhibits remarkable similarities 
both in structure and function to PsaA. LpeA has recently been shown to be 
used by Listeria spp. to invade macrophages through mechanisms still to be 
elucidated [278]. Table 3 (adapted from [279]) shows the sequence homologies 
of P4 peptide to non-streptococcal proteins. With the exception for possible 
N 
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roles of binding and adhesion, other functional similarities remain to be 
determined for proteins other than LpeA.   
 
Table 3 - P4 sequence homology with non-streptococcal proteins. Adapted from  [279] 
Source organism Putative function Sequences producing significant 
alignments* 
S. pneumoniae P4 peptide sequence 251LFVESSVKRRPMKTVSQDTNIPIYAQIF278 
S. pneumoniae PsaA 245LFVETSVDDRSMETVSKETNVPIAGTIF272 
S. pneumoniae ABC transporter substrate-
binding protein 
251LFVETSVDDRSMETVSKETNVPIAGTIF278 
Bacillus 
anthracis 
Manganese binding 
protein and adhesin 
257LFVETSVDRRSMETVSKETNVPIAGTIF284 
B. cereus Adhesion lipoprotein 253LFVETSVDRRSMETVSKETNVPIAGTIF280 
B. cereus E33L Adhesion lipoprotein 253LFVETSVDRRSMETVSKETNVPIAGTIF280 
Listeria innocua Adhesion binding protein 
and ABC transporter 
252LFVETSVDPRSMETVSKETNVPIFAKIF279 
L. 
monocytogenes 
Adhesion binding protein 
and ABC transporter 
252LFVETSVDPRSMETVSKETNVPIFAKIF279 
Leuconostoc 
mesenteroides 
ABC transport protein and 
adhesin 
255LFVESSVSPKAMEKVSKETGLPIYSKIY282 
 
 
4.2.2 Functions in vitro 
P4 peptide has been shown to activate human nasopharyngeal cells, 
modulating their cytology and cytokine secretions thereby enhancing 
adherence and internalization of pneumococcal bacteria in vitro [279]. P4-
mediated activation was also demonstrated with other eukaryotic cells, 
including mouse macrophages (RAW 261.4) and freshly isolated 
polymorphonuclear neutrophils from healthy human donors [279] [280]. 
When exposed to the peptide, HL-60 cells undergo various phenotypical 
changes such as increased pseudopods, foamy, granulated cytoplasm with 
condensed nuclei and large vacuoles with internalized materials (Figure 22)  
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Figure 22 - HL-60 cells in a normal state (A) exposed to the P4 peptide (B). The arrows highlight 
increased intra-cellular granules present. Adapted from [279].  
 
The increased activation seen in phagocytes following P4 exposure also leads 
to enhanced phagocytosis. In opsono-phagocytosis assays, in the presence of 
species specific antibody and complement, P4 is able to increase the uptake 
and subsequent killing of bacteria by >70%. This has been established in the 
HL60 cell line as well as mouse & human derived peripheral blood 
neutrophils.  
 
4.2.3 Functions in vivo 
Additionally, Rajam et al (280) were able to show the potential of using P4 
mediated passive immunotherapy in vivo. In a fatal pneumococcal mouse 
model, P4 therapy was able to rescue 80% of moribund mice by giving them a 
combined treatment of P4 and pathogen specific antibodies. In contrast, only 
10% of the control strain and 30% of the mice treated purely with antibodies 
and complement survived [280]. Both in vivo and in vitro, P4 shows no signs 
of toxicity.  
 
Further research at the CDC has shown that enhanced phagocytosis in vitro 
confers therapeutic benefit in vivo [281]. Rajam et al. used reference in vitro 
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opsonophagocytic killing and uptake assays to show that P4 enhanced 
opsonophagocytosis of S. pneumoniae by human promyelocytic leukaemia 
cells (HL-60) differentiated into granulocytes [280]. In an in vivo extension of 
this study, mice were infected with S. pneumoniae, then injected with IVIG 
and/or P4 at 72 and 96 hours post-infection. Survival was 10% in untreated 
mice, ~30% in mice given IVIG or P4 alone, and 80% in those treated with 
both IVIG and P4.  
 
Adding a low dose of ceftriaxone to P4 and immunoglobulin increased mouse 
survival to 100% [280]. P4-activation of in vitro opsonophagocytosis has also 
been demonstrated with Neisseria meningitidis and Staphylococcus aureus, in the 
presence of pathogen-specific antibodies [282]. In a murine model of 
overwhelming S. aureus infection, intravenous P4 with immunoglobulin 
rescued 70% of mice, compared with 0% survival of untreated controls [282].  
 
Augmented passive immunotherapy combines commercially available pooled 
immunoglobulin G (IVIG) and the phagocyte stimulating peptide P4 to 
rapidly and effectively augment an immune response before the effect of 
antibiotic treatment would be apparent. 
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4.2.4 Summary of P4 publications 
There are currently 7 publications related to P4 peptide. Their main findings 
are summarized in Table 4. 
 
Table 4 – Main findings from previous P4 peptide publications.  
Year  Main findings Ref 
2007  P4 treatment of epithelial cells leads to cytological changes allowing for 
increased binding and internalization of S. pneumoniae.  
 
NP cells reduce their secretion of FGF-β, but increase their secretion of IL-6, 
IL-8 and VEGF cytokines following peptide treatment.  
[279] 
2008  P4 treatment of HL-60 neutrophil cell line leads to increased phagocytosis in a 
dose-dependent manner. 
 
P4 and antibody treatment of S. pneumoniae infected mice increased survival 
from 10% to 80%.  
[280] 
2009  P4-antibody therapy as an adjunct to antibiotics reduced the need for dual 
administration and led to 100% survival (compared to 90% P4-antibody alone 
and 20% control). 
 
Repeat therapy was effective following infection of previously rescued mice.  
 
Septic blood neutrophils from mice showed enhanced phagocytosis 
following peptide treatment. 
[281] 
2010  Peptide-antibody treatment of two strains of aged mice led to significantly 
increased survival.  
[283] 
2011  Survival was improved from 20% to 80% in mice with S.pneumoniae-influenzea 
co-infection and treated with P4. Survival correlated with increased clearance 
of bacteria and virus and decreased lung consolidation.  
[284] 
2011  API increased survival of S. aureus infected mice infected mice from 20% to 
70%  
 
P4 stimulation led to enhanced phagocytosis of S. aureus by HL-60 neutrophil 
cells in vitro.  
[282] 
2012  Increased survival following API treatment of sepsis due to increased 
phagocytic activation and recruitment. 
 
Intranasal administration of P4 to treat pneumococcal pneumonia.  
 
Ex vivo and in vitro macrophages increase phagocytosis following peptide 
treatment. 
[285] 
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E. Aims and objectives 
 
There were four main aims in this project, which are addressed in their 
relevant chapters. The first aim was to characterise the phagocytic host 
response to peptide administration in the absence of infection (chapter III). 
The second aim was to translate these findings into infection studies by 
assessing phagocytic host responses to infection and treatment (chapter IV). 
The third aim was to determine potential mechanisms by which P4 augments 
phagocytic killing (chapter V). The final aim was to translate the murine and 
in vitro findings to primary human phagocyte studies (chapter VI). 
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2.1 Microbiology 
2.1.1 Bacterial strains  
Table 5 details the strain and type of pneumococci used in this thesis. 
Laboratory serotype 2 strain D39 pneumococci were passaged once in a 
murine host to standardize their virulence prior to in vivo studies (see chapter 
III). For each serotype, a single culture broth was batch processed and 
pneumococci stored in single-use aliquots for < 6 months. A total of eight 
pneumococcal serotypes were used for the in vitro and ex vivo studies. Both 
laboratory and clinically derived strains of pneumococci were used.  
 
Table 5 – The type, source and use of S. pneumoniae strains for in vivo studies. 
Serotype (Strain) Type/Source Use 
2 (D39) 
In vivo passaged 
Laboratory (NCTC 7466) 
 
Acute IPD studies 
Carriage studies 
3 (WU2) 
 
Laboratory  (ATCC WU2) 
 
IPD studies 
Aged mice studies 
2 (D39) Laboratory (NCTC 7466) Ex vivo, in vitro 
4 (TIGR4) 
Laboratory (ATCC 
BAA344) 
In vitro 
2, no capsule (D39) Laboratory (7466Δcps) In vitro 
4, no capsule (TIGR4) Laboratory (BAA344Δcps) In vitro 
19F (ST180) Clinical (Invasive) Ex vivo, In vitro 
6B (ST138) Clinical (Invasive) Ex vivo, In vitro 
14 (ST124) Clinical (Invasive) In vitro 
23F (11902) Clinical (Invasive) Ex vivo 
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2.1.2 Standard media 
Blood agar base (BAB) culture plates  
16 gram of BAB medium (SIGMA) was mixed with 400 ml of distilled water 
and autoclaved at 15 psi (103 kPA) for 20 minutes. Following autoclaving and 
once the medium reached ~56C, 20 ml of Sterile Defibrinated Horse Blood 
(SIGMA) was added and gently mixed. The resulting medium was then 
poured into sterile petri dishes (90 mm), left to dry >3 hours then stored 
inverted either at RT or at 4C. 400 ml of medium resulted in ~25 BAB culture 
plates and were stored for <7 days. 
 
BAB culture plates +5% v/v horse blood with gentamicin 
BAB culture plates were prepared as above with a minor modification: 
Immediately after the addition of Horse Blood, 2 μg/ml of gentamicin 
(SIGMA) was added to the broth and gently mixed. 
 
Brain heart infusion (BHI) broth 
37 gram of BHI medium (SIGMA) was mixed with 1 litre of distilled water 
and autoclaved at 15 psi (103 kPA) for 20 minutes. Following autoclaving, the 
medium was checked to ensure it’s pH value was 7.4  0.2 and stored at RT 
for <6 weeks. 
 
BHI serum broth 
BHI broth was prepared as above with a minor modification: After 
autoclaving, 20 ml of Fetal Bovine Serum (FBS) was added to 80 ml of 
medium to reach 80% v/v BHI medium with 20% v/v FBS. BHI Serum Broth 
was prepared fresh for each use. 
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Cryopreservation solution 
In order to optimally cryopreserve isolated leukocytes, a freezing solution 
was prepared using the ratios of 75% RPMI medium (Sigma), 15% Foetal 
bovine serum (FBS, Gibco) and 10% dimethyl-sulphoxide (Sigma).  
 
2.1.3 Viable count of bacteria (Miles & Misra Method) 
The Miles & Misra is an accurate dilution method for determining the number 
of colony forming units (CFU) present in a given sample [286] [287]. It relies 
on serial dilutions, culturing and visual counting of CFU. The number of CFU 
detected in a given dilution is used to extrapolate the CFU / ml of sample.  
 
20 μl of sample (e.g. aliquot, infection dose, blood or tissue homogenate) for 
viable count testing was added to 180 μl sterile PBS and serially diluted (10-
fold) until dilutions of 106 were reached. BAB culture plates were divided into 
six sections, and 60 μl (3 x 20 μl) of each dilution was plated into each 
corresponding sector and incubated at 37C 5%CO2 (Figure 23).  
 
 
Figure 23 - Miles and Misra. Arrow indicates sector in which 30-300 CFUs were counted.  
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The following day, sectors in which 30-300 CFU were visible were counted 
and the CFU/ml or CFU/mg calculated as follows: 
 
To evaluate numbers of CFU in blood or infection dose: 
   
  
                                                         
    
  
 
 
To evaluate numbers of CFU in lung or nasopharyngeal tissue: 
   
  
 
   
  
          (                               )               
 
2.1.4 Preparing stocks of pneumococci 
Pneumococci from laboratory bead collections were streaked for isolation on 
BAB culture plates and grown overnight at 37°C (5% CO2). In addition, an 
optochin disk was placed on the initial site of inoculation (Figure 24). A zone 
of inhibition around the optochin disk indicates susceptibility of the inoculum 
to optochin; a hallmark of the pneumococcus and the most common method 
of distinguishing between pneumococcus and Streptococcus viridans.  
 
                             
Figure 24 - Streaking pneumococci for isolation. S. pneumoniae grown on BAB culture plates and 
tested for optochin susceptibility. (O) shows the zone of inhibition surrounding the optochin disk 
while (S) shows single colonies.  
O 
S 
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Following overnight culture, a sweep-full of colonies was used to inoculate 10 
ml BHI (pre-warmed to 37°C) in a sterile universal tube. The inoculum was 
incubated for 16-18 hours at 37°C (5% CO2) until OD500 1.4-1.6.  
 
The BHI pneumococcal culture broth at correct OD was centrifuged at 1500 x 
g for 15 minutes, the supernatant carefully removed and the remaining pellet 
re-suspended in 1ml BHI serum broth. 700 μl of the re-suspended pellet was 
added to 10ml of BHI serum broth to reach an OD500 0.7 (adjusted if necessary 
by addition of BHI serum or pellet) and incubated statically for 5 hours at 
37°C (5% CO2) until OD500 ≥ 1.6. Following incubation, the culture broth was 
centrifuged at 1500 x g for 15 minutes, the supernatant discarded and the 
pellet re-suspended in 10 ml fresh BHI Serum Broth.  
 
The resulting serum broth containing pneumococci was then divided into 500 
μl single use aliquots in sterile cryotubes and slow-frozen at -80°C.  After 48 
hours in the freezer, aliquots were thawed and numbers of pneumococci / ml 
determined using the Miles and Misra Method. 
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2.2 Murine strains  
Table 6 shows the age, sex, genetic background and supplier that were used 
in this thesis. Mice were allowed to acclimatize for one week upon arrival and 
kept in groups of 5 in individually ventilated micro-isolator cage (IVC) racks.  
Food and water was provided ad libitum. All in vivo experiments were 
conducted following guidelines from ethical review and animal welfare 
committee and under authority of UK Home Office licence (project licence 
PPL:80/2111, personal licence PIL:40/9700) or the Institutional Animal Care 
and Use Committees (IACUC)  at the Centres for Disease Control and 
Prevention. 
 
Table 6 - Strain, age, sex, supplier of the mice and their application used for in vivo studies. 
Strain Age Sex Supplier Application 
MF1 8-12 weeks Female Charles River UK Acute IPD studies 
Carriage studies 
Ex vivo studies 
Animal Passage 
Virulence test 
Swiss 
Webster 
8-12 weeks Female Charles River 
USA 
IPD studies 
Swiss 
Webster 
15 months Female Charles River 
USA 
Aged mice IPD studies 
BALB/c 11 months Female Charles River 
USA 
Aged mice IPD studies 
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2.2.1 Monitoring murine behavior 
Following infection, the physical appearance of mice was assessed frequently 
to judge the course of infection and the wellbeing of mice. The scoring system 
[288] used  to assess the ability of mice to groom themselves, their posture 
and their activity is detailed in Table 7. 
 
To ensure objective scoring, cage-identification cards were concealed prior to 
scoring. Once mice reached a point score of “lethargic ++” they were culled in 
accordance to the severity limits of the UK Home Office Licence under which 
these experiments were performed. 
 
Table 7 - Description and score used to assess the development of infection in murine models.  
Score Description 
Normal  Mouse is moving around the cage normally and has a normal coat. 
Hunched + Mouse is slightly arched over in the middle and walking on tip toes. 
Hunched ++ Mouse is very arched over and walking on tip toes. 
Starry + Coat of the mouse is not groomed well around the neck area and fur is 
upright. 
Starry ++ Coat of the mouse is not groomed all over and fur is upright. 
Lethargic + Mouse is slower at moving around the cage. 
Lethargic ++ Mouse is not moving around the cage unless encouraged. 
Moribund Coat of the mouse is not at all groomed, mouse has stopped moving 
around that cage, and mouse has labored breathing. 
 
2.3 Viable count of leukocytes (haemocytometer) 
A haemocytometer is a thick glass microscope slide with laser-etched grids 
creating chambers with known volume. As such, the volume of any cell 
solution added to these chambers is known and the number of cells / ml can 
be extrapolated. Trypan blue is used to determine cell viability (Figure 25). 
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Figure 25 - Assessing viability using Trypan Blue. Dead cells do not maintain membrane integrity 
and take up Trypan blue dye thereby indicating non-viability. (A) Shows a viable HL-60 cell not 
taking up the dye while (B) has clearly taken up the dye indicating the cell is not viable. 
 
Cell suspensions were thoroughly mixed and two 50 μl samples added to 50 
μl Trypan blue solution (diluted 1:4 with PBS). The resulting suspension was 
added to the haemocytometer chamber and cells counted in specific grids 
using a light microscope (Figure 26).  
 
 
Figure 26 –Schematic diagram of a haemocytometer and its gridded chambers. (A) The blue areas 
(and red circle) represent area in which cells are counted. (B) High contrast image focused on one 
section (highlighted in red on left panel) of a haemocytometer. White dots indicate cells. Image taken 
at 40x magnification. 
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Using the number of alive & dead cells counted in each grid, and by 
incorporating the dilution factors, the number of cells / ml and their viability 
was calculated as follows: 
 
     
  
 (
                                
 
      )       
 
             
                                               
                          
       
 
2.4 Infection studies  
2.4.1 Lung and nasopharyngeal tissue 
Lung or nasopharyngeal tissue were harvested and placed into universal 
tubes containing 10 ml or 5 ml sterile PBS, respectively. Tissue weight was 
determined by comparing weight of tube before and after the addition of lung 
or nasopharyngeal tissue. Once the weight was recorded, tissue was 
mechanically disrupted by homogenization with an Ultra-Turrax T8 
homogeniser (IKA) for ~1 minute. The resulting homogenate was briefly 
vortexed and two 20 μl samples were taken and assessed for the numbers of 
CFU using the Miles and Misra method.  
 
2.4.2 Blood tissue 
Blood was collected by cardiac puncture following terminal anesthesia or, on 
live mice, by removal of a small volume from the tail vein and immediately 
placed into eppendorf tubes containing 2 μl heparin (10 units / ml, Sigma) to 
avoid blood clotting. Two 20 μl samples were taken from the blood samples 
and assessed for CFU using the Miles and Misra Method. 
 
Chapter II   Materials & Methods 
71 
2.5 Cell population studies  
2.5.1 Tissue preparation (lungs) 
Lung tissue was first weighed then placed in a sterile petri dish and cut into 
small pieces using a scalpel. To further break down lung tissue, thereby 
releasing immune cells, the disrupted lung tissue was enzymatically digested 
by placing it in a 1.5ml eppendorf tube containing 1ml of PBS and 10 mg/ml 
of Collagenase D (Roche) for 30 minutes at 37°C. Following digestion, cell 
suspensions were yielded by passing the lung tissue through a 40 μm pore 
diameter cell sieve (BD Biosciences) with the aid of a cell plunger and by 
flushing the sieve twice with 10 ml sterile PBS. The cell suspensions were then 
centrifuged at 300 x g for 10 minutes and the supernatant discarded. The 
resulting cell pellet was re-suspended in cryopreservation solution and 
immediately placed in a slow-freezing jar at -80°C. Aliquots of frozen cells 
were quickly thawed in a room temperature water bath when required.  
 
2.5.2 Tissue preparation (blood) 
Samples were first subjected to red blood cell (RBC) lysis using the BD Pharm 
Lyse kit (BD Biosciences). All reactions were done at RT. RBC-lysis solution 
was diluted 1:10 with distilled H20 and added to blood samples at ratio of 1:3 
(1ml blood: 2ml RBC-lysis). 10 minutes later, lysis was stopped by dilution 
with PBS. The tube was then centrifuged at 300 x g for 10 minutes, the 
supernatant discarded and the resulting cell pellet re-suspended In PBS for 
another washing step. The resulting cell pellet was re-suspended in 
cryopreservation solution and immediately placed in a slow-freezing jar at -
80°C. Aliquots of frozen cells were quickly thawed in a room temperature 
water bath when required.  
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2.5.3 Leukocyte preparation 
Leukocytes derived from blood or lungs were stored in DMSO-containing 
cryopreservation solution, which can be toxic to cells and interfere with 
antibody binding. Cells were therefore thawed and then washed twice by 
centrifuging aliquots at 300 x g for 10 minutes, discarding the supernatant and 
re-suspending the cell pellet in 5ml RPMI. Following the washing steps, the 
cell suspension was counted using a haemocytometer and the volume 
adjusted to obtain ~5 x 106 cells/ml of suspension (If necessary, cells were 
centrifuged at 300 x g for 10 minutes, the supernatant discarded and the pellet 
re-suspended in a volume to obtain the desired cell concentration).  
 
2.5.4 Antibody staining 
Labeled anti-CD antibodies purchased from Biolegend, USA, were used. 
200μl of the cell suspensions were stained for 30 minutes at 4°C using 50μl 
optimized antibody concentrations (see Table 8) of CD45 FITC (hematopoietic 
cells marker, 30-F11), F4/80 APC (macrophage/monocyte marker, BM8), GR1 
PE/CY7 (neutrophil marker, RB6-865), and CD16/32-PE (Fc-γRII/III marker, 
93). Further staining involved using CD45 and isotype-matched control 
antibodies for each primary antibody. Following staining, excess/unbound 
antibody was removed by centrifuging cells twice at 300 x g for 10 minutes, 
discarding the supernatant and re-suspending the resulting pellet in 1ml PBS 
(first wash) and 200μl PBS (second wash). 300 μl of PBS was added to the 
final cell solution. 
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Table 8 - Antibodies and their relative isotype control used for Flow Cytometry staining of immune 
cells populations. 
Antibody Conjugate Dilution 
CD45 (haematopoietic cells) FITC 1/300 
F4/80 (monocyte/macrophage) APC 1/400 
Gr-1 (granulocyte/neutrophil) PE/Cy7 1/300 
CD16/32 (Fcy RII/III) PE 1/250 
Rat IgG2b -  Isotype Ctrl FITC 1/300 
Rat IgG2b -  Isotype Ctrl PE/Cy7 1/300 
Rat IgG2b -  Isotype Ctrl PE 1/250 
Rat IgG2b -  Isotype Ctrl APC 1/400 
 
2.5.5 Acquisition and analysis 
Following staining, leukocytes were acquired using a FACSCalibur Flow 
Cytometer (BD). Prior to acquisition, a dot plot displaying the forward scatter 
parameter and FITC CD45 was created. A gate was placed around the CD45+ 
population and 50,000 events within this gate collected.  
 
Flow Cytometry data was analysed using the CellQuest Pro software 
supplied by the manufacturer (BD). CD45+ events were gated to isolate 
hematopoietic cells from red blood cells and tissue debris. The CD45+ 
population was plotted so that macrophages (F4/80) or neutrophils (Gr1) 
could be isolated based on their fluorescence (APC and PE-Cy7, respectively). 
Within the macrophage/neutrophil populations, PE fluorescence was used to 
measure relative Fcγ receptor expression.  
 
For blood and BAL cell populations, the percentage of each cell type was 
determined by dividing the number of F4/80+ or Gr1+ events collected by the 
number of CD45+ events acquired. For lung cell populations, cells/mg tissue 
was calculated by extrapolating from the 50,000 collected events the total 
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number of each population in the complete tissue sample and then dividing 
by the tissue weight.  
 
For all samples, the fluorescence from isotype control stains was used as 
baseline during analysis. Figure 27 shows an example of using CD45-FITC 
fluorescence to isolate hematopoietic cells and Gr1-PE/CY7 fluorescence to 
isolate neutrophils from a blood sample and how baseline fluorescence was 
determined using isotype control fluorescence.  
 
 
Figure 27 - Example of gating strategy to detect neutrophil populations and account for unspecific 
binding (isotype control) during analysis. Blood samples are first plotted against side scatter and 
CD45 FITC fluorescence. A gate is drawn around the CD45+ population and plotted on a new graph 
using side scatter and either Gr1 or PE-Cy7 isotype fluorescence parameters. Fluorescence measured 
in the isotype stain was used as background and subtracted from Gr1 fluorescence to determine 
actual expression.  
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2.6 P4 peptide  
2.6.1 Peptide synthesis 
The 28 amino acid peptide P4 (LFVESSVKRRPMKTVSQDTNIPIYAQIF) was 
synthesized and purified at the Centers for Disease Control and Prevention, 
Atlanta, GA and the Emory University Microchemical Facility. Peptide 
synthesis was performed in an Advanced ChemTech 396 multiple peptide 
synthesizer by means of standard and modified 9-fluorenyl-methoxycarbonyl 
(Fmoc) protocols [289-291] resulting in a free N- and C-terminus.  
 
2.6.2 Peptide control and storage 
Each fresh batch of peptide was quality controlled for purity by the Emory 
University Microchemical facility; a minimum of 97% purity only was used 
for all studies. P4 peptide was best solubilized in DEPC-treated water (280) 
(Ambion, USA). Peptide activity was quality controlled using the 
standardized HL-60 OPKA for each received batch of peptide. Peptide 
solutions were prepared fresh on the day of experiment and stored at 4°C 
(melting ice) until use. For in vivo work, peptide solution was hand-warmed 
(37°C ) for 1 minute prior to administration.   
 
2.7 Opsonophagocytosis killing assay 
Opsonophagocytosis killing assays (OPKA) were performed using a variety 
of phagocytes. Minor modifications were applied to the method in order to 
account for the difference in cell types. The opsonophagocytosis assay can be 
divided into three stages: opsonisation, phagocytosis and analysis.  
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2.7.1 Opsonisation 
An aliquot of non-passaged pneumococci was thawed and diluted in sterile 
PBS to reach 5 x 104 CFU / ml. Intravenous immunoglobulin (IVIG, Gamunex, 
Lot 26NG042, Talecris) was used as a source of pathogen-specific antibody. 1 
ml of the diluted bacterial suspension was added to a universal tube 
containing 1 ml of IVIG diluted 1:4 in sterile PBS. Additionally, 1 ml of the 
bacterial suspension was added to a universal tube containing 1 ml of sterile 
PBS as a non-opsonized control. Control and IVIG tubes were then added to a 
shaking (300 RPM) incubator at 37°C for 15 minutes to allow for opsonisation 
to occur. 
 
2.7.2 Phagocytosis 
For murine BAL, peritoneal, J774 and human BAL macrophages. Medium 
(see chapter methods for specifics) was carefully removed from the wells 
containing 5x104 adhered macrophages and replenished with 30μl fresh 
medium. 10 μl of baby rabbit complement (PelFreeze, USA) and 20μl of 
opsonized bacterial suspension (containing 5 x 102 pneumococci) was then 
added to the wells. Finally, 20μl of DEPC treated water or 20μl of P4 solution 
(10 μg peptide in 20 μl DEPC treated water) was added to the wells to make a 
final volume of 80 μl / well.  
 
For HL-60 neutrophils, blood derived neutrophils and THP-1 monocytes. 
20μl of opsonized bacterial suspension (containing 5 x 102 pneumococci) and 
10 μl of baby rabbit complement were added into wells of a 96-well plate. 20 
μl of cell suspension (containing 1 x 107 cells) was then added to each well 
giving a multiplicity of infection (m.o.i.) of 1:400 (1 pneumococcus to 400 
phagocyte). Finally, 20 μl of DEPC treated water or 20 μl of P4 solution (10 μg 
peptide in 20 μl DEPC treated water) was added to the wells to make a final 
volume of 80 μl / well. 
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Control reactions. Control wells included the use of non-opsonized bacteria 
or the use of heat-inactivated complement (inactivated by incubating for 30 
minutes at 56°C) with and without P4 solution. Wells containing opsonized 
bacteria and complement only were used to establish the bacterial dose.  
 
Incubation time. For neutrophils (freshly derived & HL-60), monocytes 
(THP-1) and murine macrophages, cells were incubated for 45 minutes at 
37°C (5% CO2). For human alveolar macrophages, cells were incubated for 
two hours at 37°C (5% CO2). 
 
Culturing. Following incubation, 10 μl from each well was plated in 
duplicates onto blood agar plates and incubated for 18-24 hours at 37°C (5% 
CO2). The remaining volume from the wells were collected, centrifuged at 300 
x g and the resulting supernatant stored at -80°C. 
 
2.7.3 Analysis 
The following day, CFU on blood agar plates were counted. In order to 
determine the efficacy of killing of opsonized pneumococci, the number of 
bacterial CFU in the bacterial dose (opsonized pneumococci and complement) 
was compared to the number of bacterial CFU recovered from reaction wells 
(opsonized pneumococci, complement, macrophages and ± P4 solution). A 
successfully diluted bacterial dose (see opsonisation 2.9.1) resulted in 60 ±10 
CFU. The killing index was then calculated as follows: 
 
 
                    ( 
                                   
                               
       )   
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An example of counting CFU cultured overnight from the wells of an 
opsonophagocytosis killing assays is shown in Figure 28. 
 
 
 
Figure 28 - (A) Pneumococcal CFU on blood agar cultured from the supernatant following an 
opsonophagocytosis killing assay. (B) Example of CFU counting to determine bacterial killing. 27 
CFU were recovered from control wells compared to 15 and 13 from wells containing a stimulant.  
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A. Introduction 
 
3.1 Introduction 
Inflammatory mediators during infection significantly modulate cellular 
immune responses. The aim of this chapter was to assess in vivo responses to 
peptide administration in the absence of infection in order to establish 
baseline responses to peptide treatment in a healthy host prior to the infection 
studies in chapter IV.  
 
3.1.1 Behavioral studies 
It is well established that the administration of inflammatory mediators such 
as LPS or Interleukin-1 affects neuronal responses and induces “sickness-like” 
behavior in mammals [292-295]. Symptoms of sickness-like behavior include a 
loss of appetite, sleepiness, withdrawal from normal social activities, fever 
and fatigue and are thought to be part of a motivational system that prioritize 
the host’s recovery from infection [296]. To determine whether peptide 
administration would induce such responses, P4 at the treatment dose and a 
dose 10 x higher was administered intravenously into mice and their behavior 
was monitored with respect to activity, breathing, ability to groom themselves 
and posture as previously established [288].  
 
3.1.2 Cell response studies 
Previous studies on augmented passive immunotherapy (API) in vivo 
described host survival and pathogen clearance but did not define host 
cellular immune responses to infection and treatment [274, 281, 283]. As 
infection and associated cytokines strongly modulate cellular responses, naïve 
healthy mice were chosen to determine baseline levels in cellular responses 
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following peptide administration. Both intravenous and intranasal routes of 
peptide administration were used and cellular responses defined in 
peripheral blood and BAL, respectively. Due to the nature of API 
(augmenting phagocytosis in the presence of pathogen specific 
immunoglobulin), monocytes, macrophages and neutrophils were chosen as 
the main phagocytic cells likely to respond to API.  
 
3.1.3 FcγR expression  
 API relies on the presence of pathogen specific immunoglobulin G to be 
effective [274, 281, 283]. It is therefore likely that the phagocytic Fcγ receptor 
is involved during augmented phagocytic clearance of pathogens. To 
determine the phagocytic potential of neutrophils, monocytes and 
macrophages following in vivo peptide stimulation, Fcγ receptor expression of 
phagocytes in BAL and peripheral blood was determined using flow 
cytometry. In addition, to confirm flow cytometry results and determine the 
relative localization of Fcγ receptors, immunogold staining and electron 
microscopy was employed to visualize and enumerate Fcγ receptor 
expression.  
 
3.1.4 Phagocytosis assays   
Previously, murine peripheral blood neutrophils were shown to augment 
their phagocytic killing of opsonised pneumococci following peptide 
administration [281]. The phagocytic response of murine macrophages was 
unknown. Murine alveolar and peritoneal macrophages were therefore 
extracted from healthy mice and challenged with IVIG opsonised 
pneumococci in the presence or absence of P4. In addition to ex vivo 
macrophages, the murine macrophage cell line J774 was used to determine 
phagocytic killing of a range of IVIG opsonised pneumococcal serotype in the 
presence of P4.  
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B. Materials & Methods 
 
3.2 Behavioral response to P4 dosage in the MF1 
mouse host 
P4 peptide was pre-tested in mice to determine behavioural responses to 
peptide administration. Two doses were chosen: (A) the treatment dose of 100 
μg P4 peptide / 100 μl DEPC treated water and (B) a 10 x higher dose of 1 mg 
P4 peptide / 100 μl DEPC treated water. Three mice per group were injected 
twice, 6 hours apart and monitored based on their ability to groom 
themselves, their posture and their activity as previously established [288]. 
Mice that received peptide solution were observed thrice daily (8AM, 2PM, 
8PM) for two days and their behavioral responses compared to healthy naïve 
littermates.  
 
3.3 Cellular responses to peptide administration 
The effect of in vivo peptide administration on phagocyte populations was 
observed in the absence of infection. P4 solution was administered either 
intravenously or intranasally (see Table 9 for peptide concentration) and 
peripheral blood phagocytes or BAL phagocytes isolated for Flow Cytometry 
staining. 
Table 9 - Volume and concentration of intravenous and intranasal peptide administration in the 
absence of infection. 
Administration DEPC volume P4 Peptide 
Intravenous 100 μl  100 μg  
Intranasal 40 μl  100 μg  
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3.3.1 Intravenous administration 
Solubilized peptide (see Table 9 for peptide concentration) was injected into 
dorsal tail veins (n=5 per time point). Blood tissue was collected by cardiac 
puncture following terminal anesthesia at 1, 4 and 24 hours following 
injection. Blood samples were then purified and prepared for staining as 
described in chapter II. 
 
3.3.2 Intranasal administration 
Solubilized peptide (see Table 9 for peptide concentration) was administered 
intranasally to mice (n=5 per time point). Mice were first lightly anaesthetized 
using 2.5% v/v inhaled Isofluorane (1.6-1.8 L O2/min) in an anaesthetic box. 
The absence of reflex reactions and twitching of whiskers confirmed 
anesthesia. Once anaesthetized, the mice were scruffed and P4 solution 
administered equally into both nostrils in a drop-wise fashion, allowing each 
drop to be inhaled before the next was administered. At 1, 4 and 24 hours 
following administration, BAL fluid was collected following terminal 
anesthesia using the methods described in this chapter. BAL samples were 
centrifuged and re-suspended in PBS for staining as described in chapter II. 
 
3.4 Immunogold receptor staining 
FcγR membrane protein was stained using colloidal gold and viewed using 
TEM to determine receptor localization on membranes and in phagosomes as 
well as relative numbers per cell. Primary antibody solution was prepared by 
diluting 1 μl of rat anti-mouse CD16/32 (Fc-γRII/III marker, 93) antibody in 
250 μl PBS. Secondary antibody solution was prepared by diluting 1 μl of 10 
nm colloidal gold-labeled anti-rat IgG antibody (Sigma, G7035) in 200 μl PBS.  
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3.4.1 Leukocyte preparation 
P4 solution (100 μg/100 μl DEPC per mouse) was administered into tail-veins 
and blood was collected by cardiac puncture 24 hours later before cervical 
dislocation. Blood samples were subjected to red blood cell lysis and the 
resulting cell pellet washed, adjusted to obtain ~5 x 106 cells/ml of suspension, 
centrifuged at 300 x g for 10 minutes and the supernatant discarded 
 
3.4.2 Immunogold staining 
The resulting cell pellet was then stained for 30 minutes at 4°C using 50 μl of 
primary antibody solution. Following incubation, the cells were washed twice 
by centrifuging at 300 x g for 10 minutes and the resulting cell pellet stained 
using 50 μl of secondary antibody solution for 30 minutes at 4°C. Following 
incubation, the cells were washed twice by centrifuging at 300 x g for 10 
minutes then fixed and submitted for transmission electron microscopy 
(TEM). Control samples were stained using secondary antibody solution 
alone were used to address non-specific binding.  
 
3.4.3 Analysis 
Images of peripheral leukocytes generated from TEM were randomly selected 
and blindly assessed by two independent observers for the presence of gold 
particles internalized and on the surface of membranes. An example of the 
distinct black spots indicating the presence of gold can be seen in Figure 29.  
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Figure 29 – Example of immunogold detection using TEM. Mice were intravenously injected with P4 
solution and blood collected at 24 hours for immunogold staining. (A) shows part of the membrane 
of a murine monocyte cell. The arrows are indicating the presence of gold particles. The three panels 
below are close-up images from (A) and show the presence of gold particles (B) internalized into 
phagosomes, (C) attached to pseudopods and (D) about to be engulfed.  
 
3.5 Murine macrophages: Alveolar, peritoneal, J774.2 
Alveolar and peritoneal macrophages are the resident phagocytes that first 
respond to pneumonia or peritonitis respectively. P4 was tested for the ability 
to augment the killing of opsonized pneumococci by peritoneal and alveolar 
ex vivo derived macrophages. Additionally, the hypothesis that macrophages 
from the J744.2 murine cell line would be able to phagocytose higher amounts 
of opsonized pneumococci irrespective of bacterial capsule following peptide 
treatment was tested. 
A. 
B. 
C. D. B. 
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3.5.1 Standard media used for macrophage cell culture 
Dulbecco’s Modified Eagle Medium (DMEM, Sigma, UK]) was used for all 
macrophage cell culture. Medium was supplemented with 10% FBS and 5% 
antibiotic/mycotic (10,000 units penicillin, 10 μg streptomycin + 25 μg 
amphotericin B/ml [Sigma, UK]) solutions to maintain growth and prevent 
contamination. Additionally, DMEM supplemented with 10% FBS without 
the addition of antibiotic/mycotic solution was prepared for use in 
phagocytosis assays. 
 
3.5.2 Obtaining peritoneal macrophages 
Peritoneal macrophages (PM) were obtained by exposing the peritoneum of 
mice euthanized by cervical dislocation and washing the peritoneal cavity 
twice using 2.5ml medium and a 14-gauge syringe (Figure 30A) The resulting 
cell suspension was centrifuged at 300 x g for 10 minutes, the supernatant 
discarded and the pellet resuspended in 2 ml medium containing antibiotics. 
The number of PM/ml was determined using a haemocytometer. Cells were 
then plated onto tissue culture treated 96-well reaction plates at a 
concentration of 5 x 104/well and incubated at 37°C (5% CO2) for 3 hours. 
Following incubation, wells were gently washed twice with sterile, pre-
warmed (37°C) PBS to remove non-adherent cells and antibiotic-free medium 
was added to the wells. 
  
Chapter III   P4 peptide studies in healthy mice 
87 
3.5.3 Obtaining BAL and alveolar macrophages 
BAL. Alveolar macrophages (AM) were obtained by lavaging murine lungs 
and retrieving the fluid. Following euthanasia by pentobarbital overdose, 
murine lungs were exposed and the trachea cannulated with a 24 gauge 
plastic catheter (BD Instye, Becton Dickinson). A 2ml syringe was adapted to 
the catheter and lungs lavaged twice with 1.5 ml medium as shown in Figure 
30B. 
 
 
Figure 30 - Diagram of the method used to obtain ex vivo derived macrophages. (A) peritoneal 
macrophages were obtained by exposing the peritoneal membrane and carefully injecting and 
retrieving medium into the peritoneal cavity taking care not to damage organs. (B) Alveolar 
macrophages were extracted from mice by exposing and cannulating the trachea of mice and washing 
the lungs with medium taking care not to burst lung tissue. 
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Alveolar macrophages. The resulting cell suspension was centrifuged at 300 x g 
for 10 minutes, the supernatant discarded and the pellet re-suspended in 2 ml 
medium containing antibiotics. The number of AM/ml was determined using 
a haemocytometer. Cells were then plated onto tissue culture treated 96-well 
reaction plates at a concentration of 5 x 104/well and incubated at 37°C (5% 
CO2) for 3 hours. Following incubation, wells were gently washed twice with 
sterile, pre-warmed (37°C) PBS to remove non-adherent cells and antibiotic-
free medium was added to the wells.  
 
3.5.4 Establishing and maintaining J774.2 cell culture 
J774.2 is a murine derived macrophage cell line. Frozen cell aliquots were 
quickly thawed in a 21°C water bath and centrifuged at 300 x g for 10 minutes 
to remove the potentially toxic DMSO from the cryopreservation solution. 
The supernatant was discarded and cells re-suspended in 10 ml sterile PBS for 
another wash (300 × g for 10 minutes). The supernatant was then discarded, 
the resulting cell pellet re-suspended in 15 ml of medium and this cell 
solution added to a 75 ml tissue culture flask (BD Biosciences, UK) for 
overnight incubation at 37°C (5% CO2). The following day, viable cells had 
attached to the tissue culture treated flask. Medium was carefully removed 
from the flask and the cells washed once with 10 ml of RT Dulbecco’s 
Phosphate Buffered Saline (DPBS [Gibco, UK]). 15 ml of fresh medium was 
added and the cell culture maintained by washing cells and replenishing 
medium every two days. The cell line was split as soon as macrophage 
attachment to the flask reached 50% confluence, judged by assessing the flask 
using an inverted microscope. Medium was removed and cells washed with 
10 ml DPBS. 8 ml of medium was added to the flask and a cell suspension 
created by gently detaching cells using a cell scraper. 1 ml of the resulting cell 
suspension was added to 14 ml fresh medium, placed into a new 75 ml tissue 
culture flask and cell culture maintained as above. Similarly, cells were also 
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detached, counted and added to reaction wells for use in opsonophagocytosis 
killing assays. 
3.6 Opsonophagocytosis using murine macrophages 
 
Opsonophagocytosis was performed using ex vivo derived alveolar and 
peritoneal macrophages as well as J774 tissue culture macrophages.  
 
3.6.1 Opsonisation 
See General methods: Chapter II (p. 75) 
3.6.2 Phagocytosis 
See General methods: Chapter II. (p. 76) 
3.6.3 Analysis 
See General methods: Chapter II. (p. 77) 
 
3.7 Statistical analysis 
Groups of five mice per time point or condition were used with the exception 
of behavioral studies where groups of three mice were used. All in vivo 
experiments were performed in duplicates on separate occasions. Through 
the use of age, sex and strain matched, data from biological replicates were 
pooled and presented as means ± standard deviation. Each in vitro or ex vivo 
assay consisted of > three technical replicates and were performed on separate 
assay days. Data from separate assay days were pooled and shown as means 
± standard deviation. Distribution of data was assessed using D’Agostino and 
Pearson omnibus normality test. For normally distributed data, an unpaired 
or paired T-test was used to test for significance. For non-normally 
distributed data, a Mann-Whitney T-test was used to test for significance. 
Differences between data sets were designated significant if p<0.05.  
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C. Results 
 
3.7 Behavioral response to P4  
Two groups of mice (n=3) receiving (A) the treatment dose and (B) a dose 10x 
higher were assessed for differences in behavioral signs compared to healthy 
mice from the same colony.  Group A were treated with 100 μg P4 / 100 μl 
and observed at 8AM (immediately after injection), 2PM and 8PM. Group B 
were treated with 1 mg P4 / 100 μl and observed at 8AM (immediately after 
injection), 2PM and 8PM. The data regarding animal behavior are shown in 
Table 10. There was no difference between Group A, Group B and control 
mice at any timepoints. 
 
Table 10 - Behavioral responses to peptide administration. Group A (n=3) were treated with 100 μg 
P4 / 100 μl while Group B (n=3) were treated with 1 mg P4 / 100 μl. Mice were checked visually 
immediately after injection and six and 12 hours following injection. Changes in behavior relating to 
their movement in the cages (activity), rate of breathing, condition of fur (grooming) and posture 
were assessed. 
Behavior Control Group A Group B 
 Day 1 Day 2 Day 1 Day 2 Day 1 Day 2 
Activity baseline No change No change 
Breathing baseline No change No change 
Grooming baseline No change No change 
Posture baseline No change No change 
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3.8  Cell populations in blood: intravenous P4 
Mice (n=10 per group) were injected with peptide solution and blood was 
collected at 1, 4 and 24 hours following injection for Flow Cytometry staining. 
 
3.8.1 Neutrophil migration and FcγR 
Twenty-four hours following IV injection of P4 solution, a significant increase 
in systemic neutrophil numbers was detected as compared to the DEPC  
water control administration (control 6.1% vs. treated 14.6%, p=0.02)  (Figure 
31A) No significant differences in neutrophil numbers were detected at 1 or 4 
hours between groups. While neutrophil numbers did not increase until 24 
hours, their relative Fc-γ RII & III expression was rapidly modulated and a 
significant increase was detected in P4 treated mice compared to control mice 
at 4 (control 11.2% vs. treated 46.7%, p=0.02) and 24 (control 11.1% vs. treated 
75.1%, p<0.0001) hours following administration (Figure 31B). 
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Figure 31 – Neutrophils detected per ml blood at 1, 4 and 24 hours following intravenous injection of 
P4 or DEPC treated water in naïve healthy mice (n=10 per group). (B) Percentage Fc-γ RII/III 
expression on neutrophils in blood. (*) denotes significant differences compared to control at time 
points using ANOVA where p<0.05. 
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3.8.2 Monocyte migration and FcγR 
Differences in the proportion of circulating monocytes compared to control 
mice were seen at 1 (control 1.6% vs. treated 4.5%, p=0.06), 4 (control 1.7% vs. 
treated 4.3%, p=0.0005) and 24 hours (control 1.7% vs. treated 7.6%, p=0.0005) 
(Figure 32A). Fcγ RII & III expression was rapidly modulated in monocytes 
within the first hour and was significantly increased compared to control 
mice at 4 (control 22.6% vs. treated 51.6%, p=0.02) and 24 (control 22.4% vs. 
treated 56.4%, p=0.002) hours following injection (Figure 32B). 
 
 
Figure 32 – (A) Monocytes detected per ml blood at 1, 4 and 24 hours following intravenous injection 
of P4 or DEPC treated water in naïve healthy mice (n=10 per group). (B) Percentage Fc-γ RII/III 
expression on monocytes in blood. (*) denotes significant differences at time points using ANOVA 
where p<0.05. 
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3.9 Cell populations in BAL: intranasal P4 
3.9.1 Neutrophil migration and FcγR 
There was no significant difference detected in the relative numbers of 
neutrophils present in BAL (Figure 33A). Fc-γ RII & III expression was 
however significantly up-regulated 4 hours following administration (control 
11.6% vs. treated 26.6%, p=0.04) and remained elevated at 24 hours (but non 
significant to control at same time point) (Figure 33B). 
 
 
Figure 33 - Neutrophils detected per ml BAL at 1, 4 and 24 hours following intranasal administration 
of P4 or DEPC treated water in naïve healthy mice (n=10 per group). (B) Percentage Fc-γ RII/III 
expression on neutrophils in BAL. (*) denotes significant differences at time points using ANOVA 
where p<0.05. 
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3.8.1 BAL macrophages and FcγR 
Relative numbers of macrophages in BAL did not increase following 
intranasal administration as shown in Figure 34A. The expression of Fcγ RII 
& III was up-regulated at 4 hours (control 24.7% vs. treated 39%, p=0.01) 
whereas at 1 and 24 hours Fc-expression was elevated but this did not reach 
statistical significance (Figure 34B).  
 
 
Figure 34 - Macrophages detected per ml BAL at 1, 4 and 24 hours following intranasal 
administration of P4 or DEPC treated water at 12 and 18 hours following infection in naïve healthy 
mice (n=10 per group). (B) Percentage Fc-γ RII/III expression on macrophages in BAL. (*) denotes 
significant differences at time points using ANOVA where p<0.05. 
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3.10 Immunogold staining of Fcγ receptors 
Twenty-four hours after IV injection of P4 solution or DEPC water, peripheral 
blood leukocytes were stained and assessed for the presence of gold particle 
(Figure 35). A significant increase in Fcγ receptors (control 10 vs. treated 22, 
p=0.0009) was observed in monocytes (n=23 per group) while no significant 
difference was seen in neutrophils. Significant differences were also seen in 
the localization of FcγR: P4 stimulated cells had internalized more receptors 
than unstimulated controls (control 35% vs. treated 52%, p<0.005). 
 
 
Figure 35 – Number of gold particles found on P4 treated and control monocytes (n=23 per group). 
Black shading shows number of internalized gold particles per cell, grey shading shows external 
binding of gold particles per cell. (*) denotes significant differences between groups using ANOVA 
where p<0.05. 
 
  
  * 
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3.11 Murine macrophage opsonophagocytosis 
3.11.1 J774.2 OPKA 
Following opsonisation of bacteria, J774.2 murine macrophages showed a 
significantly increased ability to kill capsulated ST2 D39 (control 15.7% vs. 
treated 33.28%, p=0.01) and unencapsulated ST2 D39 (control 50.4 % vs. 
treated 66%, p=0.04) pneumococci when treated with P4. Using a different 
serotype, non-stimulated cells were unable to induce detectable killing of 
opsonized ST14 pneumococci. Following P4 stimulation however, J774.2 
macrophages were able to phagocytose 11% of the bacterial ST14 inoculum. 
Un-encapsulated pneumococci were more susceptible to phagocytosis than 
their capsulated homologues (capsulated 15.7% vs. unencapsulated 50.5%, 
p=0.0002) (Figure 36) 
 
Figure 36 - P4 mediated opsonophagocytosis killing of capsulated and unencapsulated strains of 
D39-ST2 as well as ST14 pneumococi by J774.2 murine macrophages. N=3 per group per cell type. (*) 
denotes significant differences between groups using ANOVA where p<0.05 
 
 
 
  
* 
* 
* 
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3.11.2 Alveolar and peritoneal macrophage OPKA 
Peritoneal and alveolar macrophages were obtained from naïve MF1 mice. 
Following peptide stimulation, both peritoneal (control 44% vs. treated 68%, 
p<0.03) and alveolar (control 53% vs. treated 74%, p=0.01) macrophages were 
able to significantly increase their phagocytosis of opsonized ST2 D39 S. 
pneumoniae (Figure 37).  
 
 
Figure 37 - Ex vivo opsonophagocytosis assay of serotype 2 (D39) S. pneumoniae by peritoneal and 
alveolar murine macrophages. (*) denotes significant differences at time points using ANOVA where 
p<0.05.  
 
In addition, P4-mediated phagocytosis assays using alveolar and peritoneal 
macrophages were conducted in the absence of either antibody (i.e. non-
opsonized bacteria) or functional complement. Functional complement was 
deactivated by placing an aliquot in a 56°C water-bath for 30 minutes. Non-
opsonized S. pneumoniae and inactivated complement incubated cells had 
minimal levels of killing (<5% killing) using either peritoneal (Figure 38A, 
n=2) or alveolar (Figure 38B, n=2) macrophages. In the absence of antibody or 
complement, P4 stimulation of peritoneal or alveolar macrophages led to no 
significant increases in killing.  
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Figure 38 - Ex vivo opsonophagocytosis assay of serotype 2 (D39) pneumococci by stimulated and un-
stimulated peritoneal (top panel) or alveolar (bottom panel) macrophages in the absence of antibody 
or complement. 
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D. Discussion 
 
3.12 Discussion 
This chapter aimed to assess the cellular responses to both intravenous and 
intranasal peptide administration in the absence of infection.  
 
3.12.1 Behavioral responses 
It is promising that no changes in behavioral responses were observed 
following peptide administration at the treatment dose and a dose 10 x 
higher. During infection, the host regulates neuronal responses to induce 
physical changes in order to assist in the immune response to infection [294]. 
Further modulation of these responses could disadvantage the host by 
negating the benefits of a therapeutical compound. Increasing the sample size 
and observing behavioral responses in a range of murine strains could 
strengthen these observations. In addition, behavioral responses could be 
correlated with inflammatory cytokines in the brain, such as interleukin-1 (IL-
1) and tumor necrosis factor-α (TNF-α), which are thought to induce sickness-
like behavioral responses [297]. 
 
3.12.2 Cell populations 
The responses of the main phagocytes to intravenous and intranasal peptide 
administration were measured in blood and BAL, respectively. Following 
intravenous administration of P4, a rapid increase of peripheral blood 
monocytes at 1, 4 and 24 hours was observed. In addition to bone marrow 
monocytes, a large proportion of monocytes reside in the spleen [133, 142, 
298]. It is unclear from these data whether the increased monocyte 
populations are derived from bone marrow or spleen reservoirs, or whether 
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they are produced in the bone marrow in response to peptide stimulation. 
The release of monocytes from bone marrow is mediated by inflammation 
and is dependent on the presence of CCL2 while the release from spleen is 
mediated by tissue injury and is dependent on the presence of angiotensin II 
[133].  Studies inhibiting CCL2, angiotensin II or their respective receptors 
could elucidate whether the peptide induced monocyte population is derived 
from the spleen or bone marrow and therefore inform on the role of recruited 
monocytes.  
 
In comparison to monocytes, neutrophil numbers did not increase until 24 
hours following intravenous administration. At 24 hours, however, the 
proportion of circulating neutrophils more than doubled compared to control 
mice. The production of neutrophils in the bone marrow takes approximately 
4-5 days, after which a small percentage are released into the blood stream 
while the majority are stored in the bone marrow [299]. The increased 
neutrophil population detected 24 hours following peptide administration is 
therefore likely to stem from the bone marrow reserve as opposed to freshly 
produced neutrophils. Release of neutrophils from the bone marrow is a 
complex process mediated by granulocyte-macrophage colony stimulating 
factor (GM-CSF), as well as granulocyte colony stimulating factor (G-CSF), 
produced by stromal cells in the bone marrow [300]. G-CSF reduces the 
secretion of the chemokine SDF-1α (CXCL12) by stromal cells leading to 
increased CXCR4 expression on neutrophils and their release into the blood 
stream [301]. It is unlikely that P4 acts on stromal cells to reduce SDF-1α 
expression in a G-CSF-like manner, as this results in rapid (within minutes) 
release of neutrophils [302], and P4 mediated neutrophil release was not 
detected until 24 hours. Instead, P4 may indirectly lead to the production of 
G-CSF via activation of macrophages (release G-CSF following endotoxin 
stimulation [303]) or endothelial cells (release G-CSF following TNF-α and IL-
1 stimulation [304]) or stimulate the release of other neutrophil 
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chemoattractants such as IL-8 (released by macrophages and epithelial cells 
[305]). 
 
In comparison to intravenous administration, intranasal administration of P4 
did not lead to a significant recruitment of monocytes or neutrophils into the 
alveoli. Administration of P4 into the lungs is likely to stimulate alveolar 
macrophages, which are responsible for the recruitment of phagocytes. As no 
increase in phagocytes was detected in BAL, intranasal peptide 
administration does not induce the recruitment of phagocytes through 
secretion of pro-inflammatory cytokines by alveolar macrophages. The 
proportion of peripheral blood monocytes or neutrophils were not measured 
following intranasal administration of P4, so it is difficult to determine 
whether (a) monocytes and neutrophils were released similar to intravenous 
studies but did not migrate to the alveoli or (b) intranasal administration of 
P4 does not induce the release of phagocytes into the blood stream. A study 
looking at circulating blood phagocytes, lung tissue phagocytes and 
phagocytes present in BAL following intranasal peptide administration 
would help clarify this point. 
 
3.12.3 Receptor expression 
In addition to measuring the proportion of phagocytes following peptide 
administration, Fcγ membrane expression was measured using flow 
cytometry. Following intravenous P4 administration, monocytes and 
neutrophils rapidly upregulated their expression of Fcγ receptors by 1 hour, 
with further increases detected at 4 and 24 hours. Intranasal administration 
only led to significant up-regulation of Fcγ receptors at 4 hours, where 
expression levels were similar to control at 1 and 24 hours. The differences 
may arise in the cell types measured, as opposed to the route of 
administration chosen. Circulating blood monocytes and neutrophils are 
short-lived phagocytes that rapidly respond to stimulants, such as 
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chemokines secreted by cells present at the site of infection or P4 peptide. 
Alveolar macrophages, in comparison, are sentinel cells that orchestrate the 
immune response, including the recruitment of neutrophils and monocytes. 
As such, alveolar macrophages remain mostly anti-inflammatory to avoid 
unnecessary recruitment of phagocytes. P4 may therefore only transiently up-
regulate alveolar macrophage Fcγ expression, where normal expression levels 
are re-instated in the absence of infection.  
 
The use of FcγR immunogold staining and electron microscopy confirmed the 
increased FcγR expression seen using flow cytometry. In addition, it was 
observed that Fcγ receptors were frequently found internalized into 
phagosomes. This could suggest that phagocytes are primed following 
peptide exposure leading to rapid uptake following FcγR ligation. In the 
context of augmented passive immunotherapy this is beneficial as the 
administration of immunoglobulin leads to the formation of 
immunecomplexes that need to be rapidly cleared.  
 
3.12.4 Phagocytosis  
Peptide stimulation of ex vivo derived peritoneal and alveolar macrophages 
led to a 30% and 20% increase in phagocytic killing of opsonized 
pneumococci, respectively. Previous studies have shown a two-fold increase 
in phagocytic killing by murine neutrophils [280]. The modest, albeit 
significant, increase in phagocytic killing by murine macrophages correlates 
with the expression of FcγR seen on macrophages during FcγR expression 
studies. As peripheral blood neutrophils expressed higher amounts of FcγR 
than alveolar macrophages following peptide stimulation, their phagocytic 
killing ability is also greater. 
 
The J774 murine macrophage cell line increased the killing of a range of IVIG 
opsonized pneumococci, independent of the presence of capsule. In the 
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absence of antibody or complement, however, phagocytosis was reduced and 
there were no detectable differences between stimulated and un-stimulated 
groups. This suggests that P4 enhances the natural process of phagocytosis as 
opposed to inducing unspecific killing mechanisms such as degranulation. 
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CHAPTER IV. 
 
P4 peptide studies in disease 
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A. Introduction 
 
4.1 Introduction 
Studies in chapter III established that in vivo peptide administration led to the 
recruitment and activation of phagocytes in the absence of infection. This 
chapter assessed the efficacy of augmented passive immunotherapy (API) in 
invasive and acute invasive models of pneumococcal disease. Mice were 
infected with a virulent strain of S. pneumoniae and treated with augmented 
passive immunotherapy (API) i.e. the concomitant administration of pathogen 
specific immunoglobulin (IVIG) and P4 peptide.  
 
4.1.1 Survival of young and aged mice in invasive models of 
pneumococcal disease (IPD) 
In order to account for genetic variation and therefore differences in 
susceptibility to pneumococcal infection [306], two strains (Swiss Webster, 
BALB/c) of young, outbred mice were used to model and treat invasive 
pneumococcal disease. In addition, mice were purchased and aged in house 
until >50% of the initial colony died of natural causes, thereby providing an 
aged population . Aged mice were infected and treated with API to assess 
whether treatment would be effective in hosts affected by senescence. 
 
4.1.2 Models of acute invasive pneumococcal disease (aIPD) 
A highly susceptible mouse strain (MF1) was chosen to model rapidly 
progressing, fatal invasive pneumococcal disease. Using this model, API was 
administered during bacteraemic infection to assess whether treatment would 
be effective at the most severe stage of infection. To further elucidate the 
effect of API during infection, the bacterial burden in lungs and blood as well 
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as the expression of Fcγ receptors on phagocytes was measured following 
infection and treatment.  
 
4.1.3 Intranasal administration 
In the MF1 mouse model, pneumococcal infection of the lung leads to the 
activation and recruitment of phagocytes to affected tissue before 
pneumococci seed into the blood stream. Using intranasal administration of 
P4 during acute infection of the lungs, it was assessed whether API of 
pneumonic lungs would affect the outcome of infection. The bacterial burden 
in lungs and blood as well as the expression of Fcγ receptors on phagocytes 
were measured following infection and intranasal peptide administration. 
 
4.1.4 Nasopharyngeal carriage 
 Pneumococcal disease is always preceded by pneumococcal carriage. The 
effect of API on nasopharyngeal carriage by S. pneumoniae during acute and 
asymptomatic infections was tested. Bacterial CFU numbers in 
nasopharyngeal tissue were enumerated following (a) intranasal peptide 
administration during asymptomatic carriage of S. pneumoniae and (b) 
intravenous peptide administration during invasive pneumococcal disease. 
 
4.1.5 Peptide pre-treatment 
In order to determine whether the effects of recruited and activated 
phagocytes seen in the previous chapter would translate to augmented 
phagocytic defense, mice were pre-treated with intravenous peptide prior to 
infection. The bacterial burden in lungs and blood as well as survival was 
measured following P4 pre-treatment and infection.  
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4.1.6 Publications 
These studies form part of two studies published in the Journal of Infectious 
Diseases and Clinical and Vaccine Immunology: 
 
Mathieu Bangert, Laura M. Bricio, Suzanna Gore, Gowrisankar Rajam, Edwin 
W. Ades, Stephen B. Gordon, Aras Kadioglu. “P4 mediated antibody therapy 
in an acute model of pneumococcal disease.” The Journal of Infectious Diseases 
(2012):205(9):1399-1407. 
 
Rajam Gowrisankar, Mathieu Bangert, Gabrielle M. Hammons, Nikkol 
Melnick, George M. Carlone, Jacquelyn S. Sampson, and Edwin W. Ades. "P4 
Peptide Therapy Rescues Aged Mice from Fatal Pneumococcal Sepsis." 
Clinical and Vaccine Immunology 17.11 (2010): 1823-824.  
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B. Materials & Methods 
 
4.2 Animal passage of pneumococci 
4.2.1 Bacterial stock preparation 
Non-passaged aliquots of pneumococci (chapter II) were thawed on ice and a 
loop full of pneumococci streaked on BAB culture plates for isolation 
followed by overnight incubation at 37°C (5% CO2). A sweep of colonies from 
the culture plates was then inoculated into a universal tube containing 10 ml 
BHI medium and again incubated at 37°C (5% CO2) overnight. 18-24 hours 
later, the BHI culture broth was centrifuged at 1500g for 15 minutes, the 
supernatant discarded and the resulting pellet re-suspended in 5 ml sterile 
PBS (to give an OD500 of 1.4-1.6). A 100 μl sample was taken for a viable cell 
count using the Miles & Misra technique.  
 
4.2.2 In vivo passage 
Using a 0.5 ml fine insulin syringe, 100 l of pneumococci suspension was 
injected intraperitoneally into two MF1 mice (100 μl each). The mice were 
monitored to ensure that 22-28 hours following injection signs of disease 
characteristic of a systemic infection were visible, meaning that the passage 
was successful. Cardiac puncture was then performed to obtain blood 
samples.  
 
4.2.3 Culturing and storing passaged stocks  
50 μl of blood from the cardiac puncture was inoculated into a universal tube 
containing 10ml BHI medium and statically incubated overnight at 37°C (5% 
CO2). Following incubation, cloudy suspension (bacteria) above the loose 
sediment (red blood cells) was carefully transferred to a sterile universal tube, 
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centrifuged at 1500g for 15 minutes, the supernatant discarded and the 
resulting pellet re-suspended into 1ml BHI serum broth. 700 μl of the re-
suspended pellet was added to 10ml of BHI serum broth until OD500 0.7 and 
incubated statically for 5 hours at 37°C (5% CO2) until OD500 ≥ 1.6. Following 
incubation, the culture broth was centrifuged at 1500 x g for 15 minutes, the 
supernatant discarded and the pellet re-suspended in 10 ml fresh BHI Serum 
Broth. The culture was then divided into 500 μl single use aliquots in sterile 
cryotubes and immediately stored at -80°C.  After > 48 hours in the freezer, 
aliquots were thawed to determine the number of pneumococci present in 
each aliquot using the Miles and Misra technique. 
 
4.3 Intranasal infection  
The intranasal route of infection can be used to instill pneumococci into the 
lungs to establish invasive pneumonia [306] or to the nasopharynx to 
establish carriage [307], depending on the bacterial and murine strains. A 
summary of murine bacterial strains used to establish different infection 
models is detailed in Table 11. 
 
Table 11 - Mouse strain, bacterial dose and volume used for different models of infection. 
Model Mouse Strain Bacterial Strain Dose Volume 
IPD Swiss Webster 
BALB/c 
WU2 1 x 107 CFU 40 μl 
Acute IPD MF1 D39 1 x 106 CFU 50 μl  
Carriage MF1 D39 1 x 106 CFU 10 μl 
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4.3.1 Preparing pneumococcal inoculum 
Once stocks were prepared, passaged and the viable number of pneumococci 
/ ml in each aliquot was determined, dosing for infection studies could be 
prepared. Aliquots of frozen passaged stocks were quickly thawed in a RT 
water bath and centrifuged at 900 x g for 3 minutes. The supernatant was 
discarded and the resulting cell pellet re-suspended in 1ml sterile PBS for 
another centrifugation at 900 x g for 3 minutes, following which the 
supernatant was discarded and the cell pellet re-suspended in 400 μl sterile 
PBS. The bacterial suspension was then diluted in sterile PBS to establish the 
desired infection dose (Table 11). 
 
4.3.2 Intranasal dose administration 
Mice were first lightly anaesthetized using 2.5% v/v inhaled Isofluorane (1.6-
1.8 L O2/min) in an anaesthetic box. The absence of reflex reactions and 
twitching of whiskers confirmed anesthesia. Once anaesthetized, the mice 
were scruffed and the bacterial suspension (see Table 11 for volume and dose) 
administered equally into both nostrils in a drop-wise fashion, allowing each 
drop to be inhaled before the next was administered. Following infection, the 
dose was measured for viable count as described using the Miles and Misra 
technique. 
 
4.4 Virulence testing passaged pnemococci 
In order to assure reproducible and effective modeling of acute invasive 
pneumococcal disease using the MF1 mouse strain as a host, animal passaged 
pneumococci were tested for virulence in a small number of mice. 
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4.4.1 Infection and monitoring 
An aliquot was thawed and prepared for intransasl infection as described in 
section 4.3. Five eight-week old female MF1 mice received a dose to establish 
the acute IPD model (see Table 11). Following infection, mice were monitored 
for signs of disease. If mice reached  “lethargic ++” (see Chapter II) stage then 
it was assumed they would progress to moribund and so they were humanely 
culled before this stage was reached after 44-52 hours. 
 
4.5 Augmented Passive Immunotherapy (API) 
Augmented passive immunotherapy is the combined treatment of pooled 
Immunoglobulin and the immunomodulating peptide. Infection is 
established in a mouse host prior to the administration of augmented passive 
immunotherapy. For peptide solution, two routes of administration were 
chosen. The peptide concentration and volume for each route of 
administration is detailed in Table 12. 
 
Table 12 – Route, volume and concentration of P4 peptide solution administration (per mouse) used 
for augmented passive immunotherapy in models of pneumococcal disease.  
Administration Treatment DEPC Water P4 Peptide 
Intravenous Sepsis secondary to acute 
pneumonia 
100 μl  100 μg  
Intranasal Acute pneumonia 40 μl  100 μg  
Intranasal Asymptomatic carriage 15 μl 100 μg  
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4.5.1 Intraperitoneal immunotherapy 
IVIG was used as a source of pathogen specific immunoglobulin. Gamunex 
(Talecris, Lot 26NG042) was used for all in vivo studies in this thesis. IVIG was 
always administered intraperitoneally, 20 minutes before peptide 
administration to allow for opsonisation to occur in vivo. Mice were scruffed 
and held at a slight downward angle. Using an insulin syringe, 100 μl of IVIG 
solution (equivalent to 10 μg pooled IgG) was injected into the lower right 
quadrant of the abdomen as shown in Figure 39. Care was taken to insert only 
the tip of the syringe into the abdomen in order to avoid accidental damage of 
vital organs.  
 
 
 
Figure 39 - Intraperitoneal injection of IVIG into mice. (A) Mice were scruffed and held at a slight 
angle for administration of 100 μl IVIG using an insulin syringe. (B) Circle indicates the injection 
site in the lower right quadrant of the mouse abdomen. This site helps avoids damage of internal 
organs through accidental puncture. Adapted from [308]. 
 
4.5.2 Intravenous peptide administration 
Solubilized peptide was administered intravenously (IV) following infection 
and IVIG administration. Mice were placed in a cage-warmer (37°C) for 
>2minutes to allow for vasodilation of veins to occur. Mice were then placed 
in a restrainer allowing access to the tail veins. The tails were sterilized using 
70% ethanol solution. Using an insulin syringe, peptide solution (see Table 12 
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for concentration and volume) was injected into dorsal tail veins as shown in 
Figure 40.  
 
 
 
Figure 40 - Schematic diagram of a transverse section of a mouse-tail indicating the various veins 
available for intravenous administrations. Mouse-tails were pre-warmed to allow for vasodilation to 
occur and facilitate injections. P4 solution was injected into the dorsal caudal vein. 
 
4.5.3 Intranasal administration 
Solubilized peptide was administered intranasally (IN) following infection 
and IVIG administration. Mice were lightly anaesthetized using 2.5% v/v 
inhaled isofluorane, (1.6-1.8 L O2/min) in an anaesthetic box. The absence of 
reflex reactions and twitching of whiskers confirmed anesthesia. Once 
anaesthetized, mice were scruffed and P4 solution (see Table 12 for 
concentration and volume) was administered equally into both nostrils in a 
drop-wise fashion, allowing each drop to be inhaled before the next was 
administered.  
 
4.6 Invasive pneumococcal disease (IPD) 
In the IPD model, untreated outbred Swiss Webster or BALB/c mice become 
moribund 72-96 hours following infection as shown in Figure 41. Ageing in 
both humans and mice causes a general reduction of biological function 
including in the immune system. At very young ages, the immune system of 
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both mice and humans has not fully developed. As a result, pneumonia is 
common in young (<5 years) and aged (>65 years) populations where 
infections can develop acutely. As such, we assessed whether augmented 
passive immunotherapy would be effective in these populations. 
 
 
Figure 41 - Schematic diagram showing the course of infection during the invasive pneumococcal 
disease model using Swiss Webster or BALB/c mice and intranasal administration of WU2 ST-3 
pneumococci. 24-48 hours following infection, mice establish pneumonia, which develops to 
bacteraemia between 48-72 hours. 72-96 hours following infection, 80-100% of untreated mice are 
expected to be dead or moribund due to sepsis.  
 
4.6.1 IPD in young mice 
Four groups of eight-week old female Swiss Webster mice were infected with 
1 x 107 CFU of WU2 ST-3 pneumococci as described in Chapter II. Augmented 
passive immunotherapy was administered intravenously at 48 and 72 hours 
following infection.  
 Group 1 (n=5) received DEPC-treated water alone 
 Group 2 (n=5) received IVIG alone 
 Group 3 (n=5) received P4 peptide alone  
 Group 4 (n=5) received P4 peptide and IVIG 
Mice were monitored for signs of disease for up to 96 hours following 
infection. These experiments were performed in duplicate on separate days. 
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4.6.2 IPD in aged mice 
Female Swiss Webster and female BALB/c mice were purchased and aged in-
house at the Centres for Disease Control and Prevention Animal Research 
Facility until >50% of the initial colony died of natural causes (15 months for 
Swiss Webster and 11 months for BALB/c mice). This in effect provided an 
“aged population” which can be used to model disease in mice affected by 
senescence [309]. Eleven-month-old BALB/c (n=20) and 15-month-old Swiss 
Webster mice (n=20) were infected intranasally with WU2 ST-3 pneumococci 
and split into treatment and control groups (n=10 per group). Mice were 
monitored and visually scored twice daily for moribund characteristics. P4 
therapy was administered intravenously at 48 and 72 hours post infection. 
Treated and untreated animals were monitored for 168 hours. 
 
4.7 Acute invasive pneumococcal disease (aIPD) 
In the aIPD model, MF1 mice develop pneumonia by 12 hours, bacteraemia 
by 24 hours and become moribund by 48 hours following infection (Figure 
42). This process is highly reproducible and more rapid than in the IPD 
model. The aIPD model reflects infections that in a clinical setting rapidly 
progress to fatal sepsis and where antibiotic administration does little to affect 
mortality. Two treatment methods were tested in both pneumococcal 
pneumonia and sepsis secondary to pneumococcal pneumonia. 
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Figure 42 – Schematic diagram showing the course of infection during the acute invasive 
pneumococcal disease model using MF1 mice and intranasal administration of in vivo passaged D39 
ST-2 pneumococci. Twelve hours following infection, mice develop pneumonia, which develops to 
bacteraemia and sepsis at 24 and 36 hours following infection, respectively.  At 48 hours (not shown) 
100% of untreated mice are expected to be dead or moribund. 
 
4.7.1 Intravenous P4 and pneumococcal septicemia 
In an attempt to treat the most severe cases of acute infection, augmented 
passive immunotherapy was administered intravenously at 24 and 30 hours 
following infection where pneumonia and bacteraemia was already 
established. Three studies were done using this model: (A) Survival study to 
establish the P4 treatment model in the MF1 mouse and to confirm the lack of 
protection using IVIG or peptide alone (B) Tissue CFU study to assess 
bacterial growth during infection and treatment and (C) cell population study 
to describe cellular responses during infection and treatment. The time points 
in which blood, lung and nasopharyngeal tissue were extracted in this 
treatment model were at 0, 24, 36 and 48 hours following infection. 
 
4.7.2 Intranasal P4 and pneumococcal pneumonia 
In these studies, augmented passive immunotherapy was given intranasally 
at 12 and 18 hours following infection, when pneumonia was established but 
had not yet progressed to bacteraemia. Three studies were done using this 
model: (A) Survival study to test whether IN peptide administration 
treatment is effective compared to control administrations (B) CFU study to 
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assess bacterial load in the lungs and blood during infection and treatment 
and (C) Cell population study to describe cellular responses to infection and 
treatment. The time points in which blood and lung tissue were extracted in 
this treatment model were at 0, 24 and 48 hours following infection. 
 
4.7.3 In vivo study design for intravenous and intranasal P4 
(A) Survival studies 
Four groups of five mice were infected intranasally: 
o Group 1 (n=5) received DEPC-treated water alone 
o Group 2 (n=5) received IVIG alone 
o Group 3 (n=5) received P4 peptide alone 
o Group 4 (n=5) received P4 peptide and IVIG.  
Mice were monitored for signs of disease for up to 48 hours following 
infection and survival recorded. These experiments were performed in 
duplicate on separate days. 
 
 
 
(B) Infection studies 
Two groups of mice were infected intranasally: 
 Group 1 (n=5 per time point) received DEPC-treated water alone  
 Group 2 (n=5 per time point) received P4 peptide and IVIG.  
Mice were monitored for signs of disease for up to 48 hours following 
infection. Lung, blood and nasopharyngeal tissue was collected at 24, 36 and 
48 hours following infection. These experiments were performed in duplicate 
on separate days. 
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(C) Cell population studies 
Two groups of mice were infected intranasally: 
 Group 1 (n=5 per time point) received DEPC-treated water alone  
 Group 2 (n=5 per time point) received P4 peptide and IVIG.  
Mice were monitored for signs of disease for up to 48 hours following 
infection. These experiments were performed in duplicate on separate days. 
 
4.8 Pneumococcal Carriage 
A pre-requisite for invasive pneumococcal disease is the successful 
colonization of the nasopharnyx. From there, pneumococci can be aspirated 
into the lungs causing pneumonia. In order to understand the immunological 
events that occur during pneumococcal colonization, animal models were 
established in which pneumococci are stably carried in the nasopharynx for 
up to 28 days without causing disease [307]. Preventing, reducing or blocking 
carriage is of great interest.  
 
4.8.1 Infection to establish pneumococcal carriage 
This study assessed whether peptide treatment of the nasopharynx alongside 
IVIG would alter carriage in a mouse model. 20 mice were infected with 1 x 
106 CFU / 10 μl to establish pneumococcal carriage in the nasopharync. Three 
time points were chosen at which nasopharyngeal tissue was collected and 
level of colonization determined: Day 0 (n=3) to establish whether the correct 
dose was administered, Day 3 (n=3) to confirm stable colonization and Day 7 
(n=7 per group) as a final timepoint. 100 μg of P4 solubilized in 15 μl of DEPC 
treated water was administered intranasally and 100 μl of IVIG peritoneally 
on days 5 and 6 (48 and 24 hours before final time point, respectively).  
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4.9 Pre-treating before aIPD  
To assess whether the effect seen when administering P4 solution in the 
absence of infection would benefit the host during pneumococcal infection, 
peptide solution only (i.e. no IVIG) was intravenously administered 24 hours 
prior to an aIPD infection. A survival study and infection study was done. For 
the survival study, two groups (pre-treatment, no pre-treatment, n=5 per 
group) were infected and their survival rate recorded. For the infection 
studies two groups (pre-treatment, no pre-treatment, n=10 per group) were 
infected and blood and lung tissue collected at 24 and 48 hours following 
infection (n=5 per time point per group). 
 
4.10 Statistical analysis 
Groups of five mice per time point or treatment were used. All in vivo 
experiments were performed in duplicates on separate occasions with the 
exception of the “aged mice” and “pneumococcal carriage” studies, where 
experiments were performed once with groups of eight and seven mice, 
respectively. CFU, Flow Cytometry and survival data from the primary and 
repeat in vivo studies were pooled resulting in groups of n=10. Data is 
presented as means ± standard deviation. Distribution of data was first 
assessed using D’Agostino and Pearson omnibus normality test. For normally 
distributed data, an unpaired or paired T-test was used to test for statistical 
differences between treated and control groups. For non-normally distributed 
data, a Mann-Whitney T-test was used to test for statistical differences 
between treated and control groups. For survival studies, data were plotted 
into a Kaplan-Meier estimator and analyzed for statistical difference 
compared to control groups using a logrank test. Differences between data 
sets were designated significant if p<0.05.  
 
  
Chapter IV    P4 peptide studies in disease   
    121 
B. Results 
 
A summary of infection studies in Chapter IV showing the infection model, 
bacterial and murine strain, route of API administration and outcomes 
measured is shown in Table 13.   
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Table 13 - Summary of infection studies in Chapter IV showing the infection model, bacterial and murine strain, route of API administration and outcomes measured.  
Expt Model SPN Mouse API administration Outcomes Notes Page 
1 IPD (young) ST3 Swiss 
Webster 
Intravenous Survival Invasive model, Increased survival following API 
compared to control groups (peptide or IVIG alone) 
123 
2 IPD (aged) ST3 Swiss 
Webster 
Intravenous Survival Model of senescence, Increased survival following API 124 
3 IPD (aged) ST3 BALB/c Intravenous Survival Model of senescence, Increased survival following API 125 
4 aIPID 
(young) 
ST2 MF1 Intravenous Survival 
CFU 
Phagocytes 
Susceptible model, Increased survival, decreased CFU, 
increased phagocyte recruitment and activation following 
API during bacteraemia 
126 
5 aIPD (young) ST2 MF1 Intranasal Survival 
CFU 
Phagocytes 
Susceptible model, no bacteraemia and mortality, 
decreased lung CFU, increased phagocyte recruitment 
and activation following API during pneumonia 
132 
6 Carriage  ST2 MF1 Intranasal CFU Asymptomatic carriage, increased CFU following API 137 
7 Carriage  ST2 MF1 Intravenous CFU Carriage during invasive disease, no significant changes 
in CFU following API 
138 
8 aIPD  ST2 MF1 Intravenous 
(Pre-treatment) 
Survival 
CFU 
Peptide alone (no IVIG) prior to infection, increased 
survival, decreased CFU  
139 
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4.11 Invasive pneumococcal disease (IPD)  
Using a model of invasive pneumococcal disease (IPD), the ability of 
combined administration of P4 peptide & IVIG to rescue moribund mice was 
compared to that of P4 peptide administration alone, IVIG or DEPC treated 
water alone. Mice were infected with 2 x 107 ST3 pneumococci and treated at 
24 and 48 hours post infection with either DEPC treated water, P4 solution, 
IVIG or a combination of P4 and IVIG.  
4.11.1 Survival in young Swiss Webster mice 
Survival of 8-12 week old mice in different groups following infection and 
treatment is shown in Figure 43. 96 hours following infection 0% (0/10) mice 
in the control group survived, 20% (2/10) in the IgG alone and P4 alone 
groups survived whereas there was 80% survival (8/10) in the P4-IVIG 
treatment group (p=0.01). 
 
 
Figure 43 – Survival in a model of invasive pneumococcal disease using young Swiss Webster mice 
and ST3-WU2 pneumococci. Mice were infected and treated with either DEPC treated water (blue), 
P4 solution alone (orange), IVIG alone (green) or P4 solution and IVIG (black) (n=10 per group). 
Treatment was administered at 24 and 48 hours following infection.  
Dose 2 
 
Dose 1 
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Aging is known to reduce the effectiveness of the immune system and the 
elderly population is highly susceptible to pneumococcal infection. P4-IVIG 
treatment was assessed in a host whose immune system is weakened as a 
result of ageing.  
 
4.11.2 Survival in aged Swiss Webster mice 
15 month old Swiss Webster mice were infected with 2 x 107 ST3 pneumococci 
and monitored for signs of disease. Survival of treated and untreated mice 
following infection is shown in Figure 44. At 48 h post challenge, 80% (16/20) 
were moribund. The moribund mice were randomly divided into a control (n 
= 8) and a treatment group (n = 8). Following intra-nasal infection, 73% of 
treated 15-month-old Swiss Webster mice survived with complete remission 
of symptoms, compared to 20% survival in the control group (p=0.0002). 
 
 
Figure 44 - P4 peptide alongside IVIG confers protection to 15-month-old Swiss Webster mice 
against intranasal S. pneumoniae serotype 3 (WU2) challenge. Intravenous injection of P4 (100 
μg/mouse) with IVIG (100 μl/mouse) at 48 and 72 h after challenge provided highly significant 
protection (73%; P = 0.0002) from S. pneumoniae WU2 infection. Published figure [283]. 
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4.11.3 Survival in aged BALB/c mice 
BALB/c mice are naturally more resistant to pneumococcal infection than 
Swiss Webster or MF1 mice [310]. 11 months old BALB/c mice were infected 
with 2 x 107 ST3 pneumococci and monitored for signs of disease. Survival of 
treated and untreated mice following infection is shown in Figure 45. At 48 h 
post challenge, 80% (16/20) were moribund. The moribund mice were 
randomly divided into a control (n = 8) and a treatment group (n = 8). Similar 
to Swiss-Webster aged mice, 95% of the treated 11-month-old BALB/c mice 
survived, while only 45% of the mice from the control group survived 
following infection (p=0.02). 
 
 
Figure 45 - P4 peptide alongside IVIG confers protection to 11-month-old BALB/c mice against 
intranasal S. pneumoniae serotype 3 (WU2) challenge. Intravenous injection of P4 (100 μg/mouse) 
with IVIG (100 μl/mouse) at 48 and 72 h after challenge provided highly significant protection (95%; 
P=0.02) from S. pneumoniae WU2 infection. Published figure [283]. 
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4.12 Acute invasive pneumococcal disease (aIPD) - 
intravenous P4 during pneumococcal septicemia 
 
4.12.1 Survival studies 
8-12 week old mice were infected intranasally using an acute dose (1 x 106 
CFU) of D39 pneumococci and treated intravenously with P4-IVIG or DEPC 
solution at 24 and 30 hrs post-infection. Figure 46 shows a Kaplan-Meier 
survival plot of control and P4-IVIG treated mice. 48 hours following 
infection, mice in the P4-IVIG group exhibited 60% survival as compared to 
0% survival (p=0.03) in the control group.  
 
 
Figure 46 – Kaplan-Meier survival plot of control of P4-IVIG treated groups in a model of acute 
pneumococcal disease using MF1 mice and ST2-D39 pneumococci. Mice were infected and (A) DEPC 
treated water or (B) P4 and IVIG was administered at 24 and 30 hours following infection. Published 
figure [285].   
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Survival of control groups, where mice were treated with P4 peptide alone or 
IVIG is shown in Figure 47. Following treatment at 24 and 30 hours post 
infection, neither P4 alone nor IVIG alone treated mice showed significant 
differences (p=0.1 and p=0.3, respectively) in augmenting survival compared 
to the control group, which received DEPC treated water alone.  
 
 
Figure 47 – Kaplan-Meier survival plot of control groups in a model of acute pneumococcal disease 
using MF1 mice and ST2-D39 pneumococci. Mice were infected and (A) DEPC treated water or (B) P4 
and IVIG was administered at 24 and 30 hours following infection. 
 
4.12.2 Infection studies 
The CFU count in treated and untreated mice are compared in Figure 48. 
Panel (A) shows CFU/mg of lung tissue and panel (B) shows CFU/ml of 
blood. P4-IVIg mice had significantly fewer bacteria in their lungs at 36 hrs 
(control Log10 6 CFU vs. treated Log10 4.5 CFU, p=0.04) and 48 hrs (control 
Log10 6.9 CFU vs. treated Log10 3.9 CFU, p=0.004), 12 and 24 hours following 
the first treatment respectively, as compared to the control group (Figure 
48A). Bacteremia levels, which in control mice steadily increased as a result of 
uncontrolled lung infection, was reduced in P4-IVIG treated mice where a 
significant decreased amount of bacteria in the blood was detected at 48 hrs 
(control Log10 8.8 CFU vs. Log10 4 CFU, p=0.01) (Figure 48B). 
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Figure 48 - Log10 S. pneumoniae colony forming units (CFU) recovered per (A) mg of lung tissue and 
(B) ml of blood at 0, 24, 36 and 48 hours following infection in treated and non-treated mice. Mice 
were treated with either DEPC water or P4-IVIG at 24 and 30 hours following infection. (*) denotes 
significant differences at time points using ANOVA where p<0.05. Published figure [285]. 
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4.12.3 Cell population studies 
Neutrophil numbers and activation are compared between treated and 
untreated mice in Figure 49. Panel (A) shows cells/mg of tissue and panel (B) 
shows FcγR expression. Throughout infection and treatment, neutrophil 
numbers remained similar between both groups following the same pattern 
of early increase peaking at 36 hrs, followed by a decline in numbers by 48 hrs 
(Figure 49A). Neutrophil Fc expression levels were increased in both groups 
by 36 hours, where neutrophils from P4 treated mice had elevated, albeit non-
significant levels of Fc expression compared to the DEPC treated mice 
(control 38.2 % FcγR+ vs. treated 72.4% FcγR+, p=0.07). At 48 hours, FcγR 
expression decreased in control mice but remained higher and significantly 
different in P4-IVIG treated mice (control 15.7 % vs. treated 66.9 %, p=0.02) in 
comparison (Figure 49B).  
Chapter IV    P4 peptide studies in disease   
     
  130 
C
h
a
p
te
r IV
   
 
 
 
 
Figure 49 – (A) Neutrophils detected per mg lung tissue at 0, 24, 36 and 48 hours following infection 
in treated and non-treated mice. (B) Fc-γ RII/III expression in neutrophils detected in lungs at 0, 24, 
36 and 48 hours following infection in treated and non-treated mice. Mice were treated with either 
DEPC water or P4-IVIG at 24 and 30 hours following infection (*) denotes significant differences at 
time points using ANOVA where p<0.05. Published figure [285]. 
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While neutrophil numbers remained similar in the lungs of treated and 
control mice, macrophages in lungs of P4-IVIG treated mice were significantly 
higher at 36 hrs (control 1,069/mg vs. treated 3,850/mg, p=0.001) (Figure 50A). 
By 48 hours, macrophages in the control group also increased while numbers 
in the P4-IVIG group remained at the same level. There was no significant 
difference in Fc- expression levels in macrophages as was observed for 
neutrophils (Figure 50B). 
 
 
Figure 50 - (A) Macrophages detected per mg lung tissue at 0, 24, 36 and 48 hours following infection 
in treated and non-treated mice. (B) Fc-γ RII/III expression in macrophages detected in lungs at 0, 24, 
36 and 48 hours following infection in treated and non-treated mice. (*) denotes significant 
differences at time points using ANOVA where p<0.05. Published figure [285]. 
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4.13 Acute invasive pneumococcal disease (aIPD) - 
intranasal P4 during pneumococcal pneumonia 
 
4.13.1 Survival studies 
Intranasal infection was used to test whether very early pre-emptive P4-IVIG 
treatment of lungs during invasive pneumonia, prior to the development of 
bacteremia, would alter the course of infection. Mice were infected and 
intranasally treated with P4 and IVIG at 12 and 18 hrs post-infection and their 
survival is shown in Figure 51. By 48 hrs following infection, 100% (10/10) of 
P4-IVIG mice survived compared to 80% moribund mice in the control group 
(p=0.01). 
 
 
Figure 51 - Survival of MF1 mice intranasally infected with 106 S. pneumoniae (D39) and treated with 
intranasal P4 and intraperitoneal IVIG at 12 and 18 hours. Treatment groups: P4-IVIG (100 μl IVIG, 
100 μg P4) and DEPC water (100 μl) control (n=10 per group). Published figure [285]. 
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No significant differences were seen when P4 or IVIG was administered alone 
and compared to the DEPC treated water control group as shown in Figure 
52. Mice intranasally treated with P4 solution alone showed 40% survival 
(4/10) while IVIG alone treated mice showed 30% (3/10) survival. Both control 
groups (P4 alone and IVIG alone) in the IN study had slightly higher survival 
rates as compared to control groups in the IV administration studies.  
 
 
 
Figure 52 – Kaplan-Meier survival plot of MF1 mice intranasally infected with 106 S. pneumoniae 
(D39) and treated with intranasal P4 and intraperitoneal IVIG at 12 and 18 hours. Treatment groups: 
P4 (100 μl IVIG, 100μg P4) and IVIG (100 μl) controls (n=10 per group). Published figure [285]. 
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4.13.2 Infection studies 
Lung and blood tissue was collected during the course of infection and 
treatment in order to assess bacterial load. At 24 hrs following infection, there 
was no significant difference (p=0.09) in bacterial lung CFUs between control 
and P4-IVIG treated groups (Figure 53A). By 48 hrs however, bacterial loads 
in control mice significantly increased compared to 24 hrs levels while 
pneumococcal loads in P4-IVIG treated mice remained the same as 24 hrs and 
were significantly less compared to the control group (control Log10 4.9 CFU 
vs. treated Log10 2 CFU, p=0.002). The presence of bacteria in the blood of 
control mice significantly increased by 48 hrs while none of the P4-IVIG 
treated mice had any bacteria in blood at either 24 or 48 hrs (Figure 53B). 
 
 
Figure 53 - Log10 S. pneumoniae colony forming units (CFU) recovered per (A) mg of lung tissue and 
(B) ml of blood at 0, 24 and 48 hours following infection in treated and non-treated mice. (*) denotes 
significant differences at time points using ANOVA where p<0.05. Published figure [285]. 
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4.13.3 Cell population studies 
An influx of neutrophils by 24 hrs was detected in both control and P4-IVIG 
treated groups. However, by 48 hrs, P4-IVIG treated mice had significantly 
lower numbers of neutrophils in their lungs (control 13,496/mg vs. treated 
4,638/mg, p=0.03), while neutrophil numbers remained constant in control 
mice (Figure 54A). Fc- RII/III expression on neutrophils was significantly 
higher at 48 hours in P4-IVIG treated mice than in control mice (control 10.2% 
vs. treated 45%, p=0.03) (Figure 54B).  
 
 
Figure 54 – (A) Neutrophils detected per mg lung tissue at 0, 24 and 48 hours following infection in 
treated and non-treated mice. (B) Fc-γ RII/III expression on neutrophils detected in lungs at 0, 24 and 
48 hours following infection in treated and non-treated mice. (*) denotes significant differences at 
time points using ANOVA where p<0.05. Published figure [285]. 
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Macrophage numbers in lungs remained similar between all groups 
throughout infection except at 48 hrs, where a substantial decrease (albeit 
non-significant, control 1,604/mg vs. treated 2,742/mg, p=0.06) in macrophages 
was detected in P4-IVIG treated mice (Figure 55A). Throughout the course of 
infection and treatment, Fc- RII/III expression on macrophages remained 
statistically similar (Figure 55B) but elevated levels of Fc- RII/III were 
detected on macrophages in the P4 treated group at 24 hours (control 42 % vs. 
treated 73%, p=0.08). 
 
 
Figure 55 - (A) Macrophages detected per mg lung tissue at 0, 24 and 48 hours following infection in 
treated and non-treated mice. (B) Fc-γ RII/III expression on marcophages detected in lungs at 0, 24 
and 48 hours following infection in treated and non-treated mice. (*) denotes significant differences 
at time points using ANOVA where p<0.05. Published figure [285]. 
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4.14 Pneumococcal carriage 
4.14.1 Nasopharyngeal carriage (asymptomatic infection) 
Pneumococci were instilled intranasally to murine nasopharynx to establish 
long-term nasopharyngeal carriage. P4 was administered to the nasopharynx 
alongside IVIG on days 5 and 6. The CFU levels in nasopharyngeal tissue of 
treated and control mice are shown in Figure 56. At days 0, 3 and 7, CFU 
levels detected in the nasopharynx of control mice were similar (Log10 means 
of 2.73, 2.59 and 2.49 CFU respectively), with no significant changes detected. 
P4-IVIG treated mice had significantly higher levels of CFU (control Log10 2.59 
vs. treated Log10 3.1, p=0.03) in their nasopharyngeal tissue at day 7. No CFU 
were detected in the lungs of control or P4-IVIG treated mice at any time-
points.  
 
 
Figure 56 – Intranasal administration of P4 peptide during nasopharyngeal carriage of D39 
pneumococci in MF1 mice. 20 mice were infected intranasally and placed into Day 0 (n=3), Day 3 
(n=3), Day 7-Control (n=7) and Day 7-P4-IVIG (n=7) groups. Mice were treated intranasally with P4 
on days 5 and 6. Nasopharyngeal tissue was harvested at time-points and assessed for bacterial loads. 
(*) denotes statistical significance using ANOVA. 
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4.14.2 Nasopharyngeal carriage (acute invasive infection) 
Colonization of the nasopharynx was measured during the course of infection 
and treatment in an acute model of invasive pneumococcal disease. The CFU 
levels in nasopharyngeal tissue of treated and control mice are shown in 
Figure 57. Following infection at time 0, nasopharyngeal colonization levels 
dropped at 24 hours post infection but began increasing in both the control 
and P4-IVIG treated mice at 36 and 48 hours. At time point 0, 24 and 36 hours 
following infection, colonization levels were similar between Control and P4-
IVIG treated groups. P4-IVIG treated mice at 48 hours however showed less, 
albeit non-significant (control Log10 6.2 vs. treated Log10 4.8, p=0.28), levels of 
pneumococci in the nasopharynx as compared to control mice. 
 
 
Figure 57 – Nasopharyngeal carriage of D39 pneumococci in MF1 mice during an acute invasive 
pneumococcal disease model. Mice were infected (n=5 per group per time-point), treated 
intravenously with P4 and IVIG at 24 and 30 hours following infection and nasopharyngeal tissue 
extracted for CFU analysis. Statistical analysis was done using ANOVA. 
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4.15 Peptide pre-treatment 
It was tested whether recruited and activated phagocytes seen following 
peptide administration in the absence of infection would benefit the host 
during subsequent pneumococcal infection. Mice were first injected 
intravenously with P4 solution, and then infected intranasally with an acute 
dose of D39 pneumococci 24 hours later. The survival and bacterial loads in 
blood and lung was assessed following infection and are shown in Figure 58 
and Figure 59, respectively. 
 
4.15.1 Survival studies 
Control mice that were pre-treated with DEPC solution succumbed to 
infection 48 hours following infection. In comparison, mice that received P4 
solution 24 hours prior to infection showed significant improvements in 
survival (p=0.007) where no mortality was observed at 48 hours. Mortality 
was however delayed as by 72 hours, 80% of pre-treated mice had died. 
 
 
Figure 58 - Survival of mice pre-treated intravenously 24 hours prior to infection with either P4 
solution (100 μg P4 peptide / 100 μl DEPC treated water) or control DEPC treated water. n=10 per 
group. 
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4.15.2 Infection studies 
In addition to survival, bacterial loads were measured in mice pre-treated 
with either P4 solution or DEPC treated water. At 24 hours, both the lung 
CFU (control Log10 3.7 vs. treated Log10 0.8, p=0.002) and blood CFU (control 
Log10 4.6 CFU vs. treated Log10 1.2 CFU, p=0.04) levels were significantly 
lower in P4 pre-treated mice than in the control groups. By 48 hours however, 
CFU levels were statistically similar between both groups. 
 
 
Figure 59 - CFU recovered in lungs and blood of mice pre-treated 24 hours prior to infection with 
either (a) 100 μg P4 peptide / 100 μl DEPC treated water or (b) DEPC treated water alone. n=10 per 
group. (*) denotes significant differences at time points using ANOVA where p<0.05 
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C. Discussion 
 
4.16 Discussion 
In this chapter, the efficacy of API using murine models of invasive 
pneumococcal disease was assessed. Measurement of treatment efficacy 
included survival, bacterial burden, phagocyte recruitment and activation 
following both intravenous and intranasal administration of P4 and IVIG 
using a range of murine models. Furthermore, the effect of API on 
nasopharyngeal carriage of S. pneumoniae during symptomatic and 
asymptomatic infection, as well as peptide pre-treatment was assessed.  
 
4.16.1 Invasive pneumococcal disease (IPD)  
Survival of infected mice was significantly increased in young and aged Swiss 
Webster and BALB/c mice. It is well established that young (<5 years) and 
aged (>65 years) populations are more susceptible to infection [311, 312]. 
Factors influencing susceptibility include an underdeveloped immune system 
in the young [313], and dysregulated immune responses in aged populations 
[314], leading to poor recognition and killing of pathogens [315].  The efficacy 
of API in both young and aged mice is therefore promising. Studies have 
shown that neutrophils in aged populations [316] and in children >1-year of 
age [317] exhibit reduced phagocytic function. Assessing whether P4 peptide 
could augment phagocytosis of human blood neutrophils from young and 
aged populations would strengthen these data. 
 
Enhanced survival in all models was seen during concomitant administration 
of P4 and IVIG but not when P4 or IVIG was administered on their own. 
These results confirm previous results where mice infected with S. 
pneumoniae, S.pneumoniae-Influenza co-infection and S. aureus were rescued 
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only when P4 was administered in the presence of pathogen-specific 
immunoglobulin [280-282, 284]. An augmented phagocytic therapy, where 
phagocytes are stimulated for enhanced uptake, relies on the presence of 
opsonised pathogens. Similarly, passive immunotherapy, where pathogens 
are opsonised with exogenous immunoglobulin, relies on effective 
phagocytosis. The necessity for both P4 and IVIG to be present for effective 
treatment underlines the synergistic mechanism of API proposed in previous 
studies [274].   
 
4.16.2 Acute invasive pneumococcal disease (aIPD) – 
intravenous peptide 
The susceptible MF1 host was chosen to model rapidly progressing 
pneumococcal infections. In a clinical setting, acute infections are responsible 
for the majority of deaths in intensive care units due to the time taken for 
antimicrobial compounds to take effect [318]. To challenge the treatment 
model, API was administered intravenously at 24 hours, when pneumonia 
had already progressed to bacteraemia.  
 
Intravenous API increased survival by reducing the bacterial burden in lungs 
and blood as well as recruiting monocytes and activating both neutrophils 
and monocytes in the lung. Comparable to the cell population studies in the 
absence of infection in chapter III, monocyte/macrophages were heavily 
recruited to the lungs following IV peptide administration during infection. It 
was suggested in chapter III that, in the absence of infection, P4 induces 
monocyte release from either the bone marrow or spleen monocyte reservoir. 
As monocyte/macrophage recruitment to the lung is correlated with a halt in 
the progression of pneumonia, it is possible that P4 enhances the release of 
monocytes from their reservoir during infection, which migrate to the lungs 
(due to chemotactic cytokines produced by alveolar macrophages and 
epithelial cells during infection) and actively participate in clearance of 
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bacteria. An increase of activated monocytes during infection is beneficial as it 
has previously been shown that monocytes are essential in containing septic 
infections [319]. Studies looking at the expression of junctional adhesion 
molecule-like protein (JAML), an important adhesin for trensendothelial 
migration, would help understand whether increased monocyte populations 
in the lungs are due to chemotactic cytokines in the blood or surface proteins 
on monocytes [141]. 
 
Blood CFU levels in treated mice remained similar to control mice until 48 
hours following infection, where a significant reduction of CFU was detected 
in treated mice. The delayed reduction in blood CFU numbers during 
infection correlates with the delayed recruitment of neutrophils following IV 
peptide administration in the absence of infection (Chapter III). It is possible 
that P4 rapidly releases monocytes, which help clear infection in the lungs, 
and induces a delayed release of neutrophils, which contribute to the 
phagocytic clearance of bacteria in the blood. Further studies are necessary, 
however, to confirm the phagocyte recruitment and migration dynamics 
following infection and peptide administration. 
 
4.16.3 Acute invasive pneumococcal disease (aIPD) – intranasal 
peptide 
Intranasal administration of P4 alongside IVIG during acute pneumonia 
prevented the onset of bacteraemia and subsequent host mortality. P4 was 
administered into the lungs at 12 and 18 hours following infection leading to 
a halt in the progression of pneumonia, similar to the IV administration 
studies. Importantly, no CFU were detected in the blood of P4 treated mice 
meaning that host pulmonary defense was augmented sufficiently to contain 
the spread of infection. In the MF1 host, neutrophils infiltrate to infected lung 
tissue by 12 hours post pneumococcal infection and assist resident lung 
macrophages in clearing pathogens [306]. As such, it is likely that intranasal 
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peptide administration leads to augmented phagocytosis of recruited 
neutrophils and resident macrophages. This is supported by data in this 
thesis, and in previous studies [280], where P4 was able to augment murine 
neutrophil and alveolar macrophage phagocytosis ex vivo. Similar to 
intranasal administration in the absence of infection, intranasal P4 did not 
lead to enhanced recruitment of phagocytes despite the presence of infection 
and therefore chemotactic cytokines. P4 administration actually led to a 
reduction of both neutrophils and macrophages in lungs. This is most likely 
due a decrease of bacterial numbers and therefore apoptotic debris in the 
lungs, leading to reduced cytokine mediated recruitment of phagocytes [320]. 
Other intranasal studies, using TLR activation or pro-inflammatory cytokines 
to augment host defence, administered their stimulant >24 hours prior to 
infection [321, 322]. Administering treatments before infection, however, does 
not reflect the application of a therapeutic in a clinical setting and therefore 
still raises the question whether treatment during infection would also be 
effective.  
 
4.16.4 FcγR expression  
FcγR expression was measured on neutrophils, monocytes and macrophages 
in lungs following both intravenous and intranasal peptide administration. IV 
peptide administration during bacteraemia up-regulated FcγR expression on 
neutrophils at 36 hours post infection (12 and 6 hours following peptide 
administration) and significantly up-regulated FcγR expression by 48 hours. 
Control mice, in comparison, up-regulated their FcγR expression on 
neutrophils by 36 hours, but expression decreased by 48 hours. Macrophages 
and recruited monocytes in the lungs did not alter their FcγR expression 
following IV peptide administration. Similarly, expression of FcγR on 
neutrophils at 12 and 6 hours following peptide administration led to 
enhanced expression, which was statistically significant by 48 hours post-
infection (12 and 18 hours following peptide administration). Macrophage 
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FcγR expression was up-regulated at 24 hours (not significant) but leveled at 
48 hours following infection when compared to control mice. It is important 
to place FcγR expression in context to phagocytosis. In the absence of 
infection, there was a sharp increase of circulating blood monocytes 
expressing significantly higher FcγR than in the control group. During 
infection, however, a sharp increase of recruited monocytes/macrophages was 
detected in the lungs but their FcγR expression was similar to control mice. 
As the increase of monocytes is correlated with a decrease in bacterial burden, 
it is likely that available FcγR internalized through ligation of opsonised 
pneumococci. Similarly, Weeks et al found that FcγR expression on 
neutrophils was significantly down-regulated following peptide treatment in 
a model of S. pneumoniae-influenza co-infection [284]. Down-regulated 
expression correlated with reduced viral and bacterial loads. As this study 
looked at FcγR expression in 24 hours intervals following treatment, the 
initial up-regulation may not have been detected.  
  
4.16.5 Nasopharyngeal carriage 
Administration of P4 to the nasopharynx during asymptomatic carriage of 
pneumococci led to significantly increased carriage levels but no invasive 
disease. These results are not surprising when put into the context of the role 
of pneumococcal surface adhesin A (PsaA), the protein from which P4 is 
derived.  Bacterial surface adhesins have long been recognized for their ability 
to modulate the activities of various host cells [220, 279]. Yersinia enterocolitica, 
for example, uses its adhesin A to invade epithelial cells through interaction 
with various integrins [323]. Similarly, the meningococcal adhesin NadA 
augments bacterial binding and invasion of epithelial cells in vitro [324].  
Streptococcus pneumoniae possesses a range of adhesins that facilitate the 
adhesion and invasion of epithelial cells. PavA, for example binds to 
epithelial cells and facilitates meningeal infection in a murine model of 
meningitis [224, 325] while CbpA modulates epithelial cytokine secretion and 
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invades through binding to human polymeric immunoglobulin receptor 
(hpIgR) [326]. Similarly, the functional epitope of pneumococcal surface 
adhesin A (P4) has been shown to induce cytological changes in epithelial 
cells resulting in enhanced invasion by pneumococci [279].  
 
Concentrated administration of P4 to the nasopharynx of mice would 
therefore facilitate pneumococcal invasion of epithelial cells leading to the 
increased bacterial CFU detected in this chapter. In addition, IVIG is made up 
of >95% IgG which is unable to enter mucosal areas and therefore unable to 
assist in augmented phagocytosis of recruited neutrophils. The role of P4 
mediated pneumococcal invasion in the nasopharynx is supported by studies 
of nasal carriage during API treatment of invasive pneumococcal disease 
models in this chapter. Intravenous administration did not alter nasal carriage 
suggesting that direct contact of P4 to nasal epithelial cells is necessary to 
facilitate pneumococcal invasion.  
 
4.16.6 Pre-treatment 
The in vivo cell population studies in chapter III showed significant 
recruitment and activation of monocytes and neutrophils in the blood stream 
following intravenous peptide administration in the absence of infection. To 
determine whether this would translate to host protection during infection, 
mice were pre-treated with intravenous peptide 24 hours prior to infection. 
Pre-treatment with P4 peptide led to enhanced survival, with bacterial loads 
in blood and lungs significantly lower in pre-treated mice at 24 hours 
following infection. Despite this, 80% of pre-treated mice succumbed to 
infection at 72 hours. As IVIG was not administered in these studies, it is 
possible that pre-treated mice succumbed due to pathogen specific 
immunoglobulin being spent by 24 hours.  Pre-treatment studies with 
additional IVIG only and P4-IVIG control groups could help better support 
the role of IVIG in API.  
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A. Introduction 
 
5.1 Introduction 
Studies in chapter IV confirmed that API treatment rescued mice from sepsis 
and that this involved neutrophils, monocytes and macrophages. In addition, 
flow cytometry studies showed that FcγR expression was modulated on 
neutrophils and monocytes in the presence and absence of infection. In this 
chapter, the HL-60 neutrophil-like cell line was used to determine (a) the 
effectiveness of API across a range of pneumococcal serotypes and (b) the 
involvement of phagocytic Fcγ receptors in P4 mediated opsonophagocytic 
killing.  
 
5.1.1 Opsonophagocytosis killing assay  
The HL-60 opsonophagocytosis killing assay (OPKA) is a method developed 
at the Centres for Disease Control and Prevention (CDC) to determine the 
opsonising efficacy of pneumococcal vaccine induced antibodies [327]. This 
robust assay [328] was modified to measure the ability of granulocytes to kill 
opsonised pathogens in the presence of stimulants [281]. The OPKA was used 
in this chapter to determine whether P4 could augment killing of a range of 
pneumococcal serotypes by HL-60 granulocytes. These included capsulated 
and unencapsulated D39 (ST2) and TIGR4 (ST4) laboratory pneumococcal 
strains as well as ST14, 6B and 19F strains derived from invasive clinical 
isolates. In addition, the monocytic THP-1 cells were used to determine 
whether P4 could augment the phagocytic killing of opsonised pneumococci 
in this cell line. 
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5.1.2 Fcγ receptor function  
In previous chapters the expression of Fcγ receptors was correlated with 
peptide administration and survival in vivo. To confirm that Fcγ receptors are 
necessary for P4 enhanced opsonophagocytic killing of bacteria, functional 
studies using the OPK assay were performed by (a) occupying Fcγ receptors 
and (b) blocking Fcγ receptors prior to OPK assays. 
 
5.1.3 Fcγ receptor expression  
In addition to function, the ability of P4 to modulate expression of Fcγ 
receptors was assessed in the HL-60 cell line. FcγR studies in the previous 
chapters investigated expression of FcγRII and FcγRIII using an antibody that 
binds shared epitopes on both receptors. In this chapter, membrane 
expression of three phagocytic Fcγ receptors (FcγRI, FcγRII and FcγRIII) was 
measured using individual antibodies and flow cytometry. Expression was 
measured in the presence and absence of infection. 
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B. Materials & Methods 
 
5.3 HL-60 cell culture 
The HL-60 cell line was originated from a patient with promyelocytic 
leukemia in 1977 [329]. The main characteristic of this cell line is that it is 
composed of undifferentiated haemopoeitic cells that can undergo 
differentiation into functional polymorphonuclear-like (PMN) cells upon 
chemical induction. The granulocytic differentiation induced by DMF (N,N-
dimethylformamide) yields 44% myelocytes/metamyelocytes and 53% PMNs . 
 
5.3.1 HL-60 media  
RPMI 1640 (RPMI, Sigma, UK]) was used for all HL-60 cell culture. Media 
was supplemented with 20% FBS and 5% antibiotic/mycotic (10,000 units 
penicillin, 10mg streptomycin + 25mg amphotericin B/ml [Sigma, UK]) 
solutions to maintain growth and prevent contamination.  
 
5.3.2 Establishing HL-60 cell culture 
1ml aliquots of frozen HL-60 cells were kindly donated by the 
Immunobiology Laboratory at the Centres for Disease Control and Prevention 
(Atlanta, GA, USA). Vials were quick-thawed in a RT water bath and 
immediately diluted in 15 ml of RT sterile PBS for a 10 min centrifugation step 
at 300 x g. The supernatant was discarded and the resulting cell pellet re-
suspended in 15 ml RT media for another 10 min centrifugation step at 300 x 
g. The supernatant was discarded and the cell pellet re-suspended in 10 ml 
media to make up a cell concentration of ~5x105 cells / ml. The cell solution 
was transferred to a T-75 tissue culture flask and placed upright in a tissue 
culture incubator at 37°C (5% CO2). 24 and 48 hours later, 10 ml of media was 
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added to the flask. At 72 hours, the flask was observed for turbidity 
(indication of cell growth) and 20 ml of fresh medium was added to make a 
working volume of 50 ml. Cell suspension in the flask was then tested for cell 
viability using Trypan Blue and a haemocytometer to assure >80% cell 
viability and maintained as described below.  
 
5.3.3 Maintaining HL-60 cell culture 
To ensure high viability during maintenance and differentiation, growing 
flasks of cells were maintained on a strict 24 hour schedule, 7-days a week. At 
the same time each day (±2 hours), flasks were taken out of the incubator 
while making sure not to disrupt the sediment (growing cells) and 25 ml of 
medium was removed from the top down. 25 ml of fresh medium was then 
added to the flask, thereby re-suspending the cells, and a sample taken to 
assess cell number and viability. A specific amount of cell suspension 
(depending on cell concentration) was then removed and replaced with fresh 
medium to make a concentration of 5 x 105 cells/ml and the flask returned to 
the incubator. One frozen aliquot was maintained for <3 months in order to 
avoid changes in cell morphology and function as a result of passaging. 
 
5.3.4 Differentiating HL-60 cells 
DMF was used to differentiate HL-60 cells into PMN-like phagocytic cells. 750 
μl of DMF (100 mM, Fisher) was carefully added to a T-75 tissue culture flask 
containing 80 ml of fresh media. Growing, undifferentiated cells (Figure 60A) 
were tested for cell number and viability, and 20 ml of cell suspension at a 
concentration of 2 x 105 cells/ml was carefully transferred to the flask 
containing media and DMF. Cell viability of >90% only was used for 
differentiation. 4 days following chemical induction, cell morphology of 
undifferentiated cells changed towards PMN-like cells as demonstrated by 
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increased granularity and a lobe like shape (Figure 60B), indicating that the 
cells were ready for use.  
 
 
Figure 60 - HL-60 cells can be differentiated into PMN-like cells. (A) Undifferentiated, growing HL-
60 cells and (B) PMN-like cells, 4 days following chemical differentiation using DMF and stained 
with Trypan Blue for measurement of viability. 
 
5.4 Establishing and maintaining THP-1 tissue culture  
THP-1 cells are functional monocytic cells that can be differentiated into 
macrophages. In their undifferentiated state, THP-1 cells are monocyte-like 
phagocytes and express opsonic Fcγ and C3 receptors [330].  
 
5.4.1 THP-1 media  
RPMI 1640 medium (Sigma) supplemented with 10% FCS, 2 mmol/L L-
glutamine, p-mercaptoethanol and 5% antibiotic/mycotic (10,000 units 
penicillin, 10mg streptomycin + 25mg amphotericin B/ml [Sigma, UK]) was 
used. 
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5.4.2 Establishing THP-1 cell culture 
1ml aliquots of frozen THP-1 cells were quick-thawed in a 37°C water bath 
and immediately diluted in 15 ml of RT sterile PBS for a 10 min centrifugation 
step at 300 x g. The supernatant was discarded and the resulting cell pellet re-
suspended in 15 ml RT medium for another 10 min centrifugation step at 300 
x g. The supernatant was discarded and the cell pellet re-suspended in 10 ml 
medium to make up a cell concentration of ~2x105 cells / ml. The cell solution 
was transferred to a T-75 tissue culture flask and placed upright in a tissue 
culture incubator at 37°C (5% CO2). 24 and 48 hours later, 10 ml of medium 
was added to the flask. At 72 hours, the flask was observed for turbidity 
(indication of cell growth) and 20 ml of fresh medium added to make a 
working volume of 50 ml. The flask was then tested for cell viability using 
Trypan Blue and a haemocytometer to assure >80% cell viability and 
maintained as described below.  
 
5.4.3 Maintaining THP-1 cell culture 
Cells were maintained every 2-3 days or until cell concentration reached >1 x 
106 cells/ml. Flasks were taken out of the incubator while making sure not to 
disrupt the sediment (growing cells) and 20 ml of medium removed from the 
top down. 20 ml of fresh medium was then added to the flask, thereby re-
suspending the cells, and a sample taken to assess cell number and viability. 
A specific amount of cell suspension (depending on cell concentration) was 
then removed and replaced with fresh medium to make a concentration of 2 x 
105 cells/ml and the flask returned to the incubator.  
 
5.5 Opsonophagocytosis using HL-60 and THP-1 cells 
Opsonophagocytosis assays were performed using HL-60 neutrophil-like cells 
and THP-1 monocyte-like cells. Additional experiments using Fc fragments or 
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blocking antibodies to occupy or block Fc-receptors prior to phagocytosis 
assays were also performed.  
 
5.5.1 Opsonisation 
See General methods in chapter II. 
 
5.5.2 Preparation of HL-60 or THP-1 cells 
Two flasks of differentiated HL60 cells or two flasks of growing THP-1 cells 
were pooled and centrifuged at 300 x g for 10 minutes. In order to remove any 
residues of antibiotics in the media, cells were washed twice by centrifuging 
at 300 x g for 10 minutes, discarding the supernatant and re-suspending the 
cells in Hank’s Balanced Salt Solution without Calcium or Magnesium (HBSS-
/-) to minimize adherence. Cells were finally re-suspended in Hank’s Balanced 
Salt Solution with Calcium and Magnesium (HBSS+/+) supplemented with 10% 
FBS at a cell concentration of 1 x 107 cells/ml and placed in an incubator at 
37°C (5% CO2) until use. 
 
5.5.3 Phagocytosis 
See General Methods: Chapter II, section 2.9.2. 
5.5.4 Analysis 
See General Methods: Chapter II, section 2.9.3. 
 
5.6 HL-60 OPKA and Fcγ receptors 
5.6.1 Fcγ receptor occupation 
Fc-receptor occupation relies on the binding of the Fc portion of 
Immunoglobulin to unoccupied Fc-receptors on the surface on HL-60 cells 
thereby inhibiting any further interaction until the receptor is recycled or 
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freed. Fc fragments were generated and kindly donated by the 
Immunobiology laboratory at the CDC Atlanta. Polyclonal Immunoglobulin 
G was enzymatically digested using papain to create Fc and Fab fragments 
after which Fc fragments were used for OPK blocking assays (Figure 61). 
 
 
Figure 61 - Graphical representation of Fc receptor occupation method. (1) Whole IgG fragment is 
enzymatically digested (2) Fab fragments and Fc fragments are produced (3) Fc fragments naturally 
bind to available Fc-receptors thereby occupying them. 
 
The Opsonophagocytosis assay with Fc receptor occupation was performed 
using the same method as in section 5.5 with one modification. Following the 
washing steps in  (B.), neutrophils were incubated in 1.5 ml tubes containing 
100 μg of polyclonal IgG Fc fragments / 106 cells or PBS alone for 20 minutes 
at 4°C. Following incubation, cells were centrifuged and resuspended in 
medium to a final cell concentration of 1 x 107 cells / ml. 20 μl of this cell 
suspension were then added to wells containing opsonized pneumococci, 
complement and P4 solution or DEPC-treated water. 
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5.6.2 Fcγ receptor blocking 
Fc-receptor blocking relies on antibodies binding to receptors via the variable 
fragment of the antibody thereby preventing any further interaction with the 
receptor ( 
Figure 62). Anti-CD16 (FcγRIII), CD32 (FcγRII) and CD64 (FcγRI) antibodies 
were purchased from Biolegend, USA. 
 
 
Figure 62 - Graphical representation of Fc receptor blocking method. (1) Commercial antibodies 
against several Fc-receptors (2) binding of antibody to active site of Fc-receptor thereby blocking 
further interaction.  
 
The Opsonophagocytosis assay with Fc receptor blocking was performed 
using the same method as in 4.4.1 with one modification. Following the 
washing steps in 4.4.1 (B.), neutrophils were incubated in 1.5 ml tubes 
containing 10 μl of antibody (either CD16, CD32 and CD64 alone or all 
together) / 106 cells or PBS alone for 20 minutes at 4°C. Following incubation, 
cells were centrifuged and re-suspended in medium to a final cell 
concentration of 1 x 107 cells / ml. 20 μl of this cell suspension was then added 
to wells containing opsonized pneumococci, complement and P4 solution or 
DEPC-treated water as in section 4.4.1. 
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5.7 HL-60 Fcγ I, II and III expression  
We measured peptide stimulation of HL-60 cells in the absence of immune 
complexes and complement in order to determine the effect of P4 on Fcγ 
receptor expression. This was compared to the receptor expression following 
an opsonophagocytosis assay. 
 
5.7.1 Cell preparations  
Cell suspensions from two differentiated flasks of HL60 cells were pooled and 
centrifuged at 300 x g for 10 minutes. The supernatant was discarded and the 
resulting cell pellet re-suspended in 20 ml sterile HBSS for another washing 
step at 300 x g for 10 minutes. The cell pellet was then re-suspended in 10 ml 
RPMI medium supplemented with 20% FBS and samples taken from the cell 
suspension for counting and testing cell viability using a haemocytometer. 
Cell viability of >90% was used. The cell suspension was then diluted and 
aliquoted into 1.5 ml tubes at a concentration of 5 x 105 cells / 400 μl. The tubes 
were divided into two groups, un-stimulated and P4-stimulated (n=10 per 
group).  
 
5.7.2 Cell stimulation and OPKA 
Test wells received 100 μl of P4 solution (1 mg of peptide / ml DEPC treated 
water) whereas the un-stimulated wells received 100 μl of DEPC treated 
water alone and were placed in an incubator at 37°C (5% CO2). At 15 and 60 
minutes following the addition of peptide or control, tubes were removed 
from the incubator, centrifuged in a bench top centrifuge at 300 x g for 10 
minutes and the supernatant discarded. The resulting cell pellet was then 
taken for antibody staining. In addition, differentiated HL60 cells were 
allowed to phagocytose pneumococci for 60 minutes in the presence of 
antibody and complement with and without P4 stimulation. Following 
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phagocytosis, cells were centrifuged at 300 x g for 10 minutes, the supernatant 
discarded and the resulting cell pellet stained as below.  
 
5.7.3 Cell staining and acquisition 
APC-conjugated primary and isotype antibodies were purchased from 
Biolegend (USA) and used for all staining. Cells were stained using anti-FcγR 
I (CD64), II (CD32) and III (CD16) antibodies or their corresponding isotype 
control antibodies (IgG1 for CD16 and CD64, IgG2b for CD32). Large volumes 
of each diluted antibody (ratio of 1:4 in PBS) were prepared on the day of 
experiment. The cell pellet from 5.7.3.2 was stained using 50 μl of diluted 
antibodies at 4°C for 20 minutes after which the tubes were centrifuged and 
excess antibody removed by discarding the supernatant and re-suspending 
the cell pellet in 500 μl PBS for another washing step. The cell pellet was then 
finally re-suspended in 500 μl PBS and acquired using a BD LSR II Flow 
Cytometer and the supplied FACS DIVA acquisition software. Results from 
three separate assay days were pooled and presented as percentage increase 
in mean fluorescence intensity (MFI) compared to MFI of isotype controls. 
 
5.8 Statistical analysis 
All statistical tests were performed using GraphPad Prism 5.0 for Macintosh 
(TreeStar Inc., USA). Different statistical tests were used depending on the 
data set and these are described below and defined in the figure legends. Each 
in vitro assay consisted of > three technical replicates performed on separate 
assay days. Data from separate assay days were pooled and shown as means 
± standard deviation. Distribution of data was assessed using D’Agostino and 
Pearson omnibus normality test. For normally distributed data, an Unpaired 
T-test was used to test for significance. For non-normally distributed data, a 
Mann-Whitney unpaired T-test was used to test for significance. Differences 
between data were designated significant if p<0.05.  
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C. Results 
5.9 HL-60 opsonophagocytosis killing assay 
Using the HL-60 opsonophagocytosis assay we tested if P4 treatment of 
neutrophil-like cells would lead to greater internalization of opsonized 
pneumococci as compared to the un-stimulated controls independent of 
capsule. Specifically, we tested whether P4 mediated phagocytosis was 
dependent on the presence or absence of capsule. All bacteria were opsonized 
using pathogen specific pooled human immunoglobulin G (IVIG).  
 
5.9.1 Capsulated and unencapsulated D39 pneumococci 
Following peptide treatment, HL-60 cells were significantly better at 
phagocytosing both capsulated (control 14% vs. treated 73%, p<0.0001) and 
unencapsulated (control 18% vs. treated 68%, p<0.0001) strains of D39 as 
compared to the untreated control cells (Figure 63, n=3 per strain).  
 
 
Figure 63 – Opsonophagocytosis using differentiated HL-60 cells and IVIG-opsonized capsulated or 
unencapsulated D39 (Serotype 2) pneumococci (n=3 per serotype). (*) denotes statistical significance 
using a paired t-test where p<0.001.  
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5.9.2 Capsulated and unencapsulated TIGR4 pneumococci 
In addition to D39, we tested if HL-60 cells would be better at phagocytosing 
another pneumococcal laboratory strain, TIGR4 (Serotype 4), and the 
unencapsulated TIGR4 mutant following peptide stimulation (Figure 64, n=3 
per strain). Peptide stimulation significantly increased the 
opsonophagocytosis of TIGR4 (control 12% vs. 58%, p<0.0001) and 
unencapsulated TIGR4 (control 34% vs. treated 59%, p>0.05) by HL-60 cells. 
The unencapsulated strain of TIGR4 was more susceptible to 
opsonophagocytosis by control cells compared to its capsulated parent strain 
(control capsulated 12% vs. control unencapsulated 34%, p<0.05) but 
phagocytosis of capsulated and unencapsulated TIGR4 remained similar in 
peptide treated cells (treated capsulated 58% vs. treated unencapsulated 59%, 
p>0.05). 
 
 
Figure 64 - Opsonophagocytosis using differentiated HL-60 cells and IVIG-opsonized capsulated or 
unencapsulated TIGR4 (Serotype 4) pneumococci (n=3 per serotype). (*) denotes statistical 
significance using a paired t-test where p<0.0001. 
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5.9.3 Clinical strains of S. pneumoniae 
As D39 and TIGR4 are heavily passaged laboratory strains of pneumococci, 
we tested whether peptide treatment of HL-60 cells would also be effective at 
increasing the phagocytosis of clinically relevant strains of pneumococci 
(Figure 65). ST14, ST6B and ST19F were isolated from clinical samples 
obtained from patients with invasive pneumococcal disease (n=3 per 
serotype). Following peptide stimulation, HL-60 cells were significantly better 
at phagocytosing IVIG opsonized ST14 (control 10% vs. treated 72%, 
p<0.0001), ST6B (control 14% vs. treated 82%, p<0.0001) and ST19F (control 
18% vs. treated 68%, p<0.0001). No statistical difference in the rate of 
phagocytosis between serotypes in stimulated and non-stimulated cells was 
detected (p>0.05).  
 
 
Figure 65 - Opsonophagocytosis using differentiated HL-60 cells and IVIG-opsonized ST14, ST6B or 
ST19F strains of clinically isolated pneumococci (n=3 per serotype). (*) denotes statistical significance 
using a paired t-test where p<0.0001. 
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5.10 Fcγ receptors, HL-60 & OPKA 
These experiments assessed whether blocking Fcγ receptors would influence 
the effect of peptide stimulation using HL-60 cells in an opsonophagocytosis 
killing assay. Two strategies were used: Occupying receptors by adding IgG 
derived Fc fragments and blocking receptors by adding FcγR specific 
blocking antibodies. 
 
5.10.1 Occupying Fcγ receptors with Fc fragments 
HL-60 cells were stimulated with P4 peptide after which cells were incubated 
with an excess of IgG Fc fragments to occupy receptors. In control reactions 
(n=3), where no receptors were occupied, cells treated with P4 peptide were 
significantly better at phagocytosing opsonized D39 pneumococci than the 
untreated control (control 21% vs. treated 68%, p=0.001). No difference 
between stimulated and non-stimulated cells was detected where Fcγ 
receptors were occupied prior to phagocytosis (control 19% vs. treated 12%, 
p>0.05). Results from these assays are shown in Figure 66. 
 
 
Figure 66 – Opsonophagocytosis with and without Fcγ-receptor occupation using differentiated HL-
60 cells and IVIG-opsonized TIGR4 strains of clinically isolated pneumococci (n=3 per group). (*) 
denotes statistical significance using a paired t-test where p<0.0001. 
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5.10.2 Blocking Fcγ receptors with antibodies 
HL-60 cells were stimulated and incubated with either anti-CD16, CD32, 
CD64 or a combination of all three antibodies in order to block specific Fcγ 
receptors prior to phagocytosis (n=3 per antibody). In addition, control OPKA 
reactions were also performed (n=3) without any blocking. The level of 
phagocytosis was significantly increased following P4 stimulation in cells that 
received no antibody blocking (control 20% vs. treated 81%, p=0.003). The 
results from these experiments are shown in Figure 67.  
 
 
 
Figure 67 – Opsonophagocytosis assay with and without Fcγ-receptor blocking using differentiated 
HL-60 cells and IVIG-opsonized D39 strains of pneumococci (n=3 per group). Cells were incubated 
with antibodies 20 minutes prior to the phagocytosis assay. “Control OPA” are reactions without any 
blocking, “All blocked” reactions with all three antibodies added, “CD16 blocked” with the addition 
of anti-CD16 antibody, “CD32 blocked” with the addition of anti-CD32 antibody and “CD64 
blocked” with the addition of anti-CD64 antibody. (*) denotes statistical significance using a paired 
t-test where p<0.0001. 
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Stimulated and un-stimulated HL-60 cells incubated with all three antibodies 
prior to phagocytosis took up significantly less bacteria than in the control 
group (no blocking 20% vs. blocking 6%, p<0.05) and no significant difference 
was detected between peptide treated and control cells in this instance 
(control all blocked 6% vs. treated all blocked 6%, p>0.1). HL-60 cells 
incubated with anti-CD16 antibodies prior to phagocytosis did not increase 
the rate of phagocytosis in response to peptide treatment (control CD16 
blocked 43% vs. treated CD16 blocked 49%, p>0.05). Phagocytosis was 
significantly higher in non-stimulated cells incubated with anti-CD16 
antibodies than in the non-stimulated cells with no blocking (no blocking 
control 21% vs. CD16 blocked control 42%, p=0.04). Similarly, peptide 
treatment of HL-60 cells did not significantly change phagocytosis levels 
following CD32 blocking (control CD32 blocked 20% vs. treated CD32 
blocked 21%, p>0.05). Finally, there was no detectable phagocytosis in control 
cells incubated with anti-CD64 antibodies whereas phagocytosis was 
detected, and significantly higher, following peptide stimulation in CD64 
blocked cells (control CD64 blocked 0% vs. treated CD64 blocked 11%, 
p=0.04). 
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5.11 HL60 Fcγ Flow Cytometry 
We tested whether P4 stimulation of HL-60 cells would lead to Fc-receptor 
modulation in the absence of bacteria. Cells were stimulated with P4 peptide 
alone and stained with CD16 (FcγRIII), CD32 (FcγRII) or CD64 (FcγRI) 
antibodies 15 and 60 minutes later. In addition, it was tested whether Fc-
receptor expression was modulated in an HL-60 opsonophagocytosis assay in 
response to peptide treatment.  
 
5.11.1 HL-60 FcγRIII expression 
CD16 expression at 60 minutes in peptide treated cells in the absence of 
bacteria was significantly higher than in control cells (control 120 MFI vs. 
treated 179 MFI, p=0.03). No statistical difference in CD16 expression was 
detected at 15 minutes following stimulation (control 125 MFI vs. treated 112 
MFI, p>0.05) (Figure 68). 
 
 
Figure 68 – Mean fluorescent intensity (MFI) above isotype control of CD16. HL-60 cells were stained 
with anti-CD16 antibodies at 15 and 60 minutes following incubation with either control or peptide 
solution (n=3). (*) denotes statistical significance using a paired t-test where p<0.05. 
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5.11.2 HL-60 FcγRII expression 
CD32 expression remained similar in both control and peptide treated cells at 
either 15 (control 3128 MFI vs. treated 2840 MFI, p>0.05) or 60 (control 3211 
MFI vs. treated 3356 MFI, p>0.05) minutes where no statistical difference was 
detected between groups (Figure 69).  
 
 
 
Figure 69 - Mean fluorescent intensity (MFI) above isotype control of CD32. HL-60 cells were stained 
with anti-CD32 antibodies at 15 and 60 minutes following incubation with either control or peptide 
solution (n=3). (*) denotes statistical significance using a paired t-test where p<0.05. 
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5.11.3 HL-60 FcγRI expression 
In comparison, CD64 expression was significantly lowered at 60 minutes in 
HL-60 cells treated with P4 peptide (control 4078 MFI vs. treated 3298 MFI, 
p=0.03) but no detectable difference was measured at 15 minutes following 
stimulation (control 4151 MFI vs. treated 3772 MFI, p>0.05) (Figure 70). 
 
 
Figure 70 - Mean fluorescent intensity (MFI) above isotype control of CD64. HL-60 cells  were stained 
with anti-CD64 antibodies at 15 and 60 minutes following incubation with either control or peptide 
solution (n=3). (*) denotes statistical significance using a paired t-test where p<0.05. 
 
5.11.4 HL-60 FcγR expression following OPKA 
Finally, it was measured whether P4 treatment during phagocytosis of 
opsonized pneumococci by HL-60 cells would alter the expression of CD16, 
CD32 or CD64. Following an opsonophagocytosis assay, HL-60 cells were 
stained using anti-FcR I, II & III antibodies. CD16 expression remained similar 
between stimulated and non-stimulated control (control 533 MFI vs. treated 
542 MFI, p>0.05). Both CD32 and CD64 expression was modulated, however, 
where CD32 expression increased (control 5742 MFI vs. treated 6001 MFI, 
p=0.03) and CD64 expression decreased (control 15077 MFI vs. treated 14209 
MFI, p=0.02) in response to peptide treatment (Figure 71). 
Chapter V    In vitro peptide studies   
  168 
 
 
 
 
 
 
 
Figure 71 - Mean fluorescent intensity (MFI) above isotype control of CD16, CD32 or CD64. 
Stimulated or non-stimulated HL-60 cells (n=3) were stained following a 45 min opsonophagocytosis 
assay using IVIG-opsonized D39 pneumococci. (*) denotes statistical significance using a paired t-
test where p<0.05. 
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5.12 Opsonophagocytosis using THP-1 monocytes 
Using undifferentiated THP-1 cells and the standardized HL-60 
opsonophagocytosis assay, it was tested whether peptide treatment of 
monocyte-like cells would up-regulate the phagocytosis of IVIG-opsonized 
D39 pneumococci (Figure 72, n=3). 45 minutes following opsonophagocytosis, 
there was no significant difference in the rate of phagocytosis between 
stimulated and non-stimulated THP-1 cells (control 56% vs. treated 63%, 
p=0.054). 
 
 
Figure 72 - Opsonophagocytosis using undifferentiated THP-1 monocyte like cells and IVIG-
opsonized D39 (Serotype 2) pneumococci (n=3). (*) denotes statistical significance using a paired t-
test where p<0.001. 
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D. Discussion 
 
5.13 Discussion 
In this chapter, the HL-60 cell line was used to determine the ability of P4 to 
upregulate the phagocytic killing of a range of IVIG opsonised pneumococcal 
serotypes. In addition, using flow cytometry, the effect of P4 to modulate Fcγ 
receptor expression was assessed. Specifically, FcγRI, FcγRII and FcγRIII 
expression was measured in the presence and absence of immunecomplexes 
and P4.  
5.13.1 Opsonophagocytosis assay  
The opsonophagocytosis killing assay (OPKA) was used to measure the 
efficacy of pneumococcal killing by P4 stimulated HL-60 cells. Two laboratory 
strains, ST2 (D39) and ST4 (TIGR4), as well as their unencapsulated mutants 
showed significantly enhanced susceptibility to phagocytic killing by P4 
stimulated cells. Unencapsulated strains were more susceptible to killing than 
capsulated strains in the absence of P4. This is not surprising as the capsule 
has long been shown to inhibit phagocytosis [331]. In the presence of P4, 
however, phagocytic killing of unencapsulated strains was similar to 
capsulated strains suggesting that P4 up-regulates phagocytic killing 
independent of the presence of capsule. This is most likely facilitated through 
the use of IVIG, as serum typically contains antibodies against membrane 
proteins as well as pneumococcal capsule [332, 333]. In addition, P4 
stimulated cells also killed pneumococcal strains isolated from patients with 
invasive pneumococcal disease at significantly higher rates. These results are 
important as the invasiveness of pneumococcal serotypes differs between 
geographical locations [334], and serotype replacement and switching 
(previously non-invasive strains becoming invasive) has been reported as a 
result of widespread vaccination [335, 336]. These data strengthen the case of 
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using IVIG as an opsonin for passive immunotherapy and further 
demonstrate the ability of P4 to upregulate the phagocytic killing of S. 
pneumoniae.  
 
In addition to HL-60 cells, the OPK assay was adopted to assess the ability of 
the THP-1 monocytic cell line to up-regulate phagocytic killing in response to 
peptide stimulation. No differences in phagocytic killing were detected in 
stimulated and control cells in this chapter. THP-1 cell lines are mostly used 
for their ability to differentiate into macrophages and dendritic cells [337] 
which lead to better responses to stimuli than undifferentiated THP-1 cells 
[338]. Some studies have looked at undifferentiated THP-1 cell phagocytosis 
but the outcome was measured using fluorescent beads and flow cytometry 
and not viable bacteria [339]. While it is possible that undifferentiated THP-1 
cells do not respond to peptide treatment, these data cannot rule out the 
ability of P4 to upregulate monocyte phagocytosis, particularly as monocyte 
migration played key role in API during in vivo infection studies. Further 
studies, using peripheral blood derived monocytes as well as other monocyte 
cells lines (i.e. HL-60 cells differentiated into monocytes), could help 
understand the role of monocyte phagocytosis in API. 
 
5.13.2 Fcγ receptor function and expression 
By using two techniques, receptor occupation and receptor blocking, the role 
of FcγR in P4 mediated opsonophagocytosis was assessed. Exposing whole 
IgG or Fcγ fragments to granulocytes leads to the occupation of Fcγ receptors 
[340], which are then unable to ligate opsonised pathogens until the receptor 
is internalized and recycled to the cell membrane [341]. The occupation of Fcγ 
receptors did not affect the ability of control cells to kill opsonised 
pneumococci. In contrast, FcγR occupation of P4 stimulated cells prevented 
the augmented killing of pneumococci seen in the absence of FcγR 
occupation. It is likely that the effect of P4 mediated FcγR up-regulation and 
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priming of cells was reversed through Fc fragment occupation. Ligation and 
internalization of Fc fragment bound FcγR would not stimulate TLR or NOD 
like receptors, which are important for downstream activation signaling and 
may be necessary for P4 stimulation to be effective [342, 343]. Alternatively, it 
is possible that Fc fragments ligated inhibitory FcγR leading to the reversal of 
P4 mediated activation of HL-60 cells [344]. Measuring Fc fragment 
internalization in P4 stimulated and control cells would help understand the 
role of FcγR occupation in these assays. 
 
Blocking Fcγ receptors de-activates the receptor’s function by preventing 
ligation with IgG [345, 346]. Blocking specific Fcγ receptors, namely FcγRI 
(CD64), FcγRII (CD32) and FcγRIII (CD16), led to a range of phagocytic 
killing responses in this chapter. When all Fcγ receptors were blocked, 
phagocytic killing of stimulated and control cells was significantly reduced 
compared to control assays. Blocking of FcγRIII led to enhanced killing by 
both stimulated and control cells while blocking of FcγRII resulted in 
phagocytosis similar to control cells in the absence of receptor blocking. There 
was no detectable phagocytic killing following FcγRI blocking in control cells, 
but P4 stimulation resulted in some phagocytic killing in this instance. In the 
absence of infection, peptide stimulation increased expression of FcγRIII, 
decreased expression of FcγRI but did not alter expression of FcγRII. 
 
The use of anti-FcγRIII antibodies may have resulted in activation of receptor 
as well as preventing further Fc-FcγRIII interactions. As FcγRIII activation 
leads to increased neutrophil phagocytosis through the generation of 
phosphatidylinositol-3 kinase (PI-3K) [347, 348], it is possible that the 
enhanced phagocytic killing seen by both control and P4 stimulated cells is 
mediated by FcγRIII activation. In the absence of infection P4 upregulated the 
expression of FcγRIII. It is therefore likely that P4 mediated phagocytic killing 
is enhanced through the upregulation of FcγRIII leading to internalization of 
immune complexes and subsequent enhanced PI-3K activity. Assays 
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measuring FcγRIII and PI-3K activity during P4 mediated OPK assays would 
assist in confirming these observations. 
 
The affinity of specific FcγR to IgG may also have contributed to the observed 
differences. FcγRIII, for example, is a low-affinity IgG receptor [349] meaning 
that its absence would affect immune complex ligation to a lesser extent than 
the high affinity FcγRI receptor. This is supported by data in this chapter 
where blocking of the high affinity FcγRI receptor resulted in complete 
cessation of phagocytic killing in control cells. In the absence of infection, P4 
stimulation led to a decrease of FcγRI. High expression of FcγRI is correlated 
with activation of cells [350] and used as a measure of the severity of infection 
during sepsis [351] while decreased expression is observed following 
hydrocortisone administration during sepsis [352].  
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A. Introduction 
 
6.1 Introduction 
In previous chapters, P4 peptide treatment of pneumococcus-infected lungs 
prevented the onset of sepsis and subsequent host mortality. In addition, P4 
upregulated the phagocytic killing of opsonised pneumococci by murine 
alveolar macrophages and the HL-60 neutrophil like cell line. This chapter 
assessed whether P4 treatment of human phagocytes ex vivo would lead to 
enhanced phagocytic function with no or limited generalized inflammation. 
 
6.1.1 Opsonophagocytosis killing assays 
Similar to HL60 phagocytic killing assays in chapter V, the CDC 
opsonophagocytosis killing assay (OPKA) was used to determine the ability 
of alveolar macrophages and neutrophils to kill IVIG opsonised pneumococci 
following peptide stimulation. Healthy adult volunteers from two 
populations (Liverpool, UK and Blantyre, Malawi) with different experience 
of pneumococcal disease were invited to consent to bronchoscopy and lavage 
in order to isolate alveolar macrophages. Healthy adult volunteers from 
Liverpool (UK) were invited to consent to venesection to isolate peripheral 
blood neutrophils.  
 
6.1.2 Intracellular oxidation  
The effect of P4 treatment on human alveolar intracellular oxidation was 
assessed using DCFH oxidation assays. Specifically, it was tested whether P4 
mediated OPK assays would lead to increased intracellular oxidation. In 
addition, intracellular oxidation by P4 stimulated alveolar macrophages in the 
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absence of infection was measured and compared to LPS stimulated alveolar 
macrophages. 
 
6.1.3 Cell surface markers and cytokine secretions following 
OPKA 
Phagocytes are activated and alter their inflammatory mediators, including 
cytokine secretion and expression of markers of inflammation, following 
phagocytosis of pathogens. To determine whether P4 would modulate 
inflammatory mediators on alveolar macrophages following OPK assays, cell 
surface markers and cytokine secretions of control and P4 stimulated cells 
were measured using flow cytometry.   
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B. Materials & Methods 
 
6.2 Volunteer recruitment for blood and BAL 
Volunteers were invited to give informed consent to a study in Liverpool 
(UK) and Blantyre (Malawi) involving venesection, bronchoscopy and lavage 
(BAL). Inclusion and exclusion criteria were identical for recruitment in both 
countries. 
 
6.2.1 Inclusion criteria  
i. Adults aged 18-65 years. 
Age chosen to minimise risk of bronchoscopy. 
ii. Fluent spoken English. 
To ensure a comprehensive understanding of the research project 
and their proposed involvement. 
 
6.2.2 Exclusion criteria 
Individuals who are at increased risk during bronchoscopy. Patients in whom 
clinical features might affect the interpretation on the results will be 
excluded. Exclusion criteria are therefore: 
i. Asthma or pre-existing lung disease requiring regular 
immunoregulatory treatment or having any recent ill health 
ii. Cigarette smoking of greater than 10 pack years (20 cigarettes per 
day for 10 years) 
iii. Chronic illness 
iv. Pregnancy 
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6.2.3 Ethics 
Ethical approval was obtained from the National Health Service Research 
Ethics Committee, Sefton, Liverpool (11/NW/0011 - sponsored by the Royal 
Liverpool and Broadgreen University Hospitals Trust) and the Malawi 
College of Medicine Ethics committee (COMREC, P.03/11/1063 - sponsored by 
Liverpool School of Tropical Medicine).  
 
6.3 Alveolar macrophage and peripheral blood 
neutrophil isolation 
 
6.3.1 Cell culture medium 
For all alveolar macrophage and peripheral blood neutrophil cell culture in 
this chapter, RPMI 1640 medium (2mM L-glutamine (Sigma, UK), 10% fetal 
bovine serum (Invitrogen, UK), with or without antibiotics (penicillin 40U/ml, 
streptomycin 40μg/ml, neomycin 80μg/ml) and fungicide (amphotericin B 
0.5μg/ml) (Sigma, UK)) was used.  
 
6.3.1 Alveolar macrophage isolation  
Macrophages were extracted from lungs by gently placing a bronchoscope in 
the middle-lobe subsegmental bronchus and lavaging with 200 ml of warm 
sterile saline [353]. BAL (bronchoalveolar lavage) fluid collected during 
bronchoscopy (variation of 30ml – 140 ml) was strained through sterile gauze 
into 50ml Falcon centrifuge tubes to remove any large debris and mucous. 
The tubes were centrifuged at 300 x g for 10 minutes, the supernatant stored 
and the cells re-suspended in 15 ml media with antibiotics. A sample was 
taken from the cell suspension to enumerate number and viability of cells. 
Alveolar macrophages were plated onto 96-well culture plates (Greiner Bio, 
UK) at a concentration of 1 x 105 cells / well and incubated at 37°C (5% CO2) 
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for three hours in antibiotic supplemented media to allow for macrophages to 
adhere. Following incubation, non-adherent cells were carefully removed by 
washing wells twice with PBS and fresh RPMI media + 10% FBS without 
antibiotics was added to the wells. Cells were then kept in an incubator at 
37°C (5% CO2) for > 2 hours until use.  
 
6.3.2 Peripheral blood neutrophil isolation 
50 ml peripheral blood was obtained from healthy volunteers and collected in 
heparin containing tubes (10 units / ml, Sigma). Neutrophils from peripheral 
blood were isolated using gradient density centrifugation, which relies on 
components of blood being separated by their ability to pass through 
differing densities of solutions (Histopaque). First, 12 ml of Histopaque 1119 
(Sigma) was added to a 50ml tube followed by carefully layering 12 ml of 
Histopaque 1077 (Sigma) on top. Whole blood, diluted 1:2 with sterile PBS, 
was then carefully layered on top of both Histopaque solutions (Figure 73A). 
The tube was then centrifuged at RT for 30 minutes at 700 x g to allow for 
separation to occur. Following centrifugation, two clear white bands were 
seen containing the monocyte and neutrophil populations (Figure 73B).  
 
 
Figure 73 - Density gradient separation of peripheral blood leukocytes. (A.) Peripheral blood is 
layered on top of two histopaque solutions with differing densities. Following centrifugation, (B.) 
monocytes and neutrophils are separated into two distinct bands. 
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The layers above the neutrophil population were carefully removed using a 
Pasteur pipette and the neutrophil layer then transferred to a fresh 50ml tube, 
taking care not to carry over red blood cells. The tube containing neutrophils 
was brought up to 50 ml using PBS and washed by centrifuging the tube at 
300 x g for 10 minutes after which the supernatant was discarded and the cell 
pellet re-suspended in PBS for another washing step. Finally, the cell pellet 
was re-suspended in 10ml RPMI 1640 media and the cell number and viability 
assessed using Trypan Blue and a haemocytometer. Freshly isolated cells 
were used within two hours of density separation to ensure maximum 
viability. 
 
6.4 Alveolar macrophage OPKA 
6.4.1 Opsonisation 
Pneumococcal strains were opsonised using IVIG as described in chapter II. 
 
6.4.2 Phagocytosis 
IVIG-opsonised pneumococci were used to infect alveolar macrophages as 
described in chapter II. 
 
6.4.3 Analysis 
A killing index was established as described in chapter II. 
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6.5 Fcγ receptor occupation  
Fcγ-receptors are frequently occupied using pooled IgG prior to Flow 
Cytometry assays to avoid non-specific binding during staining. This 
technique was adapted to occupy Fcγ-receptors following peptide 
stimulation, and prior to phagocytosis, in order to assess whether FcγR 
occupation influences the ability of P4 to up-regulate phagocytosis. 
 
6.5.1 Opsonisation 
Pneumococcal strains were opsonised using IVIG as described in chapter II. 
 
6.5.2 Fcγ-receptor occupation and phagocytosis 
Adhered alveolar macrophages were pre-treated with DEPC treated water or 
P4 solution for 20 minutes followed by a 20 minute incubation with 100 μl of 
1 mg/ml human IgG (Sigma I4506). Following incubation, wells were washed 
twice with pre-warmed (37°C) PBS to remove unbound IgG. The 
phagocytosis assay was then performed without additional P4 solution 
(DEPC treated water for control and treated wells). 
 
6.5.3 Analysis 
A killing index was established as described in chapter II. 
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6.6 Intracellular killing of pneumococci  
The adhesion and invasion assay was originally developed to test the ability 
of bacteria to adhere and invade cultured epithelial cells [354]. It was used to 
determine whether P4 mediated opsonophagocytosis also mediated 
intracellular killing (Figure 74).  
 
 
Figure 74 - Schematic diagram of the opsonophagocytosis assay and how to determine bacterial 
killing and presence intracellularly. Alveolar macrophages are incubated with opsonized 
pneumococci and complement for two hours with and without peptide stimulation in duplicate 
wells. (1) Uptake of pneumococci is measured by sampling the supernatant. (2) Intracellular killing 
is measured by removing the supernatant, incubating wells with bactericidal antibiotics that do not 
penetrate cells to remove adhered pneumococci. Cells are then burst open using a detergeant and 
viable intracellular pneumococci cultured. A=alive bacteria, D=dead bacteria. 
 
6.6.1 Opsonisation 
Pneumococcal strains were opsonised using IVIG as described in chapter II. 
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6.6.2 Phagocytosis 
IVIG-opsonised pneumococci were used to infect alveolar macrophages as 
described in chapter II.  
 
6.6.3 Intracellular pneumococci and killing 
Following OPKA, a sample from the supernatant was taken for Miles & Misra 
enumeration. The supernatant was then removed and wells gently washed 5 x 
with pre-warmed (37°C) sterile PBS. Once the supernatant was washed off, 
200 μl of antibiotic solution (100 μg ampicillin/200 μl) was added to wells for 
a 2 hour incubation at 37°C (5% CO2). This killed any adherent bacteria while 
not affecting internalized pneumococci. Following incubation, wells were 
washed gently 5 x using sterile pre-warmed (37°C) PBS to remove traces of 
antibiotic and then incubated with 1% saponin solution to burst cells and 
release intracellular pneumococci.  
 
6.6.4 Analysis 
A killing index was established as in chapter II. Percentage internalized 
pneumococci was calculated by comparing the number of CFU recovered 
from the intracellular compartment and relating it to the original dose 
(opsonized bacteria in the presence of complement added to the reaction). 
 
 
                         
                 
          
       
 
 
6.7 Neutrophil OPKA 
6.7.1. Opsonisation 
Pneumococcal strains were opsonised using IVIG as described in chapter II. 
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6.7.2 Phagocytosis 
IVIG-opsonised pneumococci were used to infect alveolar macrophages as 
described in chapter II. 
 
6.7.3 Analysis 
A killing index was established as described in chapter II. 
 
6.8 Cytokines following OPKA 
In addition to phagocytosis, alveolar macrophages orchestrate immune 
responses by secreting cytokines following stimulation. Excessive cytokine 
secretion, however, is a hallmark of inflammation. We measured cytokine 
secretion following P4–mediated opsonophagocytosis.  
 
6.8.1 Cytokine collection 
Supernatants from the OPKAs were collected and stored at -80°C. Using the 
BD Cytokine Bead Array kits for soluble proteins (BD-CBA Flex Sets, Becton 
Dickinson, UK) we determined levels of MIP-1α, MIP-1β, MCP-1, IL-6, IL-8, 
IL-10, IL-12, IFN-γ, TNF-α and RANTES (CCL5) in the supernatants. Figure 
75 gives an overview of the method used. 
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Figure 75 - Diagram of multiplex cytokine detection in opsonophagocytosis supernatants using CBA 
FlexSet cytokine detection kit. Cytokine specific beads of varying size and fluorescence are 
incubated with cytokines present in OPKA supernatant.  The beads are washed and then further 
incubated with a cocktail of cytokine specific antibodies conjugated to a fluorescent (PE) reporter. 
The Antibody-Cytokine-Bead complex is then analyzed by flow cytometry (lower panel). Bead 
populations  are identified using a light scatter plot and gated onto a bivariate dot plot to separate 
bead populations corresponding to each cytokine analysed.  To measure cytokine concentration each 
bead population is analysed in the PE channel to determine relative brightness of the reporter and 
thus the degree of bound cytokine.  The fluorescence intensity of the reporter in the test samples is 
compared to a standard curve of known cytokine concentration from which the concentration in the 
test samples can be determined. 
 
6.8.2 Capturing and measuring cytokines 
Protein specific capture beads were incubated with dilutions of OPKA 
supernatant (neat, 1:2, 1:10, 1:100) and supplied standards followed by 
incubation with detection antibodies. Once excess detection antibodies were 
washed off, stained samples were acquired using a BD LSR II Flow Cytometer 
using FACS Diva software. Gating and comparison of each bead’s MFI to the 
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standard curve was done using the supplied FCAP Array 2.0 software. Data 
was presented as pg cytokine/ml. 
 
6.9 Phenotyping following OPKA 
Expression of cell surface markers were used to establish the activation status 
of cells following peptide treatment. Following opsonophagocytosis assay, 
wells were carefully washed twice using PBS. Alveolar macrophages were 
then detached from culture plates by incubating them for 10 minutes (37°C, 
shaking at 200RPM) in citric saline (0.15M Na citrate, 0.135M  KCl).  
 
6.9.1 Alveolar macrophage staining and aquistion 
Once detached, cells were transferred to 1.5ml eppendorf tubes and washed 
twice by centrifuging them at 300 x g for 10 minutes. Following the washing 
steps, cells were stained using mouse anti-human  HLA-DR (MHC-Class II, 
560743), CD206 (Mannose Receptor, 55089), CD11b (Adhesion molecule, 
347557), CCR7 (Chemokine receptor, 557648), CD163 (Activation marker, 
556018), CD86 (Activation marker, 555657) purchased from BD Biosciences. 
Acquisition was done using a BD LSR II Flow Cytometer using FACS Diva 
software and results presented as median fluorescence intensity (MFI) 
corrected for background fluorescence.  
 
6.10 Intracellular Oxidation 
Macrophages are able to produce an intracellular oxidative burst in order to 
degrade phagocytosed bacteria [355]. Intracellular oxidation is also required 
for the initiation of inflammatory cytokine production [355].  The classical 
inflammatory molecules IFNγ and LPS have been shown to act as an inducer 
of intracellular oxidation [356]. In order to measure oxidation, 5-6-carboxy-
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2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) can be used as a probe. 
The addition of DCFH-DA to macrophages will lead to internalization of the 
probe and enzymatic digestion to convert DCFH-DA to DCFH [357]. DCFH is 
naturally non-fluorescent but becomes fluorescent in response to oxidation 
and as such can be used to quantify intracellular oxidation [358]. We 
measured the intracellular oxidation of DCFH inside alveolar macrophages in 
response to P4 and LPS, and also during an opsonophagocytosis assay with 
and without peptide stimulation. 
 
6.10.1 Preparing alveolar macrophages 
Alveolar macrophages were isolated from BAL fluid as described in Chapter 
II and plated into a 96-well plate at a concentration of 1 x 105 cells / well. Each 
condition was performed in triplicate. Wells were first incubated with 100 μl 
of 25 μM DCFH-DA solution (Invitrogen 10086129, UK) for 30 minutes at 
37°C (5% CO2). Control wells consisted of alveolar macrophages incubated 
with 100 μl RPMI alone and was used as base-line fluorescence during 
analysis to account for auto-fluorescence. Following incubation, wells were 
washed twice with pre-warmed (37°C) PBS to remove extracellular DCFH-
DA and used for the measurement of either intracellular oxidation in the 
absence of immune complexes or intracellular oxidation during opsono-
phagocytosis.  
 
6.10.2 Intracellular oxidation in the absence of immune 
complexes 
After the DCFH-DA incubation and washing steps, wells were replenished 
with 150 μl media. 50 μl of stimulant was then added to the reaction tubes to 
make up a final volume of 200 μl / well. The stimulants were: LPS solution 
(100 μg / ml DEPC treated water) or P4 solution (1 mg / ml DEPC treated 
water). Control wells received 50 μl DEPC treated water.  
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6.10.3 Intracellular oxidation during opsono-phagocytosis 
After the DCFH-DA incubation and washing steps, wells were replenished 
with 30 μl media and components for an opsono-phagocytosis was added to 
each well. Briefly, 20 μl IVIG-opsonized ST23F pneumococci, 10 μl baby 
rabbit complement and 20 μl P4 or control solution was added to each well.   
 
6.10.4 Acquisition and Analysis 
Immediately after the addition of either stimulants (6.12.2-A) or OPKA 
components (6.12.2-B) plates were added to a MARS fluorescent plate reader( 
BMG Labtech, UK) for measurement of fluorescence every two minutes for 
200 minutes. The excitation wavelength was set at 485nm and the emission 
wavelength was set at 520nm. Following acquisition, data was analysed using 
MARS software version 1.20 (BMG Labtech, UK). Results are presented as the 
percentage increase in emission intensity corrected against control wells 
(auto-fluorescence). 
 
6.11 Statistic analysis 
Each ex vivo assay consisted of > six biological replicates and were performed 
on separate assay days. Data from separate assay days were pooled and 
shown as means ± standard deviation. Distribution of data was assessed 
using D’Agostino and Pearson omnibus normality test. For normally 
distributed data, an Unpaired T-test was used to test for significance. For non-
normally distributed data, a Mann-Whitney unpaired T-test was used to test 
for significance. Differences between data were designated significant if 
p<0.05. 
  
Chapter VI    Ex vivo peptide studies   
  189 
C. Results 
6.12 Volunteer recruitment 
Informed consent and bronchoalveolar lavage samples were obtained from 14 
subjects in Liverpool (UK) and 13 subjects in Blantyre (Malawi). Informed 
consent and peripheral blood samples were obtained from 5 subjects in 
Liverpool (UK). 
 
6.13 Neutrophil OPKA 
Neutrophils were isolated from the peripheral blood of healthy adult 
volunteers (n=5) in Liverpool (UK). We tested whether P4 stimulation of 
freshly derived neutrophils would lead to increased killing of opsonised 
pneumococci (Figure 76). Killing by freshly derived peripheral blood 
neutrophils was significantly increased following peptide stimulation (control 
18% vs. treated 43%, p=0.0005) as compared to non-stimulated control cells. 
 
 
Figure 76 – Opsonophagocytosis of IVIG-opsonized D39 pneumococci using freshly derived 
peripheral blood neutrophils with and without peptide stimulation (n=5).  Data is represented as 
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mean of replicates ± standard deviation. (*) denotes significant differences using a paired student’s 
T-test where p<0.05.  
6.14 UK and Malawian healthy HAM OPKA 
Human alveolar macrophages were isolated from healthy adult volunteers in 
the UK and Malawi to determine whether both populations would be able to 
up-regulate phagocytic killing in response to peptide stimulation.  
 
6.14.1 HAM OPKA from UK population 
Non-stimulated alveolar macrophages from the UK volunteers (n=14) killed 
an average of 40.1% and this was significantly up regulated following P4 
stimulation (control 40.1% vs. treated 68.2%, p<0.0001) (Figure 77).  
 
 
 
Figure 77 – Opsonophagocytosis of IVIG-opsonized D39 pneumococci by human alveolar 
macrophages isolated from UK adult volunteers in the presence or absence of peptide stimulation 
(n=14). (*) denotes statistical significance where p<0.0001 using a paired student’s t-test.  
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6.14.2 HAM OPKA from Malawian population 
Healthy adult volunteers were recruited in Malawi using identical inclusion 
and exclusion criteria as for UK volunteers. Non-stimulated Malawian 
alveolar macrophages killed an average of 35.8% of the IVIG opsonised D39 
bacterial inoculum. P4 stimulation significantly enhanced the killing to an 
average of 47.6% (control 35.8% vs. treated 47.6%, p<0.01) (Figure 78). 
 
 
 
Figure 78 - Opsonophagocytosis of IVIG-opsonized D39 pneumococci by human alveolar 
macrophages isolated from Malawian adult volunteers in the presence or absence of peptide 
stimulation (n=13). (*) denotes statistical significance where p<0.01 using a paired student’s t-test. 
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6.14.3. HAM OPKA control reactions 
In the absence of antibody or complement, opsonophagocytosis was reduced 
to 13.4% and 19.2%, respectively  (Figure 79). Following peptide stimulation, 
no detectable differences (n=6) could be seen in the absence of antibody 
(control 13.4 % vs. treated 14.5 %, p>0.05) or complement (control 19.2% vs. 
treated 18.3, p>0.05). Similarly, macrophages where Fcγ receptors were 
occupied following stimulation (n=6) showed a reduced ability of 
phagocytosis compared to control and no detectable differences between 
stimulated and non-stimulated groups were seen (Fcγ receptor occupied 
control 19.3% vs. Fcγ receptor occupied treated 19.8%, p>0.05). 
 
 
 
Figure 79 - Opsonophagocytosis of D39 pneumococci by human alveolar macrophages isolated from 
UK adult volunteers (n=6). “OPA” designates assays in which all components are included 
(macrophage, bacteria, antibody, complement), “No Antibody” designates assays without the 
presence of antibody, “No Complement” without the presence of complement and “FcγR Block” 
designates assays where Fcγ-receptors were occupied by IgG prior to the assay. (*) denotes statistical 
significance where p<0.0001 using a paired student’s t-test.   
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6.14.4. HAM OPKA of ST23F S. pneumoniae 
In addition, it was tested whether P4 mediated opsono-phagocytosis by 
alveolar macrophages was effective using a different capsular type of S. 
pneumoniae (Figure 80). Alveolar macrophages from the UK population were 
allowed to phagocytose opsonised ST23F pneumococci (n=6). Peptide 
stimulation led to significantly increased killing using the ST23F serotype 
(control 38.6 % vs. treated 75 %, p=0.02), similar to that seen using ST2 (D39) 
pneumococci. 
 
 
Figure 80 - Opsonophagocytosis of IVIG-opsonized ST23F pneumococci by human alveolar 
macrophages isolated from UK adult volunteers. (*) denotes statistical significance where p<0.05 
using a paired student’s t-test.   
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6.15 Intracellular killing following OPKA 
P4 mediated opsonophagocytosis by alveolar macrophages leads to increased 
uptake of opsonized pneumococci. We wanted to test whether engulfed 
bacteria would persist intracellularly as a result of the higher amounts present 
due to P4 enhanced uptake.  
 
Following opsonophagocytosis (n=3), peptide stimulated alveolar 
macrophages took up higher amounts of the bacterial dose than their 
unstimulated control (control 15.9% vs. treated 49.1%, p=0.005) (Figure 81) 
consistent with the increased uptake by P4 treated cells shown in Figure 5 . 
No CFU could be detected intracellularly in control cells following a two-hour 
OPKA, while P4 treated cells had small amounts of bacteria present 
intracellularly but this was not significant (control 0% vs. treated 1.5%, p=0.1).  
 
  
Figure 81 – Percentage of the bacterial dose taken up or found intracellular in human alveolar 
macrophages following an opsonophagocytosis killing assay (n=3). Statistical tests were done using a 
paired student's t-test. 
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6.16 Cytokine secretion following P4 mediated OPKA 
Cytokine secretion of alveolar macrophages were measured following an 
opsonophagocytosis killing assay in the presence or absence of peptide 
stimulation. 2 hours following incubation with opsonized pneumococci and 
complement, alveolar macrophages (n=12) did not significantly alter their 
secretion of the cytokines MIP-1β, MCP-1, IL-10, IL12, IFN-γ, or RANTES 
(p>0.1). Higher levels, albeit non-significant, of IL-8 (control 6178 pg/ml vs. 
treated 8648 pg/ml, p=0.08), MIP-1α (control 144 pg/ml vs. treated 244 pg/ml, 
p=0.1), and IL-6 (control 71 pg/ml vs. treated 98 pg/ml, p=0.1) were detected 
following peptide stimulation (Figure 82). 
 
 
Figure 82 - Level of cytokine secretion in control or P4 activated alveolar macrophages (n=12) show 
no differences following a two-hour OPKA assay. Cytokine levels were detected in OPKA 
supernatant using a BD Flex Set kit following a two-hour OPKA. Statistical analysis was done using 
a Wilcoxon matched pairs t-test and defined not significant where p>0.05. 
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6.17 Receptor expression following OPKA  
In order to compare differences in the expression of surface markers of 
activation, alveolar macrophages from the Malawian population were 
allowed to phagocytose opsonised pneumococci in the presence or absence of 
P4 peptide. Following OPKA,  surface markers were assessed on alveolar 
macrophages using flow Cytometry. P4 treated AMs did not express higher 
levels (p>0.1) of HLA-DR, CD206 , CD11b, CCR7, CD163 or CD86 as 
compared to control cells (Figure 83).  
 
 
Figure 83 – Expression of protein markers of inflammation on alveolar macrophages is not modified 
as a result of peptide stimulation following phagocytosis. Alveolar macrophages were allowed to 
phagocytose opsonised pneumonia in the presence or absence of P4 peptide for two hours. 
Following the OPKA, alveolar macrophages were stained for surface markers and analyzed using 
flow cytometry.  
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6.18 Intracellular oxidation  
Intracellular oxidation was measured during an opsonophagocytosis assay 
with and without peptide stimulation (10) and in the presence of P4 peptide, 
LPS or PBS alone (11).  
 
6.18.1 Intracellular oxidation during OPKA 
Peptide treatment of alveolar macrophages exposed to opsonised bacteria and 
complement (n=6) led to a significantly greater increase in intracellular 
oxidation after 140 minutes of measurement (control 81% vs. treated 135% at 
140-200 minutes, p<0.05) when compared to the non-stimulated control.  
 
 
Figure 84 – Measurement of intracellular oxidation in human alveolar macrophages (n=6) during the 
opsonophagocytosis of IVIG-opsonized ST23F pneumococci. The dashed line at 140 minutes 
indicates the time-points from when statistical differences were detected using an ANOVA test 
(where p<0.05 from 140-200 mins).  
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6.18.1 Intracellular oxidation in the absence of infection 
The effect of direct stimulation of alveolar macrophages in the absence of an 
immune complex was also tested (Figure 85). Here we tested the effect of P4 
and compared it to a positive control (LPS) and a negative control (PBS).  In 
P4 peptide treated macrophages (n=6) greater fluorescence compared to non-
stimulated control cells was detected over time but did not reach statistical 
significance  (control 84% vs. treated 102% at 160 minutes, p=0.30). In 
macrophages stimulated with LPS, however, fluorescence at 160 minutes was 
significantly higher than control macrophages (control 84% vs. LPS treated 
139% at 160-200 minutes, p<0.05).  
 
 
 
Figure 85 – Measurement of intracellular oxidation in human alveolar macrophages (n=6) following 
stimulation with PBS, LPS (100 μg/ml) or P4 (1mg/ml). Dashed line at 160 minutes indicates the time-
points from when statistical differences were detected using an ANOVA test (where p>0.05 from 160-
200 mins). 
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D. Discussion 
 
6.19 Discussion 
In this chapter, both human phagocytes involved in defending the host 
against pneumococcal infection during health and disease were shown to 
respond to P4 treatment. These data are the first for human alveolar 
macrophages and confirm previous work on peripheral blood neutrophils 
[279]. It was also shown that P4 upregulates alveolar macrophage 
intracellular oxidation only in the presence of immunecomplexes and that no 
changes in inflammation could be detected by measuring cell surface marker 
expression and cytokine secretion following OPK assays. 
 
6.19.1 Alveolar macrophage and neutrophil phagocytosis 
Two different human populations with different experience of pneumococcal 
disease were deliberately compared.  UK adults of the age recruited have a 
low incidence of pneumonia (<1/1000/yr) and pneumococcal carriage (<10%) 
but in Malawi both disease and carriage are much higher, related to exposure 
and risk factors including malnutrition [359], smoke exposure [360] and 
concurrent infections [361].  In this chapter, both the UK and Malawian 
alveolar macrophages showed a significant increase in opsono-phagocytosis 
following P4 peptide treatment. Whilst both population groups showed 
enhanced activity, this was more pronounced in the UK population.  The 
lower phagocytic enhancement seen in the Malawian population was possibly 
due to the heavy carbon load of Malawian alveolar macrophages [362], which 
has been shown to reduce phagocytosis [363]. Nevertheless, it is promising to 
see P4 stimulation effective in populations most susceptible to pneumococcal 
disease. These results translate observations from chapter III, where murine 
alveolar macrophage augmented their phagocytic killing of pneumococci 
following peptide stimulation. In addition, peripheral blood neutrophils form 
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healthy adults augmented their phagocytic killing of IVIG opsonised 
pneumococci as has previously shown [280]. As neutrophils are heavily 
recruited to lungs following infection [306], these results further support the 
use of API to augment lung defence during pneumonic infections.   
 
Phagocytosis is triggered when the Fc region of a pathogen-bound antibody 
comes into contact with Fcγ receptors on immune cells, an event which can be 
mediated by complement [71]. In this chapter, phagocytosis of bacteria in the 
absence of antibodies or complement was greatly decreased and P4 did not 
up-regulate function. This suggests that the P4 enhanced phagocytosis by 
alveolar macrophages is specific, relying on the presence of the components 
necessary for phagocytosis to occur.  In previous chapters, Fcγ receptors have 
been associated with P4 administration and in this chapter their involvement 
in P4-mediated opsono-phagocytosis by alveolar macrophages was 
confirmed. Immunoglobulin G is used as a standard method in 
immunofluorescent staining to reduce non-specific binding by occupying Fcγ 
receptors. This technique was adapted to occupy Fcγ receptors following 
peptide stimulation. Similar to HL-60 Fc fragment occupation studies, 
occupation of Fcγ receptors on alveolar macrophages reduced phagocytic 
killing in both control and P4 stimulated cells. Possible mechanisms for the 
reduced killing by P4 treated cells in these assays were suggested to be due to 
(a) augmented FcγR expression being annulled through receptor occupation, 
(b) lack of TLR stimulation following internalization of free IgG and (c) 
ligation of inhibitory FcγR by IgG.  
 
Invasion assays in this chapter were performed to determine whether 
internalized pneumococci following OPK assays were also killed 
intracellularly. Following OPKA, cells were washed and incubated with a 
bactericidal antibiotic then lysed using a detergent to culture intracellular 
pneumococci. It was hypothesized that P4 not only enhanced phagocytic 
uptake but also phagocytic killing. No pneumococci could be cultured 
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intracellularly in control cells while small amounts (>2% of bacterial dose) 
were cultured in P4 stimulated cells. As >50% of the pneumococcal dose was 
internalized in P4 stimulated cells (compared to 16% in control cells), the 
amount of internal pneumococci cultured is relatively small and would have 
most likely been killed intracellularly if given more time. This could have 
been confirmed by allowing alveolar macrophages additional time to kill the 
larger proportion of internalized phagocytes. These results confirm that the 
OPK assay measures killing of opsonised pneumococci and that augmented 
phagocytosis of P4 stimulated alveolar macrophages also leads to intracellular 
killing. It would be interesting to assess P4 mediated killing of intracellular 
pathogens such as Legionella pneumophila, Listeria monocytogenes and 
Mycobacterium tuberculosis which allow themselves to be phagocytosed in 
order to escape the phagosome and reside intracellular [364].  
 
6.19.2 Intracellular oxidation by alveolar macrophages 
Phagocytic cells use intracellular oxidation and proteases to break down and 
kill ingested bacteria [356]. This chapter investigated whether alveolar 
macrophages would alter their intracellular oxidation as a result of peptide 
treatment. In the presence of immune complexes and complement, oxidation 
levels were higher in P4 stimulated alveolar macrophages as compared to the 
non-stimulated control. In the absence of immune complexes however, P4 
stimulation alone leads to little increase in intracellular oxidation as 
compared to LPS where levels rise significantly. The DCFH assay does not 
differentiate between oxidation in the cell and oxidation in the phagosome so 
it is unclear where the enhanced oxidation is occurring.  As peptide treatment 
alone does little to alter oxidation levels however, the increased levels seen 
during phagocytosis are most likely due to larger amounts of pneumococci 
present intracellularly as a result of P4 stimulation.  
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In addition to the generation of reactive oxygen species, a recent study by 
Nunes et al has shown that high Ca2+ levels within and in proximity of the 
phagosome can augment killing of internalized pathogens through the 
interaction of endoplasmic reticulum and phagosomes [365]. As calcium 
signaling is important for the maturation of phagosomes and therefore killing 
of pathogens [366], it would be of interest to assess the flow of intracellular 
calcium during P4 mediated opsonophagocytosis.  
 
6.19.3 Cell surface markers and cytokine secretions following 
OPKA 
During severe infections, an exaggerated immune response is often the main 
cause of tissue damage and reduced recovery [367]. In this chapter, it was 
investigated whether P4 treatment would exacerbate inflammation by 
measuring inflammatory cytokine and cell surface markers following 
opsonophagocytosis killing assays. P4 treatment did not significantly alter 
either cytokine secretion or surface marker expression immediately after 
stimulation, suggesting that P4 therapy could be used clinically in severe 
inflammatory conditions such as those seen during sepsis. These results are in 
line with results from chapter V, where P4 stimulation in the absence of 
infection did not alter expression of FcγRI, a marker of cell activation.  
 
Additional work is necessary, however, to ascertain the benign effect of long-
term peptide stimulation as the time point sampled in these assays may be to 
short to detect phenotypical changes on cells and cytokine secretions. mRNA 
studies could help detect rapid changes following peptide stimulation while 
extended timepoints, in the presence and absence of infection, . In addition, 
the use of IVIG which may contribute to reduced inflammation during these 
studies due to sialylated pooled immunoglobulin G acting on inhibitory Fc 
receptors [368]. This needs to be taken into consideration when assessing 
activation of cells following API.  
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Since the validation of the “germ theory of disease” by Louis Pasteur in the 
19th century, modern medicine has made great leaps in reducing deaths from 
infectious diseases. Imaginative and sometimes counter-productive 
treatments were replaced by two strategies: (1) targeting the disease through 
the use of antimicrobial compounds and (2) preventing disease through 
vaccination of the host. These strategies work in separate ways: one targets 
the pathogen to assist the immune system while the other assists the immune 
system to target the pathogen. There is no doubt that both strategies (as well 
as improvements in hygiene) have contributed to immense reductions in 
death. While vaccination continues to prevent >3million deaths every year, 
the efficacy of antibiotic treatment is fading. The development of new 
antimicrobial compounds is important and needs to be further pursued. It is, 
however, equally important to appreciate the achievements of vaccination 
and remember the successes of passive immunotherapy when developing 
new treatments.  
 
In this thesis, the efficacy of augmented passive immunotherapy (API) to treat 
pneumococcal disease was investigated. API is a synergistic treatment of 
pooled antibody in order to assist the host in recognizing pathogens and the 
immunomodulating peptide P4 to encourage the clearance of pathogen. In 
order to investigate its effectiveness, in vivo models were used to assess API in 
treating invasive pneumonia and ex vivo / in vitro assays were used to assess 
the effect of peptide stimulation on phagocytic cells. 
 
In summary, API significantly improved the survival of mice in all models of 
invasive pneumococcal disease tested. Three strains of mice were chosen with 
varying genetic backgrounds and ages as well as varying severity of infection. 
Improved survival was associated with reduced pneumococcal burden in 
lungs and blood and the recruitment and activation of phagocytic leukocytes 
following treatment. Activation of phagocytes was associated with increased 
expression of the opsonic Fcγ receptors. During acute infections of 
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pneumonia, peptide treatment of the lung alongside antibody administration 
prevented the onset of septicemia and subsequent death of mice. Peptide or 
antibody treatment alone did not significantly improve survival in all models 
tested. In the absence of infection and IVIG, in vivo peptide administration led 
to the recruitment and activation of phagocytes in a manner similar to the 
infection studies.  
 
Peptide stimulation of phagocytes derived from various tissues or through 
cell culture led to significantly enhanced killing of opsonized S. pneumoniae. 
Phagocytes tested included murine alveolar and peritoneal macrophages as 
well as a murine macrophage cell line. Human alveolar macrophages from 
two donor populations, peripheral blood neutrophils and HL-60 cell lines 
were also tested. Peptide treatment of a monocyte-like cell line did not lead to 
enhanced phagocytosis. Increased killing of S. pneumoniae by phagocytes was 
dependent on the presence of antibody, functional complement and the 
availability of opsonic Fcγ receptors.  
 
The data in this thesis support previous data that have shown the beneficial 
effect of API in treating bacterial diseases. Since it’s conception in 2008, API 
has been able to rescue moribund mice infected with invasive pneumonia 
[280], influenza-pneumonia co-infections [284] and MRSA [282]. API has also 
been administered alongside low dose antibiotics leading to enhanced 
survival rates [281]. Repeat therapy in mice whom had previously survived 
pneumococcal infection due to API was also successful [281].  
 
Murine models of disease 
Mouse models of pneumococcal disease have been used to assess the efficacy 
of vaccination, therapeutic drugs, and host-pathogen interactions. The choice 
of mouse strain is important, as differences in susceptibility to infection have 
been described in various strains of mice [310, 369, 370]. Differences in 
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susceptibility with respect to the sex of mice have also been described [367]. 
Inbred mice allow for reproducible and uniform immune responses and have 
therefore frequently been used to assess vaccine and therapeutic drug efficacy 
[371]. Outbred strains are used to observe immune responses in a 
heterozygote population. The phenotypic differences in outbred mice, despite 
being lower than in humans, can better reflect the natural variations in 
response to infection [372]. Assessing the efficacy of therapeutic agents in 
aged mice is important as ageing has been shown to increase susceptibility to 
pneumococcal infection due to the diminished capabilities of a range of 
effector functions [314, 373, 374]. The infecting dose and strain is also 
important. Laboratory strains of S. pneumoniae are frequently used for 
infection as they assure reproducibility and allow for comparison between 
different research groups. The problem is, however, that frequent passaging 
of bacteria and long-term storage changes the phenotype and virulence of the 
bacterium [375]. To overcome this, laboratory strains of D39 S. pneumoniae 
were passaged once in vivo prior to infection to increase and standardize their 
virulence. For all models of invasive disease, a high dose (106 CFU) of S. 
pneumoniae is instilled directly into the lungs of mice. Depending on the host, 
pneumonia is established within 12-48 hours after which pneumococci seed 
into blood and cause septic infections.  
 
API against invasive disease  
In this thesis, outbred strains were used to model human invasive 
pneumonia. These were MF1 (48 hours mean survival [369]), Swiss Webster 
(72 hours mean survival) and BALB/c (168 hours mean survival [369]). In 
addition, Swiss Webster and BALB/c mice were allowed to age until >50% of 
the initial colony succumbed of natural causes, thereby establishing an “aged 
population”. Survival of API treated mice was significantly increased in both 
young and aged populations of BALB/c and Swiss Webster mice. The MF1 
host was chosen to model acute infections that progress rapidly. In a clinical 
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setting, acute infections are responsible for the majority of deaths due to the 
time taken for antimicrobial compounds to take effect [318]. To challenge the 
treatment model, API was administered when bacteraemia had already set in. 
The sole administration of either P4 or IVIG did not lead to significant 
increases suggesting a synergistic effect of APIs  
 
IVIG as an opsonin 
Immunoglobulin present in pooled preparations such as IVIG is derived from 
1,000-3,000 blood donors and includes antibodies generated naturally through 
exposure to pathogens as well as antibodies generated following vaccination. 
Naturally derived antibodies have evolved in parallel to the evolution of 
pathogens and directed against several antigens. Vaccine generated 
antibodies against encapsulated bacteria are usually strong opsonisers [376, 
377] and aimed at inactivating virulence factors essential for causing disease. 
This combination reduces the ability of pathogens to avoid detection and 
evolve, making antibody administration feasible as a long-term treatment 
strategy. Several studies have shown that IVIG preparations contain 
antibodies against a wide range of common bacterial and viral pathogens 
[378, 379] and in this thesis IVIG was able to opsonize eight serotypes 
(including un-encapsulated strains) of S. pneumoniae as determined by 
opsonophagocytic killing assays in the presence and absence of IVIG 
opsonisation. This broad specificity allows for pre-emptive administration 
against a range of clinically important pathogens prior to diagnostic results.  
 
A problem with the use of IVIG to treat infectious disease is the lot-to-lot 
variation in the neutralizing titres of pathogen specific immunoglobulin [380-
382]. This is because currently commercial IVIG preparations are not tailored 
for the use against infectious diseases. This could be overcome, however, by 
establishing international standards of neutralizing antibody titres in IVIG 
preparation using existing methods [383]. In addition, IVIG preparations 
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could be further potentiated for the use against infectious diseases by 
supplementing collected serum with monoclonal antibodies against the most 
important human pathogens. There are many FDA approved monoclonal 
antibodies against a wide range of infectious pathogens that could be used for 
IVIG potentiation [274, 384]. 
 
IVIG as an anti-inflammatory  
The anti-inflammatory properties of IVIG have long been recognized [368, 
385]. It is believed that sialylation of the Fc portion of a small percentage of 
immunoglobulin present in IVIG leads to significant anti-inflammatory effects 
through it’s interaction with inhibitory Fc receptors on leukocytes [386, 387]. 
Specifically, IVIG induces the expression of inhibitory FcγRIIb, which is then 
ligated by exogenous antibody leading to dampening of immune responses 
[388]. As such, IVIG preparations are frequently used to treat inflammatory 
diseases such as arthritis [389]. In the context of infectious diseases, this is 
beneficial as an exaggerated immune response, often seen during bacterial 
infections, can be minimized or prevented leading to faster resolution of 
infection [390]. During API of pneumonia-influenza co-infected mice, lung 
tissue damage was significantly lower in API mice as judged by 
histopathological analysis [284]. This was suggested to be due to a decrease of 
bacterial burden, but reduced inflammation due to IVIG administration may 
have also contributed.  
 
In the search for treatments against sepsis, anti-inflammatory compounds 
have frequently undergone clinical trials with mixed results [391]. There have 
so far only been a few clinical trials of IVIG in sepsis [392] where most 
successful results are reported when IVIG is used as an adjunct to 
conventional treatments [273, 393]. Reduced inflammatory stimuli, however, 
also decreases the effectiveness of phagocytic clearance of pathogens. As 
such, immunomodulation to enhance phagocytosis is of benefit. In this thesis, 
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the sole administration of IVIG in the control groups increased survival of 
mice, but in combination with the immunomodulating peptide P4 this was 
significantly improved. In order to elucidate the role of IVIG in containing 
inflammation during API, studies comparing “classical” serum from 
immunized mice (i.e. no sialylation of IgG molecules, titrated to have the 
same opsonic efficacy as IVIG) to IVIG could be performed. Similarly, 
treatments using anti-pneumococcal monoclonal antibodies could be tested 
against IVIG.  
 
Intravenous administration  
IV administration of P4 was effective in all models of invasive pneumococcal 
disease. It has the advantage that administered peptide will circulate 
systemically thereby affecting a wide range of cells. A rapid effect is 
important, as survival in patients presenting with acute pneumonia or sepsis 
is greatly increased if treatments are administered during the “golden hours”, 
i.e. immediately after presenting at the clinic [394]. Antimicrobial compounds 
have not been shown to reduce deaths that occur in the initial 48-hour period 
following admission [395-397]. A rapidly effective “bridging treatment” could 
therefore contain infections before antimicrobial compounds take effect. In 
this thesis, acutely infected mice treated with API survived significantly 
longer than untreated mice. API halted the progression of pneumonia and 
bacteraemia within 12 hours of P4 & IVIG administration in the MF1 host. In a 
clinical setting this could allow for further antibiotic therapy to take effect as 
well as time for a full diagnosis and further targeted treatment. 
 
Intranasal administration  
Intranasal administration of P4 results in the exposure of the peptide to all 
sites of pulmonary immunity, including resident alveolar macrophages. It is 
assumed that peptide solution administered IN would also diffuse through 
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tissue and enter the blood circulation although at lower concentrations than 
when administered IV [398-400]. IN treatment was given at 12 hours 
following acute infection, which in the MF1 mouse model is prior to the onset 
of bacteraemia. This resulted in significant reductions of pneumococcal loads 
in lungs and therefore decreased neutrophil infiltration and the potential for 
“collateral damage” caused by them [151]. The administration of P4 at 12 
hours as compared to 24 hours in the IV model meant that treatment was 
given while infection was still at a crucial stage (in lungs rather than blood). 
Hence, IN administration of P4 alongside IVIG as a pre-emptive treatment of 
acute invasive pneumonia was able to prevent exacerbation of the disease by 
prevention of pneumococcal seeding into blood and thereby no sepsis, 
leading to complete host survival.  
 
To the best of my knowledge, this is the first time intranasal therapy of 
immunomodulating compounds has led to host protection after the onset of 
acute pneumonia and offers the potential of targeted treatments against 
bacterial respiratory infection and septicemia secondary to such infections. IN 
treatment has the advantage of directly stimulating alveolar macrophages. 
AMs make up a large phagocytic population in lungs but remain mostly anti-
inflammatory, a natural mechanism evolved to avoid unnecessary damage to 
lungs during mild infections. It has been shown that alveolar macrophages 
from patients with severe pneumonia have a reduced ability respond to LPS 
stimuli compared with healthy controls [401]. As ex vivo peptide treatment of 
alveolar macrophages led to increased bacterial killing, IN administration has 
the potential to harvest the phagocytic potential of macrophages in addition 
to recruited neutrophils and monocytes. Intranasal administration of IVIG has 
also been shown to reduce bacterial loads during pneumococcal infection (but 
to a lesser extent than intravenous administration) suggesting that both P4 
and IVIG could be administered intranasally during API to treat pneumonia 
[402].  
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Nasopharyngeal carriage of the pneumococcus precedes invasive disease. It 
was tested whether API would be able to affect pneumococcal carriage 
following intranasal administration of P4.  48 hours following the first 
administration of peptide to the nasopharynx, levels of pneumococci in the 
nasopharynx significantly increased without causing invasive disease. This is 
perhaps not surprising, as it has previously been shown that P4 affects the 
cytology of nasopharyngeal epithelial cells, including the remodeling of actin, 
thereby facilitating invasion by the pathogen [279]. This is in line with studies 
on PsaA, the protein from which P4 is derived, which showed that PsaA 
facilitates adhesion and subsequent invasion of epithelial cells by 
pneumococci [277]. In addition, the administration of IVIG during carriage 
would not be able to effectively opsonise pneumococci as IVIG is 
predominantly made up of IgG immunoglobulin, which is less efficient at 
entering mucosal areas compared to IgA.  
 
These findings suggest that intranasal administration has the potential of 
harvesting the phagocytic potential of alveolar macrophages and neutrophils 
recruited through the up-regulation of Fcγ receptors and subsequent 
clearance of pathogens. Care needs to be taken, however, to avoid exposure of 
P4 to the nasopharynx as it may facilitate the invasion by pneumococci.  
 
Modulating phagocyte recruitment 
Infection of the lung leads to the secretion of cytokines to recruit phagocytes 
to the site of infection.  Following pneumococcal infection in this thesis, 
control MF1 mice recruited both neutrophils and monocytes to the lungs as 
has been seen in previous studies [306]. Alveolar macrophages did not change 
their cytokine secretions following peptide mediated phagocytosis ex vivo but 
a slight increase in IL-8 and MIP-1α secretion (responsible for neutrophil 
recruitment) as well as IL-6 (functions include neutrophil production) was 
detected. Intravenous treatment with peptide, however, had no effect on 
pulmonary neutrophil recruitment during in vivo infection studies. Intranasal 
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administration of peptide actually led to a reduction of neutrophils in the 
lungs. The significantly increased neutrophil recruitment in peripheral blood 
after intravenous administration of peptide in the absence of infection, 
however, would suggest that P4 peptide does influence neutrophil migration.  
 
Neutrophils become the major cell phagocytosing bacteria in the alveolar 
compartment in established pneumonia [403] but can also cause “collateral 
damage” by releasing reactive oxygen species and proteolytic enzymes [404-
407]. In both intranasal and intravenous peptide administrations, significant 
reductions in bacteria were detected in lungs. This could suggest that 
neutrophils were recruited and began phagocytosing bacteria (hence the 
reduction in bacterial burden) after which they induced apoptosis. Studies 
looking for apoptotic neutrophils in lungs or the presence of cytokines 
responsible for neutrophil recruitment or release from the bone marrow (i.e. 
IL-8, G-CSF) would help better understand the role of neutrophil recruitment 
in API. An augmented, but not exaggerated recruitment of neutrophils from 
API would be beneficial as neutrophils from septic patients, particularly non-
survivors, exhibit significantly less chemotactic activity in vitro than 
neutrophils obtained from healthy volunteers [408].  
 
Most strikingly, however, was the detection of a rapid increase in blood 
monocytes following intravenous administration of P4 peptide in the 
presence and absence of infection.  As previously described there are two 
monocyte sub-populations that have distinct functions. Resident tissue 
monocytes initially phagocytose bacteria and recruit leukocytes but then 
switch into anti-inflammatory immune cells [298]. Inflammatory monocytes 
are recruited to inflamed tissue to phagocytose bacteria and further recruit 
phagocytes but then differentiate into anti-inflammatory macrophages [409]. 
This suggests that the increased monocyte population observed following 
peptide administration could be inflammatory monocytes sub-population 
that may function to either help in clearing opsonized pathogens or act as 
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anti-inflammatory cells. In order to verify this, isolated F4/80+ monocytes 
following peptide administration could be further categorized by staining for 
Ly-6Chigh (resident monocytes) and Ly-6Clow (inflammatory monocytes) 
expression. Inflammatory monocytes have previously been shown to be 
essential in containing septic infections and as such and augmented 
monocytic response from API could be of benefit [319].  
 
While the in vivo, peptide stimulation led to large effects on monocyte 
populations, this was not true in vitro. Using a monocytic THP-1 cell line, 
peptide stimulation did not lead to enhanced opsonophagocytosis in this 
thesis. It could be that THP-1 monocytes require further differentiation into 
macrophages for enhanced phagocytosis or that P4 peptide indirectly 
contributes to monocyte activity through IL-2 secretion by other effector cells 
[410]. P4 mediated phagocytosis assays using THP-1 or freshly derived 
monocytes alongside co-stimulation, such as IL-2, could help inform on the 
effect of P4 on monocyte phagocytosis.  
 
Similar to PsaA, the virulence factor NadA from Neisseria meningitidis is an 
invasin that promotes bacterial adherence and invasion into epithelial cells 
[324]. Purified soluble NadA was shown to efficiently stimulate 
monocytes/macrophage secretion of IL-8, IL-6, MCP-1, and MIP-1α as well as 
low levels of TNF-α and IL-1. In addition, NadA also inhibited monocyte 
apoptosis and induced the differentiation into a macrophage-like cells [411]. It 
is possible that P4 acts on monocytes in a similar way as NadA by enhancing 
recruitment of neutrophils and differentiating into macrophages in order to 
assist in the bacterial clearance. Studies looking at cytokine secretion and 
monocyte differentiation would help better understand the role of monocytes 
in API. 
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Modulation of Fcγ expression 
A reoccurring observation of API is the increased expression of opsonic Fcγ 
receptors on phagocytic cells. This was true in the presence and absence of 
infection, in vitro and in vivo. Using, flow cytometry, Fcγ blocking studies and 
immunogold staining it was determined that P4 up-regulates Fcγ expression 
within one hour of peptide stimulation and that this is necessary for enhanced 
phagocytosis to occur. In vivo, the IV administration of P4 solution in the 
absence of infection led to significant up regulation of Fcγ expression on 
circulating blood monocytes and neutrophils at 1 hour, peaking at 24 hours. 
Infection of these mice at 24 hours led to significantly increased survival and 
reduced bacterial load in the absence of IVIG. At 24 hours in this model, 
control mice had pneumococci seeding into blood but this was not true for P4 
pre-treated mice suggesting that host immune cells were initially primed and 
able to effectively clear invading pathogens, but the overwhelming infection 
and lack of opsonic molecules may have led to host mortality.  
 
In order to visualize increased Fcγ receptors expression, peripheral blood 
monocytes were collected 24 hours following peptide administration in the 
absence of infection and stained for FcγR using immunogold antibodies. This 
confirmed the enhanced expression of FcγR observed using flow Cytometry 
studies but also showed an augmented ability of P4 treated monocytes to 
internalize immunogold complexes. This suggests that enhanced 
internalization is independent of the presence of inflammatory mediators 
triggered when pathogens are internalized. This could have potential 
therapeutic benefits as some pathogens, such as the parasitic leishmania 
species, do not trigger phagocytosis of monocytes and macrophages in the 
absence of further stimuli such as LPS binding to TLR [150].  
 
Fcγ expression is naturally increased through inflammation and P4 was able 
to augment this during infection in vivo and in vitro. It is unclear whether P4 
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enhances the natural signaling pathway of Fcγ expression or modulates 
expression via another signaling pathway. As increased expression is seen in 
vitro, it can be assumed that up-regulation is independent of stimuli secreted 
by other immune cells. A better understanding of the pathways of Fcγ 
regulation is necessary to further elucidate the mechanism of P4 augmented 
expression.  
 
Modulating phagocytosis 
Previously it was shown that the phagocytosis of opsonized pneumococci by 
HL-60 neutrophil like cells as well as RAW macrophages would be up-
regulated following peptide treatment [279, 280].  A standardized killing 
assay was chosen which measures the ability of phagocytes to take up and kill 
pneumococci in the presence of immunoglobulin and complement, serum 
proteins important for the opsonisation of pathogens. Titrated IVIG was used 
as a source of pathogen specific antibody and titrated baby rabbit 
complement as a source of complement. The previous observations were 
extended to alveolar as well as peritoneal macrophages in mice and 
peripheral blood neutrophils and alveolar macrophages in humans as well as 
monocyte and neutrophil like human cells lines. 
 
For all immune cells tested, the presence of antibody was necessary for P4 to 
up-regulate phagocytic function. Antibody bound to pathogen initiates 
phagocytosis via FcγR and activates complement through classical activation 
of the complement cascade. As such, the absence of antibody greatly 
diminishes the ability for FcγR phagocytosis, complement activation and 
subsequent phagocytosis to occur. 
 
Similarly, the presence of complement was necessary for P4 augmented 
phagocytosis. This could be due to the regulatory function of FcγR by 
complement. Increased expression of activating Fcγ receptors is dependent on 
the presence of C5a, an anaphylactic protein activated in the final stages of the 
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complement cascade [80]. Similarly, the production of C5a protein is 
dependent on the presence of Fcγ receptors [81] suggesting that complement 
acts in a way that regulates FcγR expression and vice versa [412]. As such, it 
may be that enhanced Fcγ expression is dependent on the presence and 
activation of complement and the P4 stimulation does not override 
complement regulatory mechanisms. Further work looking at the role of 
complement during API is needed to confirm this. The necessity of the 
presence of serum components in theses assays, however, suggests that P4 
augments a natural process of phagocytosis and does not cause unspecific 
bacterial killing through other mechanism.  
 
Many patients suffering from chronic obstructive pulmonary disease (COPD) 
are colonized by bacteria in their lower respiratory tract and >50% of COPD 
exacerbations are associated with bacteria, which was suggested to be due to 
a reduced ability of phagocytes to clear pathogens [413]. Similarly, 
neutrophils from septic patients show reduced phagocytosis [414, 415] as do 
immature neutrophils released from the bone marrow during sepsis [416]. 
Septic patients who have neutrophils with reduced phagocytic activity have 
lower chances of survival [417]. Phagocytosis is thus an important component 
of host responses in critically ill patients but relies on the presence of opsonins 
for effective clearance of pathogens. The ability of API to upregulate 
phagocyte function and clear IVIG opsonised pathogens therefore offers a 
potential new treatment strategy against fulminant bacterial infections.  
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Nature has provided … in the phagocytes … a natural means of devouring and 
destroying all disease germs. There is at bottom only one genuinely scientific 
treatment for all diseases, and that is to stimulate the phagocytes. Stimulate the 
phagocytes. Drugs are a delusion. 
 
The Doctor’s Dilemma, George Bernard Shaw, 1911 
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